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Endometriosis is an estrogen dependent disease (EDD) that has no satisfying treatment option, 
as the existing ones mainly comprise endocrine treatments that lead to severe systemic hypo-
estrogenic side effects. Steroid sulfatase (STS) and 17β-hydroxysteroid dehydrogenase type 1 
(17β-HSD1) are attractive new targets for the treatment of EDDs. Their inhibition leads to 
blockage of the local biosynthesis of estrogen without significantly affecting the circulating 
estrogen. The simultaneous inhibition of both enzymes appears to be more promising than the 
blockage of only one protein.  
The main aim of this study is the development of dual inhibitors of STS and 17β-HSD1 
(DSHIs) that offers a novel treatment option for endometriosis without severe side effects. 
Using a designed multiple ligand (DML) approach, the first DSHIs were identified. Upon 
structural optimizations, highly potent inhibitors in cell-free and cellular assays were achieved 
that are characterized by high selectivity over 17β-HSD2 which plays a protective role in 
endometriosis. The DSHIs were able to efficiently reverse the E1-S and E1- induced T47D 
cell proliferation. The most interesting inhibitor described in this work is characterized by 
high metabolic stability in human and mouse hepatic S9 fraction, along with good 
physicochemical properties and high safety margins in cytotoxicity assays. Furthermore, this 






Endometriose ist eine Estrogen-abhängige Erkrankung  für die bislang keine 
zufriedenstellende Therapieoption existiert. Zum Einsatz kommen hauptsächlich endokrine 
Behandlungen, die systemisch zu stark hypoestrogenen Zuständen und damit 
zusammenhängenden, ernsthaften Nebenwirkungen führen. Die Enzyme Steroid Sulfatase 
(STS) and 17β-Hydroxysteroid Dehydrogenase Typ 1 (17β-HSD1) sind attraktive, neuartige 
Targets zur Behandlung Estrogen-abhängiger Erkrankung. Ihre Inhibierung führt zur 
Hemmung lokaler Estrogen-Biosynthese, ohne starke Beeinflussung systemischer Estrogen-
Konzentrationen. Die gleichzeitige Hemmung beider Enzyme erscheint vielversprechender als 
die Blockade eines einzelnen Proteins. 
Ein Gegenstand der vorliegenden Arbeit ist die Entwicklung dualer Inhibitoren von STS und 
17β-HSD1 (DSHIs). Solche Wirkstoffe sind  eine  neuartige Therapieoption für 
Endometriose, die nicht zu den erwähnten Nebenwirkungen führt. Unter Anwendung eines 
Ansatzes zum gezielten Design von Liganden mehrerer biologischer Targets wurden die 
ersten DSHIs identifiziert. Anschließende Strukturoptimierungen führten zu Wirkstoffen, die 
in Zell-freien und zellbasierten Assays beide Targetenzyme hochpotent hemmten. 
Darüberhinaus waren die DSHIs in der Lage, die Estronsulfat- und Estron-induzierte 
Proliferation von T47D Zellen vollständig aufzuheben. Die vielversprechendste Verbindung 
zeigt hohe metabolische Stabilität in den S9-Lebermikrosomenfraktionen von Mensch und 
Maus, vorteilhafte physiko-chemische Eigenschaften und geringe Cytotoxizität. 
Darüberhinaus zeigte sie günstige pharmakokinetische Eigenschaften in der Maus, was sie zu 
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1.1 Estrogen  
1.1.I Estrogen as a steroid hormone 
Steroid hormones are cholesterol-derived chemical messengers that exert transient 
physiological effects as well as permanent developmental actions on the body from fetal life 
to adulthood 
1,2
. They can be categorized into two groups according to the main sites of 
production in the body: corticosteroids which are mainly biosynthesized in the adrenal cortex 
and the sex steroids which are typically biosynthesized in the reproductive organs of males 
and females 
2
. The corticosteroids are further subdivided into mineralocorticoids which 
control the balance of water and minerals in the body, and glucocorticoids which control the 
glucose homeostasis and play a role in the feedback mechanism of the immune system. The 
sex steroids can be subcategorized into progestogens (C21 steroids), androgens (C19 steroids) 
and estrogens (C18 steroids). Progesterone is the most important progestogen in the human 
body which binds to the progesterone receptor and plays an important role in the female 
reproductive system during pregnancy and menstrual cycle. The main representatives of 
androgens are testosterone (T), dihydrotestosterone (DHT) which are the main sex steroid 
hormones in men. Dihydroepiandrosterone (DHEA) which is mainly secreted by the adrenal 
cortex and androstenedione (A4) are crucial androgens in the steroidogenesis pathway. 
Androstenediol (Adiol) is also a C21 steroid; however, it has an estrogenic effect 
3
. Estrogens 
are the major sex steroid in females which arise from the aromatization of androgens steroidal 
A- ring. Estradiol (E2) is the most active form of the estrogen family, while estrone (E1) and 
estriol (E3) are less estrogenic. 
1.1.II Biosynthesis and regulation 
In women of reproductive age, circulating estrogens are biosynthesized mainly in the ovaries 
and released to the systemic circulation to act on target cells or tissues (endocrine 
mechanism) 
4
. The biosynthesis (see figure 1) starts in the mitochondria in which the 
cholesterol side chain is cleaved by the action of CYP11A1 (side-chain cleavage enzyme 
SCC) to give pregnenolone. In the smooth endoplasmic reticulum, 3β-hydroxysteroid 
dehydrogenase/δ5→4-isomerase type 2 (3β-HSD2) converts pregnenolone into progesterone 
by oxidizing the 3β-hydroxy function and shifting the double bond position. The bifunctional 
17α-hydroxylase/17,20 lyase (CYP17A1) transforms the produced progestogens by oxidation 
at the 17α position  followed by lysis reaction at position 20 to give the corresponding 
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androgens DHEA and A4 
5
. In principle, there are 2 pathways for estrogen formation. The 
first is through the irreversible aromatization of the steroidal A-ring of A4 by the action of the 
microsomal aromatase enzyme (CYP19A1), followed by the reversible reduction of the C-17 
keto group by the action of 17β-hydroxysteroid dehydrogenase (17β-HSD) enzymes (will be 
discussed in details in section 1.3.3). Alternatively, the reduction step can be initially 
performed to give testosterone from DHEA via Adiol, followed by subsequent aromatization 
to give E2. In the ovaries the main pathway for estrogen biosynthesis consists of the 
conversion of DHEA to A4 by the action of 3β-HSD2, followed by aromatization with 
CYP19A1 to give E1. The latter is subsequently reduced to E2 mainly by the action of 17β-
HSD 7 and 12 
6,7
. 
Estrogen production from the ovaries is regulated through an endocrine mechanism that 
involves hypothalamus-pituitary-gonadal glands 
8
. Gonadotropin-releasing hormone (GnRH) 
is secreted by the hypothalamus to stimulate the anterior pituitary gland to produce follicle-
stimulating hormone (FSH) and luteinizing hormone (LH). FSH triggers the follicle 
maturation, while LH stimulates the ovulation process and the corpus luteum formation. In the 
thecal cells of the mature follicle, LH stimulates the formation of androgens which will be 
converted into estrogens in the granulosa cells under the stimulation of FSH through the 
abovementioned biosynthetic pathway 
8–10
. The levels of circulating E2 in premenopausal 
women are subjected to fluctuations during the menstrual cycle. In the follicular phase (the 
first half of the cycle), the E2 in the plasma comes mainly from the mature follicle cells, E2 
increases gradually, reaching its highest level at ovulation time. After ovulation, the E2 level 
decreases temporarily until the corpus luteum is formed (luteal phase) which elevates the 
estrogen levels as well as the progesterone. At the end of the cycle basal levels are reached 
again which lead to the menses bleeding.  
Estrogens are also produced by other peripheral tissues but to lower extent e.g. placenta, 
endometrium, liver, adipose tissue, brain and skin 
4,11,12
. These tissues use the inactive 
circulating sulfated forms of E1 (E1-S) and androgens which are secreted by the adrenal 
cortex (DHEA-S and Adiol-S), and convert them into their free parents by the action of the 
steroid sulfatase enzyme (STS) (will be discussed in further details in section 1.3.2). The 
formed E1 will then be converted into E2 by the reductive 17β-HSD1 enzyme in a pathway 
known as the “sulfatase pathway” 
13
. The androgens are transformed into testosterone which 
will be subsequently aromatized by CYP19A1 to give E2 “aromatase pathway” 
14
. These 
tissues mainly utilize the E2 produced intracellularly via the intracrine mechanism, in which 
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In postmenopausal women, ovarian estrogen production is stopped and the plasma E2 levels 
drop significantly to one tenth of the premenopausal levels. The peripheral estrogens become 
the dominating one in the plasma without observed fluctuation 
4,16
. Additionally, all the 
peripheral tissues become dependent on the intracellularly biosynthesized steroids which are 
utilized by intracrine fashion 
17
. 
Estrogens are metabolized mainly in the liver; this involves the conversion of E2 into less 
active E1 by the action of 17β-HSD2. E1 can be further sulfated by estrogen sulfotransferase 
enzyme (SULTE1) to give E1-S (inactive) 
4,18
.  




Figure 1  Estrogen biosynthesis from cholesterol E1-S, DHEA-S and Adiol-S.  
17β-HSD, 17β-hydroxysteroid dehydrogenase; 3β-HSD2, 3β-hydroxysteroid 
dehydrogenase/δ5→4-isomerase type 2; CYP19A1, aromatase; CYP11A1, Cholesterol 
desmolase; SULT, sulfotransferase; SULT1E1, estrogen sulfotransferase; STS, steroid 
sulfatase. 
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1.1.III Mechanism of action and physiological roles 
Estrogens exert their effects mainly by binding to the widely spread estrogen receptors (ER) 
19,20
. Currently, two subtypes of the ER are known: ERα and ERβ, having different isoforms 
with distinct tissue expression 
21
. ERs located in the cytoplasm are activated upon binding to 
E2, and then this complex is translocated into the nucleus after dimerization. In the nucleus, 
these activated ER dimers activate or repress target genes either directly or via binding to 
estrogen-responsive elements (EREs) and other DNA-bound transcription factors 
20
.  This 
pathway is known as the genomic signaling pathway of ERs (see figure 2).  
The physiological actions that result from ER activation are dependent on the organ where the 
ERs are located. Classical roles of estrogens in females are the development of secondary sex 
characters and reproduction. In the female reproductive system, E2 helps in stimulating the 
proliferation of the granulosa cells and the development of the follicles in the ovaries 
8,22
. The 
endometrial growth is stimulated by estrogen
23
, where the menstrual cycle is closely 
controlled by E2 and progesterone 
24
.  Additionally, E2 and progesterone are essential for the 
maintenance of the pregnancy and the fetal development 
25
. In the breast, the E2 stimulates 
the proliferation of the normal breast epithelium 
26,27
. In addition to its classical roles, E2 has 
a wide range of physiological roles in extra-gonadal systems 
20
. In the skeletal system, E2 
regulates the bone turnover by keeping balance between osteoblasts and the osteoclasts thus 
maintaining the bone density and preventing osteoporosis 
28,29
. Estrogens are also linked to 
the cardiovascular system, in which they have a cardio-protective effect through preventing 
the dysfunction of the myocytes in cases of ischemia and hypertension 
20,30
. Moreover, they 
exert a neuroprotective effect in the central nervous system by decreasing the inflammation in 
cases of stress and enhancing the memory 
31,32
.  
These diverse crucial physiological roles of estrogens in the female body, especially the 
proliferative anti-apoptotic effects are closely linked to the initiation and the progression of 
many diseases whenever a misbalance in the estrogen levels occurs 
33
. These diseases are 










 and osteoporosis 
43–45
 are frequent disorders that are strongly linked to estrogens in females. 




Figure 2  Genomic signaling pathway of estrogen receptor. ER, estrogen receptor; ERE, 
estrogen-responsive elements. Taken from Morselli et al. 
20
. 
1.2 Endometriosis  
1.2.I General aspects 
Endometriosis is a chronic, inflammatory, estrogen dependent disease. This gynecological 
disorder is characterized by the presence of endometrial glands and stroma in ectopic 
locations outside the uterine cavity, typically in the ovaries (ovarian endometriosis), the pelvic 
peritoneum (peritoneal endometriosis), the rectovaginal septum (deep endometriotic nodules 




Symptoms of endometriosis include chronic pelvic pain, dysmenorrhea, dyspareunia, irregular 
uterine bleeding, and in many cases infertility 
48,49
. Thus, endometriosis significantly impair 
the quality of life 
49,50
. Endometriosis is estimated to be affecting 10% of women in 
reproductive age, while the frequency rises to 50–60% within women suffering from pain 
51
. 
1.2.II Etiology and pathogenesis 
Although endometriosis is histologically a benign disorder, it has a malignant-like character 
as it can grow and develop in the surrounding tissues 
41
. Despite years of research, the 
etiology of this disease is not fully understood. However, there are two main theories that 
explain the pathogenesis of endometriosis. The first theory postulates that the endometriotic 
lesions originate from the uterine endometrium cells which reach the pelvic sites through 
retrograde menstruation through the fallopian tubes (retrograde theory) 
52,53
. The second 
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theory hypothesizes that the implants arise from non-endometrium origin, via transformation 
of the pelvic cells into endometriosis (metaplasia theory) 
54
. After the estrogen-sensitive 
endometriotic lesion is implanted on the surface of the peritoneum or ovaries, an 
inflammatory response is initiated which is accompanied by angiogenesis, adhesion to tissues, 
fibrosis, neuronal infiltration, and anatomical distortion resulting in pain and infertility 
48,51
. 
At the molecular level, there is a positive-feedback mechanism between E2 and prostaglandin 
type 2 (PGE2) productions in endometriotic tissues which induce both pain and further tissue 
growth (see figure 3) 
55
. The high levels of E2 in the endometriotic lesion on the one hand 
enhance the cellular proliferation and invasion of the endometriotic tissue (growth), and on 
the other induce cyclooxygenase type 2 (COX-2) 
56
. The induction of COX-2 results in 
increased biosynthesis of PGE2 which is the primary cause of inflammation and pain 
56
. PGE2 
stimulates the de novo androgen synthesis from cholesterol via enhancing the expression of 
the steroid acute regulatory (StAR) proteins which transfer the cholesterol from the cytoplasm 
to the mitochondria. Moreover, the expressions of CYP11A1, CYP17A1 and 3β-HSD2 are 
enhanced by PGE2 
57,58
. In the stromal cells of the endometriotic lesions, CYP19A1 -which is 
also induced by the PGE2- will aromatize A4 (from intracellular and extracellular origins) into 
E1. The latter is reduced by 17β-HSD1 which is overexpressed in the lesions to  give E2 
59
. 
This establishes a strong positive-feedback cycle that guarantees continuous biosynthesis of 
E2 and PGE2 in the endometriosis that results in continuous pain and tissue progression 
55
. 
1.2.III Current treatment interventions 
Current treatment interventions include surgical removal of the endometriotic lesions and/or 
medical therapy
51,60,61
. The surgical procedure, if possible at all, is only a temporary solution, 
since the endometriosis usually forms again after a while, even with subsequent drug therapy 
62
.  
As shown in the previous section, E2 has a vital role in progression of the disease. Therefore, 
all current hormonal treatment options aim at decreasing the circulating estrogens 
61
. This 
makes the drug treatment challenging due to the need of tolerable chronic regimen, since it 
aims at reduction of pain symptoms and progression without definitely curing the disease 
which may persist and even progress after the termination of the therapy 
63,64
.  
The first line therapy includes NSAIDs co-administered with either combined oral 
contraceptives or progestins which decrease the GnRH release from the hypothalamus. The 
second line therapy includes GnRH (ant)agonists or aromatase inhibitors 
51,61,63,64
.  
Generally, all the systemic endocrine therapies result in the suppression of the ovulation and 
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radical non-selective reduction of circulating estrogen levels leading to severe 




Danazol, an anterior pituitary suppressant that inhibits the production of gonadotropins, is 
applied when all other options are ineffective as it has severe hyper androgenic side effects 




Figure 3 Schematic representation of the positive-feedback cycle for E2 and PGE2 in 
endometriotic lesions. Revised from Bulun et al. 55. 
AA: arachidonic acid; A4, androsterone; COX-2, cyclooxegenase-2; CYP19A1, aromatase; 
E2, estradiol; PGE2: prostaglandin E2; StAR, steroidogenic acute regulatory protein.  
In summary, the existing medical treatments for endometriosis are not satisfying as they 
suffer from severe side effects which are linked to the suppression of the systemic estrogen 
levels. Thus, there is a medical need for a novel treatment approach for endometriosis that 
could efficiently regress it, without affecting the circulating E2 levels possibly offering a 
better safety profile and longer treatment window. 
Intriguingly, the intra-endometriotic tissue levels of E2 and E1 were found to be 8-10 folds 
higher than the corresponding serum estrogens 
65
. Moreover, the enzymes involved in the 
de novo estrogen biosynthesis were found to be overexpressed inside the lesions 
66,67
. These 
findings suggest that E2 inside the endometriotic tissue is actively controlled by the local 
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biosynthesis of estrogen 
68
. In the following section, the local biosynthesis of estrogen in 
endometriosis and the main enzymes involved will be discussed in detail. 
1.3 Local biosynthesis of estrogen in endometriosis  
1.3.I Sources of estrogen in endometriosis 
Endometriotic lesions are among the tissues that (over)express all the essential enzymes that 
enable the synthesis of estrogen via (see figure 4) 
69
:  
 The classical de novo steroidogenesis from cholesterol 
 The aromatase pathway from the circulating sulfated androgens 
 The sulfatase pathway from circulating E1-S  
For the de novo steroidogenesis, the StAR protein was found to be overexpressed in all types 
of endometriosis 
57
. Moreover, the mRNAs of CYP11A1, CYP17A1 and 3β-HSD2 were 
found to be overexpressed 
58,70
. This enhances the conversion of cholesterol into androgens 
(DHEA and A4). The endometriotic lesion has the ability to locally produce DHEA from its 
circulating sulfate conjugate as the STS enzyme was found to be overexpressed 
59,71
, and the 
relatively high STS activity was found to be correlated with the disease severity 
72
.  CYP19A1 
upregulation accelerates the conversion of the androgens into E1 (aromatase pathway) 
73–76
. 
E1 can also be synthesized by desulfatation of the circulating E1-S with STS enzyme 
(sulfatase pathway) 
71
. The final crucial step in E2 synthesis involves the reduction of E1 
produced from sulfatase pathway and aromatase pathway via the action of 17β-HSD1 enzyme 
which is also overexpressed in endometriosis 
59,66,70
. E2 deactivation into E1 in the 
endometriotic lesions is impaired as a consequence of reduced expression of 17β-HSD2 
66,77,78
.  
Obviously, STS and 17β-HSD1 play crucial roles in the elevation of E2 levels inside the 
endometriotic lesions. Consequently the inhibition of both enzymes can be considered a novel 
softer treatment approach for endometriosis. This approach on one hand does not completely 
cut the systemic biosynthesis of estrogen and on the other one it decreases significantly the 
peripheral biosynthesis of E2 in the endometriotic lesions as further demonstrated in the 
following chapters. 




Figure 4 Sources of estradiol in endometriosis. Revised from Huhtinen et al. 
69
. 
DHEA(-S), Dehydroepiandrosterone (sulfate); A4, androsterone; E1(-S), estrone (sulfate); E2, 
estradiol; StAR, steroidogenic acute regulatory protein 17β-HSD, 17β-hydroxysteroid 
dehydrogenase; 3β-HSD2, 3β-hydroxysteroid dehydrogenase/δ5→4-isomerase type 2; 
CYP19A1, aromatase; CYP11A1, Cholesterol desmolase; STS, steroid sulfatase. 
1.3.II Steroid sulfatases (STS) 
1.3.II.1 Sulfation and desulfatation of steroids 
The steroid sulfation and desulfatation are fundamental biological processes that regulate 
steroidogenesis in the human body 
79
. Two families of enzymes control them, the 
sulfotransferases (SULTs) and the sulfatases. The sulfation process involves the esterification 
of sulfate groups with alkyl (e.g. androgens and progestins) and aromatic rings (estrogens) 
80
. 
The sulfatase action involves the hydrolysis of the above mentioned sulfate group to 
regenerate the corresponding steroid 
81
. The sulfated steroids are highly water soluble and 
more abundant in the circulation compared to their precursors (see Table 1 taken from 
79
). 
They represent inactive forms of steroids that are considered as circulating reservoirs for the 
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Table 1. Approximate estimates of plasma concentrations of steroids and their sulfated 








DHEA 5-30 nmol/L 2-20 nmol/L 
DHEA-S 1-8 µmol/L 1-6 µmol/L 
A4 2-4 nmol/L not available 
A4-S 0.5-1 µmol/L not available 
E1 15-500 pmol/L 10-120 pmol/L 
E1-S 2-5 nmol/L 0.5-2 nmol/L 
E2 5-1000 pmol/L 5-80 pmol/L 
1.3.II.2 Biological characteristics of steroid sulfatase (STS) 
The sulfatase family of enzymes contains 3 main subtypes: aryl sulfatase A, B and C, in 
which subtype C is also known as steroid sulfatase (STS). The STS enzyme - not aryl 
sulfatases A or B- has been proven to be the primary enzyme to catalyze the hydrolysis of the 
sulfate ester bond from the steroid sulfates e.g. E1-S and DHEA-S (see figure 1) 
80
. Cells 
actively take up the hydrophilic circulating steroids (E1-S and DHEA-S) via organic anion 
transporting polypeptides (OATPs). Intracellularly, desulfatation is performed by STS, 
offering a crucial pathway in regenerating the active steroids (E1 and DHEA) from the 
predominant, circulating, inactive sulfated conjugates at steroidogenic and nonsteroidogenic 
tissues 
81
.   
STS (EC 3.1.6.2) is a membrane-bound protein with a molecular weight of 63 KDa, primarily 
localized to the endoplasmic reticulum 
81,83
. The native crystal structure of STS was published 
in 2003 
84
. The STS enzyme has a wide tissue distribution which includes placenta (the richest 




1.3.II.3 STS is a potential drug target 
The dysregulation of estrogen sulfation and desulfatation is associated with various EDDs 
79,85,86
. The local E1 production in hormone-dependent breast cancers is strongly linked to the 
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STS enzyme which shows higher activity and expression in the tumors 
87–90
. In endometriosis, 
the STS activity is elevated and so is its expression, to which the level of disease severity was 
correlated 
66,72,91
. The STS up regulation is also associated with other EDDs for e.g. 
endometrial carcinoma 
92,93
. Obviously, the ability to inhibit STS will serve as a highly 
desirable pharmacological approach for the treatment of many EDDs. 
1.3.III 17β-Hydroxysteroid dehydrogenase type 1 (17β-HSD1) 
1.3.III.1 17β-HSDs 
Hydroxysteroid dehydrogenases (HSDs) are a family of NADPH/NAD
+
-dependent 
oxidoreductase, which catalyze regio- and stereo-selective interconversion of ketones and 
their corresponding secondary alcohol 
94
. HSDs play crucial role in the endocrine as well as 
the intracrine mechanism of steroid hormone actions by transforming inactive hormones to 
their active analogues and vice versa 
95




17β-HSDs are a group of enzymes that catalyze the oxido/reduction reactions of the 
17β-hydroxy/keto group of androgens and estrogens backbone 
98
,  however, 17β-HSDs can 
also metabolize non-steroidal substrates 
99,100
. 15 mammalian 17β-HSDs have been 
discovered so far, 12 of them from the human tissues 
101
. They all belong to the short chain 
dehydrogenase/reductase (SDR) family with the exception of 17β-HSD5 which belongs to the 
aldo-keto reductase (AKR) family 
102
. Their nomenclature follows their chronological order 
of discovery, but later the international SDR-initiative proposed a new gene-based 
nomenclature 
103,104
. These enzymes have diverse tissue distributions, subcellular 
localizations, substrate affinities and catalytic preferences (oxidation or reduction).  
The reducing 17β-HSDs are mainly distributed among the steroidogenic tissues as shown in 
Table 2. Their primary physiological role is the synthesis of high levels of sex steroid 
hormones in the target tissues. Only 3 subtypes are involved in the biosynthesis of E2 from 




On the other hand, the oxidizing 17β-HSDs are widely spread in the whole body tissues and 
not confined to the gonadal tissues (Table 3). In principle, they play protective roles by the 
inactivation of the active steroids, leading to the decrease in levels of the active steroids in the 
target tissues. 17β-HSD2 is the most important steroid deactivator enzyme, which is down 
regulated or deficient in many pathophysiological disorders 
105,106
. 
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1.3.III.2 Biological characteristics of 17β-HSD1 
17β-HSD1 (EC1.1.1.62) was originally described by Langer and Engel in 1958 
107
.  It exists 
in a soluble homodimer form in the cytosol, having a molecular weight of 34.9 KDa for both 
dimers representing 327 amino acids 
108
. The crystal structure of 17β-HSD1 is known either 
in native form 
109
 or in complex with estrogenic ligands 
110
 and steroidal based inhibitors 
111
. 
It catalyzes the final step of the E2 biosynthesis, via reducing the weakly active E1 into the 
most potent estrogen E2 in the presence of NADPH as a cofactor (see Figure 1). In vivo, the 
enzyme is only a unidirectional reductive enzyme, however, the purified enzyme or cell 





. 17β-HSD1 can also reduce some forms of androgens e.g. DHEA, but only to a 
minor extent with 100 fold lower Km relative to E1, this androgen discrimination was 




1.3.III.3 17β-HSD1 is a potential drug target 
In EDDs, increased levels of expression for 17β-HSD1 are always observed on the mRNA 
and protein levels, accompanied by down regulation of 17β-HSD2 which ultimately leads to 




 breast cancer patients, the 17β-HSD1/17β-HSD2 
ratio is increased 
115–117
.  In endometriotic patients, the lesions are characterized by up 
regulation of 17β-HSD1 and decrease in the 17β-HSD2 expression when compared to normal 
endometrium tissue 
55,59,66,71
. In other EDDs, 17β-HSD1 is highly expressed, e.g. in ovarian 
cancer 
118
 and endometrial hyperplasia 
119
. Therapeutic approaches aiming to selectively 
inhibiting 17β-HSD1 enzyme without affecting the activity of 17β-HSD2, consequently, is 
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1.4 Novel treatment approaches for endometriosis  
1.4.I STS inhibitors 
The development of STS inhibitors as novel endocrine therapeutics for the treatment of EDDs 
has been initiated since the early 90s 
120
. The vast majority of these inhibitors are based on the 
aryl-O-sulfamate pharmacophore, and considered to be active-site directed, time and 
concentration dependent, irreversible inhibitors 
86,121
. It is assumed that the sulfamate group is 
covalently transferred to the post-translationally modified formyl-glycine moiety in the 
catalytic center of STS enzyme, irreversibly blocking its activity 
122
. 
Estrone-3-O-sulfamate (EMATE) and estradiol-3-O-sulfamate (E2MATE) were among the 
early highly potent (both in vitro and in vivo) STS inhibitors that were discovered (see figure 
5) 
123,124
. The steroidal backbone of EMATE and E2MATE, however, resulted in considerable 
estrogenic effect, which contradict with its principal therapeutic goal 
125
. Research has 
focused on the development of non-estrogenic and non-steroidal STS inhibitors, leading to the 
discovery of a new class of STS inhibitors based on the coumarin-sulfamate scaffold 
(Coumate, see figure 5) 
126
. STX64 (also known as 667 Coumate or Irosustat) was the most 
important candidate in the Coumate class with one digit nM IC50 values in both cell free and 
cellular assays 
127
. STX64 was orally very active (95% orally bioavailable) as it can evade the 




In vivo proof-of-principle studies of STS inhibitors in endometriosis have resulted in very 
promising outcomes. Collete et al have demonstrated that STS inhibition in a mouse 
endometriosis model led to significant regression in the development of the endometriotic 
lesion manifested by reduction in the size and weight of the lesion, without affecting the 
circulating estradiol levels 
151
. Similarly, in a phase I proof-of-principle clinical trial Pohl et 
al. found that irreversible STS inhibition in healthy premenopausal women has no significant 
effect on E2 plasma levels and was generally well-tolerated by the patients 
152
. Currently, 
phase II  clinical trials are in progress to evaluate the efficacy, safety , pharmacokinetics and 
pharmacodynamics of STS inhibitors in endometriotic patients 
85,153
.  
In other clinical trials STS inhibitors have been evaluated as therapeutics for various EDDs 
for e.g. breast cancer 
154–157
 and endometrial cancer 
158
. Generally, the drugs significantly 
decreased the STS activity in the tumor tissue while being well-tolerated by the patients.  




Figure 5 Structures of selected STS inhibitors 
1.4.II 17β-HSD1 inhibitors 
Salah et al. recently reviewed the efforts that have been dedicated over the last 35 years to 
develop 17β-HSD1 inhibitors that have acceptable selectivity over the counterpart enzyme 
17β-HSD2 
159
. Various steroidal and non-steroidal inhibitors were shown to be effective 
in vitro and in vivo.  
Steroidal inhibitors are usually derivatives of E1 or E2 that are substituted at one or more of 
the following positions: C2, C6, C15 and C16. EM-1745 (C16 derivative of E2, see figure 6) 
is one of the most potent steroidal 17β-HSD1 inhibitors that is considered a bifunctional 
hybrid inhibitor binding to both the substrate and the cofactor binding sites 
160
. An example 
for C15-substituted derivatives of E1 is compound A (see figure 6), which displayed strong 
and selective inhibition of 17β-HSD1 in cell-free and in cellular assays 
161,162
. Moreover, 
compound A showed strong reduction of E2 levels inside human endometriotic lesions in an 
ex vivo proof-of-principle study 
163
. FOR-6219 (exact structure not published) is a close 
structural analog of compound A, is currently in phase I clinical trials. In preclinical studies 
using non-human primates, it displayed the ability to act locally in the target tissues, without 
impacting systemic hormone levels 
164–166
.  
Non-steroidal inhibitors were generally showing several advantages when compared to the 
steroidal ones, such as low ER-affinity, good synthetic accessibility and drug-likeness. Our 
research group developed the best non-steroidal 17β-HSD1 inhibitors known in literature. In 
general, they belong to 3 chemical classes developed by pharmacophore models (see figure 
6): hydroxyphenyl naphthols (e.g. compound B) 
167
, bis(hydroxyphenyl) substituted arenes 
(e.g. compound C) 
168
 and the bicyclic substituted hydroxyphenyl methanones (e.g. compound 
D) 
169
 which is the most active class of non-steroidal 17β-HSD1 inhibitors. 
Thiophenepyrimidinone derivatives (e.g. compound E, see figure 6) were reported by other 
group to be potent 17β-HSD1 inhibitors 
170
. 




Figure 6 Structures and biological data of selected 17β-HSD1 inhibitors 
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1.4.III Designed multiple ligands 
As previously mentioned, STS and 17β-HSD1 activities are upregulated in endometriosis, 
playing crucial roles in controlling the intracellular E2 concentration inside the lesions 
69
. 
Moreover, it was shown that the administration of aromatase inhibitors in breast cancer 
patients led to increase in the levels of STS and 17β-HSD1, which re-elevated the local E2 
levels in these patients (estradiol escape) 
171
. This estradiol escape may also play a role in 
endometriosis if only one of the 2 enzymes (STS or 17β-HSD1) is blocked (e.g. increased 
STS expression to counteract the 17β-HSD1 inhibition and vice versa). As a result, the idea of 
inhibiting both STS and 17β-HSD1 is a promising novel approach to decrease the local 
estrogen biosynthesis in endometriotic lesions. The inhibition of additional pathways of E2 
production should ultimately lead to stronger reduction of lesion proliferation and pain, 
improving the patient’s quality of life. Moreover, this dual inhibition may block the estradiol 
escape that could happen in single therapeutic options avoiding potential relapse of the 
disease.  
This dual inhibition approach could be achieved either by a multi-targeting fashion by 
co-administration of selective STS inhibitor alongside with selective 17β-HSD1 inhibitor or 
via a designed multiple ligand (DML). In the latter approach, a single rationally designed 
molecule has a multi-target mode of action. There are strong scientific arguments in favor of a 
DML approach 
172
, as it has several advantages when compared to the multi-component 
therapy. In DML, complex pharmacokinetic/pharmacodynamics relationships that could occur 
in multi-component therapy are avoided, more patient compliance, easier and less expensive 
clinical development, no drug-drug interaction, and possible decrease in the overall dose 
when compared to co-administration of 2 selective inhibitors 
172
. A drawback in DML 
approach is the possible difficulty to adjust the ratio of activity at both targeted enzymes; 
however, this complicated design optimization is thought to be minimal in case of STS and 
17β-HSD1 inhibition as a result of the high structural similarity between the substrates of both 
targeted enzymes (E1-S and E1).  
In this context, STS inhibition has been successfully coupled to aromatase inhibition in a 
DML fashion by using a merged pharmacophore strategy, in which potent aromatase inhibitor 
was used to build in the aryl sulfamate pharmacophore (essential for STS activity) giving 
potent dual aromatase and STS  inhibitors (DASIs) see figure 7 
173
. In preclinical studies, 
STX681 was able to inhibit in vivo the growth of human breast cancer induced in a xenograft 
nude mouse model 
174
, however, it was shown that dual inhibition of STS and aromatase leads 
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to significant drop in the circulating estrogens which is accompanied by severe hypo-




Figure 7 Structure of selected DASI 
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2. Aim of the thesis 
In endometriotic patients, the inhibition of the local biosynthesis of estrogen is currently 
considered as a superior therapeutic option compared to the conventional endocrine therapy. 
The latter treatment option aims at stopping the ovulation leading to severe drop in the 
circulating estrogens accompanied by intolerable hypo-estrogenic side effects that limits the 
duration of the treatment to 6-9 months. On the other hand, targeting the peripheral E2 
synthesis is believed to decrease the progression of endometriosis without significantly 
affecting E2 plasma levels. 
STS and 17β-HSD1 are pivotal enzymes in the local biosynthesis of E2 in the endometriotic 
lesions, as they were found to be overexpressed in all types of endometriosis where the levels 
of STS expression were correlated to the severity of the disease. The most abundant form of 
estrogen in the circulation (E1-S) is transformed by STS in the lesion to E1 which is further 
activated by 17β-HSD1 into E2. This biosynthesis sequence is known as sulfatase pathway. 
E2 is the most potent activator of ER α/β that induces cell proliferation and pain inside the 
lesion. 17β-HSD2 activity inside the lesion is down regulated, weakening its beneficial action 
in deactivating E2 into E1. 
Recently, several proof-of-principle studies have shown the efficacy of STS or 17β-HSD1 
inhibition in endometriotic models. In endometriotic mouse model, STS inhibition led to 
significant decrease in the lesion size. Moreover, in a phase I clinical trial effective STS 
inhibition was found to have no significant effect on E2 levels in premenopausal women. On 
the other hand, 17β-HSD1 inhibition in an ex vivo proof-of-principle study normalized the 
increase in E2 synthesis in endometriotic tissue of patients. Additionally, no effect was 
detected on the systemic E2 level in preclinical studies using non-human primates treated with 
potent 17β-HSD1 inhibitor. Since the inhibition of STS or 17β-HSD1 was shown to be 
effective in endometriosis, it was thought that their dual inhibition would even be more 
effective. This dual inhibition could be achieved by multi-component therapy or designed 
multiple ligands (DML). The DML approach has several advantages, e.g. less complicated 
pharmacokinetic and pharmacodynamics relationship, easier clinical development, avoiding 
drug-drug interaction and good patient compliance. 
Accordingly, the aim of the thesis was to develop potent dual STS and 17β-HSD1 
inhibitors (DSHIs) that are suitable for in vivo application. These inhibitors could be used as 
scientific tools in proof-of-principle studies to elucidate the effect of the dual inhibition on the 
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local biosynthesis of E2 regulation in endometriotic models, and also serve as lead 
compounds for a novel therapeutic option for the treatment of endometriosis. 
To achieve this purpose, the first DSHIs class shall be rationally designed via a combined 
pharmacophore strategy (see figure 8), in which the aryl sulfamate moiety has to be 
introduced to potent drug-like 17β-HSD1 inhibitors. This should be followed by optimizing 
the position of the sulfamate group on the aryl system and evaluating the influence of adding 
different substituents on the biological activities of the synthesized compounds. The 
biological evaluation of the compounds should not be confined to their ability to inhibit STS 
and 17β-HSD1 in cell-free assays, but also their selectivity towards 17β-HSD2 should be 
evaluated. Furthermore, T47D cells (ER
+ 
breast cancer cell line) which express both enzymes 
can be used to evaluate the intracellular potency of the promising DSHIs to have insights 
regarding their cellular permeability. Generally, sulfamate group containing STS inhibitors 
are irreversible active-site directed inhibitors, so the mode of STS inhibition by the most 
promising DSHIs has to be examined using intracellular assay. Evaluation of the effect of 
estrogen stimulation on the growth of T47D cells using E1-S or E1 or E2 should be done in 
order to show that the cells can convert E1-S and E1 into E2 leading to stimulation in the 
proliferation. Then the effect of the DSHIs on E1-S and E1 stimulated growth shall be 
investigated to appraise the outcome of dual inhibition of STS and 17β-HSD1 on proliferation 
and hence the local estrogen biosynthesis. In this context, possible estrogenic activity, ER 
antagonism and cytotoxicity should also be evaluated for the most promising DSHIs. These 
results of investigations are presented in paper A chapter 3.1.I. 
In order to develop drug-like DSHIs that could be used as probes for in vivo 
proof-of-principle studies, a new class of DSHIs has to be developed after the former class 
showed poor metabolic stability (see figure 8). The same design approach shall be followed 
but using a new 17β-HSD1 inhibitor class with a promising metabolic stability profile. 
Initially, structural modifications have to be performed to optimize the sulfamate group 
position and the influence of added substituents on the biological activity of the compounds in 
cellular assays using T47D cells. The metabolic stabilities of the most interesting compounds 
have to be evaluated using human and mouse hepatic S9 fraction. Cytotoxicity of the 
metabolically stable compounds shall be evaluated using HEK293 and HepG2 cells. The latter 
is a hepatocellular carcinoma cell line that assesses the cytotoxicity of the compounds as well 
as their metabolites. The compounds with promising results in the aforementioned 
experiments will enter candidate selection phase, in which their pharmacokinetic (PK) 
profiles are examined in mice using subcutaneous route of application. Further PK 
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assessments have to be performed to the candidate with the best plasma levels profile to 
optimize the route of administration (per oral or subcutaneous), frequency of dosing (daily or 
every second day) as well as evaluating its effect on the CYP metabolizing enzymes (either by 
induction or inhibition) after multiple dosing regimens. This work is introduced in paper B 
chapter 3.1.II. 
 
Figure 8 Proposed design and overview of the molecules described in this thesis 
 




3.1 Dual STS and 17β-HSD1 inhibitors (DSHIs) 
3.1.I First Dual Inhibitors of Steroid Sulfatase (STS) and 
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3.1.II Potent Dual Inhibitors of Steroid Sulfatase (STS) and 
17β-Hydroxysteroid Dehydrogenase Type 1 (17β-HSD1) 
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Steroids play fundamental physiological roles as hormones. Generally, their action is 
mediated by intracellular nuclear receptors. Estrogens are among the major steroid hormones 
in humans, where 17β-estradiol (E2) is the most potent one. They exert proliferative and 
antiapoptotic effects that are beneficial to many organs 
1
. However, they are also involved in 
the onset and progression of many estrogen-dependent diseases (EDDs) such as endometriosis 
2,3
 and a high percentage of breast cancers 
4
.  
Endometriosis is a chronic gynecological disorder characterized by the presence of 
endometrial glands and stroma outside the uterine cavity, typically in the ovaries (ovarian 
endometriosis), the pelvic peritoneum (peritoneal endometriosis), the rectovaginal septum 
(deep endometriotic nodules of the rectovaginal septum) and other pelvic sites (fallopian 
tubes, vagina, cervix and uterosacral ligaments) 
5,6
. Symptoms of endometriosis include 
chronic pelvic pain, dysmenorrhea, dyspareunia, irregular uterine bleeding, and/or infertility 
7,8
 which significantly impair the quality of life of these women 
8,9
. Endometriosis is estimated 
to be affecting 10% of women in reproductive age, while the incidence rises to 50–60% 
within women suffering from pain 
10
. Current treatment interventions include surgical 
removal of the endometriotic lesions and/or medical therapy 
10,11
. The surgical procedure, if 
possible at all, is only a temporary solution, since the endometriosis usually forms again after 
a while, even with subsequent drug therapy. Drug treatment aims at reduction of symptoms 
(NSAIDs, combined oral contraceptives, progestins) or consists of systemic endocrine therapy 
with GnRH receptor desensitizers or aromatase inhibitors. Generally, all the systemic 
endocrine therapies result in a radical non-selective reduction of circulating estrogen levels 
leading to severe postmenopausal-like side effects (e.g. loss of bone mineral density) that 
restrict its use to 6-9 months 
10,11
. Danazol, an anterior pituitary suppressant that inhibits the 
production of gonadotropins, is applied when all other options are ineffective as it has severe 
hyperandrogenic side effects that limit its use 
10
. In summary, the existing medical treatments 
for endometriosis are not satisfying as they suffer from severe side effects which are linked to 
the suppression of the systemic estrogen levels. Thus, there is a medical need for a novel 
treatment approach for endometriosis, without strongly affecting the circulating E2 levels that 
could offer better safety profile and longer treatment window. 




Figure 1: The sulfatase pathway of local estrogen biosynthesis 
Interestingly, the progression of endometriosis is closely linked to the local biosynthesis of 
E2, i.e. the formation of active estrogen in the endometriotic tissue itself 
12
; especially via the 
sulfatase pathway (see figure 1) in which steroid sulfatase (STS) and 17β-hydroxysteroid 
dehydrogenase type 1 (17β-HSD1) play major roles and are found to be over-expressed in the 
endometriotic tissue, and the amount of STS over-expression correlates with the severity of 
the disease 
13,14
. In addition, the activity of 17β-hydroxysteroid dehydrogenase type 2 (17β-




Thus, STS and 17β-HSD1 are crucial enzymes for the local estrogen biosynthesis in 
endometriosis, so their inhibition offers a promising approach for the treatment of the disease. 
This concept is supported by various findings in the literature. In an ex vivo study, it was 
observed that a 17β-HSD1 inhibitor normalized the increased E2 synthesis in endometriotic 
tissue of endometriosis patients 
15
. 17β-HSD1 inhibition was found to reverse the estrogen-
induced endometrial hyperplasia in transgenic mice
 16
. On the other hand, the growth of 
endometriotic lesions was significantly reduced after the inhibition of STS in a mouse 
endometriosis model 
17
.  In a randomized phase I proof-of-principle clinical study it was 
found that the STS inhibition has no effect on the levels of systemic E2
 18
.  
In a recent work, our group introduced the idea of simultaneous inhibition of both STS and 
17β-HSD1 by a dual inhibitor (designed multiple ligand) as a novel approach for the 
treatment of EDDs e.g. endometriosis 
19
. Compound 1 (Table 1) had a promising profile, as it 
showed well-balanced intracellular activity against both target proteins, with IC50 values of 
about 20 nM and an irreversible mode of action towards STS. Moreover, it displayed good 
selectivity over 17β-HSD2 (SF=33). At 400 nM it efficiently reversed the E1-S and E1 
stimulated proliferation of T47D cells, showing neither cytotoxicity nor estrogen receptor 
interference.  
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Table 1: Inhibitory activities towards hSTS and h17β-HSD1 in cellular assays and metabolic 





















1  15.4 22.2 33 <5 <5 
2  n.i 7.9 24 <5 n.d 
3  n.i 2.9 563 38.1 19.1 
STX64 2.1 n.i n.a n.d n.d 
a
 Mean value of at least two independent experiments each conducted in triplicates using intact T47D cells, 








H]-E1 + E1 [50 nM];
 d
 SF 
(selectivity factor): IC50(17β-HSD2) / IC50(17β-HSD1); 
e
 Mean value of three independent experiments, standard 
deviation less than 15%; 
f
 t1/2: half-life; 
g
 Human liver S9 fraction;
 h
 Mouse liver S9 fraction;  ni: no inhibition (< 
10% inhibition at 1 µM); n.d: not determined; n.a: not applicable. 
Unfortunately, compound 1 turned out to be metabolically unstable when tested using human 
liver S9 fraction (see table 1). Further metabolic stability investigations showed that the core 
structure (without the sulfamate moiety) e.g. compound 2 (see table 1) is also metabolically 
unstable. However, compound 1 showed relative metabolic stability when evaluated against 
phase I only. This concludes that the metabolic instability of 1 is linked to phase II 
metabolism. This can be strongly attributed to the free hydroxyl function on the benzoyl 
moiety. This group additionally plays an essential role in the inhibition and selectivity profiles 
towards 17β-HSD1 enzyme 
20,21
. Consequently, any further structural optimization on 1 like 
the omission or protection of the hydroxy group to enhance the metabolic stability will 
negatively affect the activity and selectivity.  
Fortunately, another class of 17β-HSD1 inhibitors has been recently discovered by our group 
seems to be more promising from the metabolic stability point of view. This class is based on 
a hydroxy phenyl furan carboxamide scaffold. The most potent member in this class 
compound 3 (see Table 1) has exceptionally high selectivity over 17β-HSD2, and a very 
promising metabolic stability data. 
In this report we will describe the design, synthesis and biological evaluation (in vitro and 
in vivo) of a new class of dual STS and 17β-HSD1 inhibitors based on the newly discovered 
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17β-HSD1 class (see figure 2), which would probably bear a higher degree of metabolic 
stability and enhanced selectivity over the 17β-HSD2 enzyme compared to the thiophene 
based class (e.g. compound 1). This class could be potentially used for an in vivo proof a 
principle study in a mouse endometriosis model. 
Design 
The new class of dual STS and 17β-HSD1 inhibitors (DSHIs) was rationally designed based 
on the successful approach which has been previously implemented by our group and led to 
the development of the first DSHI class (e.g. 1) 
19
.  The structure activity relationship of the 
recently discovered furan carboxamide 17β-HSD1 inhibitors (e.g. compound 3) deploys that 
the substituents of ring A (Figure 2) are the main driving factors for the enhanced 17β-HSD1 
inhibitory activity, metabolic stability and selectivity over 17β-HSD2. On the other hand, the 
SAR of ring B reveals that it could bear structural modifications without losing the 17β-HSD1 
inhibitory activity. Therefore, the essential feature of STS inhibition (sulfamate group) was 
combined to ring B of compound 3, resulting in a hybrid structure that appropriately include 
the essential features for the simultaneous inhibition of both STS and 17β-HSD1. Additional 
substituents were inserted to enhance the inhibitory profile of the DSHIs. The general 
structure of the potential DSHIs (compounds 4-12) are shown in Figure 2. 
Chemistry 
The synthesis of compounds 4-12 was achieved in seven steps for each compound (scheme 1). 
5-Bromofuran-2-carbonic acid chloride was obtained from the corresponding carboxylic acid 
by reaction with SOCl2 according to method A. It was subsequently reacted with the 
corresponding aniline according to method B yielding intermediates 4a-12a. N-methylation 
was attained by the reaction with methyl iodide according to method C affording 
intermediates 4b-12b. The latter was subjected to ether cleavage (method D) with 
BF3.S(CH3)2 to achieve the phenols 4c-12c. Subsequently, Suzuki coupling reaction (method 
E) with (4-methoxy-3,5-dimethylphenyl)boronic acid gave intermediates 4d-12d. 
Sulfamoylation (method F) was achieved by the reaction with freshly prepared sulfamoyl 
chloride (method G) in DMA to obtain intermediates 4e-12e. Ether cleavage (method D) with 
BF3.S(CH3)2 in dichloromethane gave the final compounds 4-12. 




Cpd R1 R2 
Position  
-OSO2NH2 
Cpd R1 R2 
Position  
-OSO2NH2 
4 Me H 3 9 H H 5 
5 Me H 4 10 H 5-F 4 
6 Me H 5 11 H 5-Cl 4 
7 Me H 6 12 Me 5-Cl 4 
8 H H 4     
Figure 2. Structure of compounds STX64, 3-12 and the general structure of designed dual 
STS and 17β-HSD1 inhibitors (DSHIs).  




Scheme 1:  a) method A, SOCl2, DMF cat., toluene, reflux 4h. b) method B, Et3N, CH2Cl2, 
room temperature, overnight. c) method C, NaH, DMF, MeI, 0°C to rt, 0.5h. d) method D, 
BF3.S(CH3)2, CH2Cl2, -20°C to rt, overnight. e) method E, Cs2CO3, Pd(PPh3)4, DME/water 
(1:1), reflux, 4h. f) method F, DMA, sulfamoyl chloride, rt, overnight. 
In vitro biological results and discussion 
Intracellular inhibition of human STS and 17β-HSD1 
Cellular inhibitory potencies of all final compounds were evaluated using intact human breast 
cancer cells (T47D) expressing both STS and 17β-HSD1. 4-12 were pre-incubated with the 
cells for 1 hour. Subsequently, the corresponding radiolabeled substrate (E1-S or E1) of STS 
or 17β-HSD1 was added 
19
. After incubation (24 h in case of STS and 40 minutes in case of 
17β-HSD1), the radiolabeled estrogens were separated and quantified using HPLC coupled to 
a radio detector. Inhibitory activities are expressed as IC50 values (Table 2). 
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In our initial attempts to develop a new DSHI class based on compound 3, we synthesized 
compounds 4-7 to optimize the position of the sulfamate moiety on the phenyl ring of the lead 
compound 3 (ring B in figure 2). All the 4 compounds showed high intracellular 17β-HSD1 
inhibitory activity, where compounds 5 and 6 showed the most potent IC50 values of this new 
class (10.7 nM and 3.2 nM, respectively) compared to the lead compound 3 (2.9 nM). 
Moreover, compounds 5 and 6 also showed intracellular inhibition of STS with IC50 values in 
the range of 400 nM . 














1 - - - 15.4 22.2 
3 - Me H ni 2.9 
4  3 Me H ni 58.2 
5  4 Me H 400.3 10.7 
6  5 Me H 448.1 3.2 
7  6 Me H ni 137.3 
8  4 H H 148.5 106.5 
9  5 H H 92.5 78.5 
10  4 H 5-F 83.2 138.5 
11  4 H 5-Cl 38.3 87.5 
12  4 Me 5-Cl 76.1 53.3 
a
 Mean value of at least two independent experiments each conducted in triplicates using intact T47D cells, 








H]-E1 + E1 [50 nM]; ni: no 
inhibition (< 10% inhibition at 1 µM). 
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The STS inhibitory activity of compounds 5 and 6 was aimed to be enhanced. For this 
purpose the removal of the methyl group on ring B was thought to be beneficial as it was 
previously found in other compound classes that alkyl substituents on the sulfamate ring lead 
to a decrease of STS inhibition 
22-24
. In agreement with this, compounds 8 and 9 showed 
higher potency against 
STS compared to their methylated analogues (Table 2). On the other hand, the removal of the 
methyl function dramatically decreased the 17β-HSD1 inhibitory activities by a factor of 10 to 
25. 
The presence of an electron withdrawing group e.g. (F or Cl) was found in several occasions 
to enhance the STS inhibition which can be attributed to the enhanced sulfamoyl transfer 
potential resulting from the increased leaving group ability of the corresponding phenol 
precursors of sulfamates 
19,24,25
. Therefore, compounds 10 and 11 were synthesized which are 
the fluorinated and the chlorinated form of compound 8, respectively. Compound 10 indeed 
showed better STS inhibition compared to 8, however this was accompanied by a slight 
decrease in the 17β-HSD1 inhibition.  Compound 11 turned out to be the most potent STS 
inhibitor of this class with an IC50 value of 38.3 nM, showing similarly potent 17β-HSD1 
inhibition compared to compound 8. 
At that point it was clear that the presence of the methyl group at position R1 (Table 2) 
revealed the highest 17β-HSD1 activity (compounds 5 and 6) and the presence of the 5-chloro 
(compound 11) resulted in the most potent STS inhibitor of this chemical class. Compound 12 
was then rationally designed to combine both features aiming to achieve good STS and 17β-
HSD1 inhibitory activity. Indeed, compound 12 showed strongly enhanced STS inhibitory 
activity compared to its non-chlorinated analog 5 (IC50 76.1 nM vs 400.3 nM) and also a 
stronger inhibition of 17β-HSD1 compared to its demethylated form 11 (IC50 53.3 vs 87.5). 
From the aforementioned results, the promising compounds that show dual inhibitory activity 
against both target enzymes (promising DSHIs) could be categorized into 2 groups:  
 The first group shows balanced intracellular activities between the 2 target enzymes 
(compounds 8-12) 
 The second group consists of highly potent 17β-HSD1 inhibitors with moderate STS 
inhibitory activity (compounds 5 and 6).  
Selectivity for 17β-HSD1 over 17β-HSD2 
The beneficial role of 17β-HSD2 in lowering the intracellular levels of E2 makes its inhibition 
unfavorable. However, this is a challenging characteristic in 17β-HSD1 inhibitors as the two 
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enzymes have relatively similar substrates (E1 and E2). Thus, all the promising DSHIs were 
evaluated for their selectivity for 17β-HSD1 over its counter partner enzyme 17β-HSD2 
(results are shown in Table 3). Inhibition of 17β-HSD1 and 17β-HSD2 was evaluated using 
the respective radiolabeled steroid (E1 or E2) and human placental 17β-HSD1 (cytosolic 
fraction) or 17β-HSD2 (microsomal fraction).  
Compound 12 was the only compound from the first group of the promising DSHIs to show  
significantly better selectivity for 17β-HSD1 over 17β-HSD2 compared to our former lead 
DSHI compound 1 (SF= 110 vs 33). Other candidates from this group, either showed weaker 
selectivity e.g. 8, 10 and 11, or they showed no advantage over compound 1 (compound 9).  
The second group of the promising DSHIs displayed the highest selectivity for 17β-HSD1 
over 17β-HSD2 of any other DSHI reported so far. Compounds 5 and 6 showed selectivity 
factors of 145 and 280, respectively.  
Table 3: Inhibitory activities of compounds 1, 3, 5, 6 and 8-12 towards h17β-HSD1 and 2 in 














1 - - - 1.1 36.1 33 
3 - Me H 5.6 3155.2 563 
5  4 Me H 42.7 6158.2 145 
6  5 Me H 15.5 4347 280 
8  4 H H 425.2 7644.6 18 
9  5 H H 175.2 6352.8 36 
10  4 H 5-F 496.7 3196.6 6 
11  4 H 5-Cl 405.7 2396.4 6 
12  4 Me 5-Cl 67.6 7420.2 110 
a
 Mean value of at least two independent experiments each conducted in duplicates , standard deviation less than 
15%; 
b
 Human placenta, cytosolic fraction, substrate [
3
H]-E1 + E1 [500 nM], cofactor NADH [0.5 mM]; 
c
 
Human placenta, microsomal fraction, substrate [
3





(selectivity factor): IC50(17β-HSD2) / IC50(17β-HSD1).  
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The selectivity towards 17β-HSD1 (over 17β-HSD2) clearly narrowed down the candidate 
selection for in vivo evaluation to compounds 5, 6 and 12. On one hand, compounds 5 and 6 
are highly potent 17β-HSD1 inhibitors with moderate inhibitory activity towards STS, but 
taken that they might be irreversible STS inhibitors (which seems to be a common 
characteristic of sulfamate containing STS inhibitors 
24,26
 e.g. compound 1 and STX64) this 
could compensate the unbalanced dual inhibition. On the other one, compound 12 is 
considered an ideal classic dual inhibitor as it displayed balanced action towards both targets. 
Therefore, all further biological evaluations will be performed on these compounds (5, 6 and 
12). 
Irreversible inhibition of human STS 
The irreversible mode of inhibition was examined for compounds 5, 6 and 12 as previously 
reported 
19
. T47D cells were pre-incubated with the compounds as described for cellular 
assays. After the removal of the compounds by extensive washing with PBS, E1-S was 
incubated with the cells for 24 h and then the STS activity was evaluated. In all cases, the IC50 
values of this assay were similar to those acquired from the normal assay for intracellular STS 
inhibition, demonstrating irreversible inhibition of the STS enzyme by compounds 5, 6 and 12  
(Table 4).  














1 - - 15.4 16.4 
5  4 H 400.3 421.8 
6  5 H 448.1 454.4 
12  4 5-Cl 76.1 78.8 
a
 Mean value of at least two independent experiments each conducted in triplicates using intact T47D cells, 




H]-E1-S + E1-S [5 nM]. 
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In vitro metabolic stability studies 
The metabolic stability is an important parameter to achieve low in vivo clearance of the 
drugs, which helps in reaching sufficient plasma concentrations for an adequate time interval 
after the in vivo application of the compounds. Thus, the in vitro metabolic half-lives of 
compounds 5, 6 and 12 were determined using human and mouse hepatic S9 fractions. The 
half-lives and the intrinsic body clearances are shown in Table 5. It is noted that compound 5 
showed the highest metabolic stabilities in both human and mouse liver S9 fraction detected 
so far for any DSHI or17β-HSD1 inhibitor developed by our group. In human  hepatic S9 
fraction, t1/2= 85.2 min and intrinsic clearance of 8.2 μL/min/mg protein, while in mouse 
hepatic S9 fraction it had a t1/2 of 52.1 min. Compound 12 showed a similar metabolic 
stability profile compared to lead compound 3. Compound 6 was the least metabolically 
stable candidate in human hepatic S9 fraction, but it had a better stability than compound 12 
in mouse hepatic S9 fraction. Obviously, the new compounds pose better metabolic stability 
than the previously discovered DSHI (exemplified by compound 1). 
In vitro toxicity evaluation 
Cytotoxicity 
Compounds 5, 6 and 12 were evaluated in cellular MTT cytotoxicity assay using HEK293 
cells over 72 h. No effect on cell viability (LC20 values) was observed up to 31 µM, 38µM and 
27 µM for compounds 5, 6 and 12, respectively. As the Derek-Nexus software (an expert 
knowledge-based software which gives predictions for a variety of toxicological endpoints) 
provided a plausible hepatotoxicity alert for compounds 5, 6 and 12, the toxicity of the 
compounds and their metabolites were also evaluated using the hepatocellular carcinoma 
HepG2 cell line in cellular MTT cytotoxicity assay over 48 h. The LC20 values were 23 µM, 
28µM and 31 µM for compounds 5, 6 and 12, respectively. These values show acceptable 
safety profiles for these compounds. 
Aryl hydrocarbon receptor activation 
The aryl hydrocarbon receptor (AhR) assay evaluates the activation of the AhR which can 
lead to carcinogenicity. AhR activation is an initial event that triggers several toxic 
biochemical responses, including the induction of CYP1A1 and CYP1A2. These enzymes are 
responsible for the metabolic activation of many promutagens for e.g. polynuclear aromatic 
hydrocarbons to carcinogenic arene oxides 
27
. At a concentration of 3.16 µM, compounds 5, 6 
and 12 did not show any activation of the AhR in HepG2 cells.  
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1 - - <5 <5 n.a 
3 - H 38.1 19.1 18.2 
5  4 H 85.2 56.1 8.2 
6  5 H 19.3 28.5 35.9 
12  4 5-Cl 35.6 22.5 19.4 
7-Hydroxycoumarin
e 
- - 5.2 7.4 138.6 
Testosterone
e
 - - 9.3 24.4 74.5 
a
 Mean value of three independent experiments, standard deviation less than 15%; 
b
 t1/2: half-life; 
c
 Human liver 
S9 fraction; 
d
 Mouse liver S9 fraction; 
e
 Reference compounds for the metabolic stability assays. 
In vivo evaluation of plasma concentration 
Single dose pharmacokinetic studies in mice 
On the basis of the in vitro results, compounds 5, 6 and 12 are considered to be possible 
candidates for a proof-of-principle study in a xenograft mouse model for endometriosis. Thus, 
their PK profiles after administration to female C57BI/6 mice were investigated. The plasma 
concentrations of the compounds were evaluated after subcutaneous administration of a single 
dose (50 mg/kg body weight, n=3) as a suspension in 0.5%gelatin|5%mannitol in water. 
Plasma samples were collected and concentrations of the compounds were analyzed using LC 
MS/MS.  
As shown in figure 3a, the plasma concentration of compound 5 was always above the in vitro 
cellular IC80 values for both target enzymes (STS and 17β-HSD1) even after 24 h, with a total 
area under the curve (AUC) of 11619 ng.h/mL. Compound 6 showed plasma concentrations 
exceeding the cellular IC80 of 17β-HSD1 all over the duration of the experiment (figure 3b). 
However, these plasma concentrations were not sufficient to reach the cellular STS IC80 of the 
compound. The compound showed an AUC of 1923 ng.h/mL which is much lower than that 
of compound 5. Similarly, compound 12 showed a low AUC value (1883 ng.h/mL) with  




Figure 3. Mean profile (±SD) of plasma concentration [nM] in C57B1/6 mice vs time after 
subcutaneous (50 mg/kg) application of compounds 5 (a), 6 (b) and 12 (c) in single dosing 
experiments (n=3). Dotted lines represent the cellular IC80 values of STS and 17β-HSD1 
values for the corresponding compound. 
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plasma levels above the cellular IC80 of both target enzymes (STS and 17β-HSD1) up to 7 h as 
shown in figure 3c. The fact that compound 5 demonstrated higher plasma concentrations 
than 6 and 12 could be a result of various parameters, among them its higher metabolic 
stability (shown in table 5), and its physiochemical properties in which the calculated log D 
(pH=7.4) and the aqueous solubility of compound 5 is better than compounds 6 and 12 
(values shown in table 6).  Based on these promising data for compound 5, an additional 
pharmacokinetic study was performed with per oral application of a single dose using the 
same dose and vehicle.   













5  542 24 2.20 40-60 µM 
6  711 10 2.68 20-40 µM 
12  156 213 2.75 20-40 µM 
a
 Mean value of at least two independent experiments each conducted in triplicates using intact T47D cells, 








H]-E1 + E1 [50 nM]; 
d 
Log 
D of the cpd, determined by ACD/Labs software; 
e 
Aqueous solubility of the compounds determined in PBS 
(Phosphate-buffered saline) with 1% DMSO. 
As shown in figure 4, in the first eight hours after application there is no significant difference 
between the plasma concentrations of compound 5 after either subcutaneous or per oral 
administration. The main difference is observed after eight hours in which the plasma level in 
case of the oral route declined continuously reaching very low levels that were not sufficient 
for the inhibition of any of the target enzymes at 24 h. On the other hand, the subcutaneous 
route offered steady plasma levels with sufficient concentrations for fulfilling the IC80 of both 
target enzymes up to 24 h. This can be a result of the extended release of the drug from the 
suspension formulation. Moreover, compound 5 showed poor oral bioavailability of about 
1.5% (see Supporting information). Therefore, the subcutaneous route was selected for 
multiple dose pharmacokinetic studies. 




Figure 4. Mean profile (±SD) of plasma concentration [nM] in C57B1/6 mice vs time after oral (50 
mg/kg) and subcutaneous (50 mg/kg) application of compounds 5 in single dosing experiments (n=3). 
Dotted lines represent the cellular IC80 values of STS and 17β-HSD1 values for compound 5. 
Multiple dose pharmacokinetic studies in mice 
In order to develop a dosage regimen that could be used for compound 5 in a proof of 
principle study, the frequency of the subcutaneous drug administration was aimed to be 
optimized. Compound 5 was administered either every day or every second day 
subcutaneously (50 mg/Kg) for 5 days as a suspension in 0.5%gelatin|5%mannitol in water. 
Plasma samples were collected at 2 h and 24 h post-dosing (in addition after 48 h in case of 
every second day regimen). As shown in figure 5, the plasma concentrations of 5 in the daily 
dose regimen were -as expected- always above the cellular IC80 values of both target 
enzymes. Interestingly, the compound has a steady state behavior from the third dose in which 
the plasma concentration fluctuate between constant Cmax which is measured 2 h post dosing 
(2350-2450 nM) and Cmin measured 24 h post dosing (800-900 nM). This shows that the 
pharmacokinetic profile of compound 5 is not altered after taking multiple doses. This comes 
in accordance to the principle of superposition, which assumes that early doses do not affect 
the pharmacokinetics of subsequent doses
 28
. The constancy of the pharmacokinetics suggests 
that compound 5 does not alter the metabolizing enzymes, neither by inhibition nor induction. 
In the every second day dose regimen, the plasma levels at 48 h post dosing were sufficient 
for the 17β-HSD1 inhibition but below the levels needed for the STS inhibition, however, if 
we take into consideration the irreversible mode of inhibition of the STS enzyme, these 
amounts might be sufficient. Obviously, the subcutaneous single daily dose regimen 
(50mg/kg) of compound 5 could be used in an in vivo xenograft model for endometriosis 
offering an easy dosing frequency with a steady state plasma levels.   




Figure 5. Mean profile (±SD) of plasma concentration [nM] in C57B1/6 mice vs time after 
subcutaneous (50 mg/kg) application of compounds 5 in multiple dosing experiments (n=3). Arrows 
represent the administration of compound 5. Dotted lines represent the cellular IC80 values of STS and 
17β-HSD1 values for compound 5. 
Conclusion 
Dual inhibition of STS and 17β-HSD1 is considered a novel promising therapeutic approach 
for EDDs especially endometriosis. The recently developed dual inhibitor 1 has a very 
promising well-balanced inhibitory profile for both target enzymes. However, it is not 
considered a suitable candidate to be evaluated in a proof-of-principle endometriosis model as 
it was found to be metabolically unstable. The aim of the current work was to develop potent 
dual inhibitors of STS and 17β-HSD1 with increased metabolic stability that can be used for 
in vivo proof-of-principle studies. A designed multiple ligand approach using the merged 
pharmacophore strategy -that was previously reported 
19
- was successfully applied. A newly 
developed metabolically stable 17β-HSD1 inhibitor class (e.g. compound 3) was used to build 
the aryl sulfamate pharmacophore which is essential for STS inhibition. In a first step, the 
position of the sulfamate moiety on the benzoyl ring (ring B, see figure 2) was aimed to be 
optimized, resulting in compounds 5 and 6 which were the first dual inhibitors of this class. In 
cellular assays, they showed weaker inhibition of STS compared to compound 1, but stronger 
17β-HSD1 inhibition, higher selectivity over 17β-HSD2 and enhanced metabolic stability 
using human and mouse S9 fractions. The decreased inhibitory potency towards STS led to 
the synthesis of compounds 8-12 which aimed at the removal of the methyl group and/or the 
addition of electron withdrawing groups while maintaining the optimum position of the 
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sulfamate moiety. In deed these modifications enhanced the STS inhibitory activity but on the 
cost of 17β-HSD1 inhibitory activity and selectivity over 17β-HSD2 compared to compounds 
5 and 6. Compound 12 showed exceptionally high selectivity over 17β-HSD2. Moreover, the 
compound has displayed good metabolic stability in human and mouse S9 fractions. 
Compounds 5, 6 and 12 showed irreversible STS inhibition like other sulfamate-containing 
STS inhibitors. They also displayed acceptable safety profiles in cytotoxicity assays using 
HEK293 and HepG2 cell lines. The PK profiles of these compounds were evaluated in mice 
after single subcutaneous application. Compound 5 showed a 6-7 fold higher AUC values 
compared to 6 and 12, maintaining the plasma levels above the cellular IC80 of both target 
enzymes up to 24 h post dosing. The oral application of compound 5 resulted in plasma 
concentrations sufficient for strong inhibition of both target enzymes up to 8 h post dosing. In 
a multiple dose PK study, the plasma levels of compound 5 were sufficiently high for strong 
inhibition of 17β-HSD1 even after 48 h post dosing. However, these plasma levels were not 
sufficient for STS inhibition after 24 h post dosing. In this PK study, compound 5 plasma 
levels showed steady state behavior up to 6 days after first dose, showing no signs of 
alteration of the CYP metabolizing enzymes neither by inhibition nor by induction. 
In summary, compound 5 was found to be a potent dual inhibitor of STS and 17β-HSD1 with 
a suitable pharmacokinetic profile for an in vivo proof-of-principle study in a xenograft 
mouse endometriosis model. 
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3.2 Selective inhibitors of 17β-HSD1, 2 and 14 
3.2.I Treatment of estrogen-dependent diseases: Design, 
synthesis and profiling of a selective 17β-HSD1 inhibitor 
with sub-nanomolar IC50 for a proof-of-principle study 
Ahmed S. Abdelsamie, Chris J. van Koppen, Emmanuel Bey, Mohamed Salah, 
Carsten Borger, Lorenz Siebenbürger, Matthias W. Laschke, Michael D. Menger, 
Martin Frotscher 
 
Reprinted with permission Eur. J. Med. Chem. 2017, 127, 944–957. 
DOI: 10.1016/j.ejmech.2016.11.004 
Copyright (2017) ELSEVIER 
Publication C  
Contribution Report 
The author contributed to the design, synthesis and characterization of the compounds. He 
further contributed in the biological assays and the interpretation of the results.  
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3.2.II Targeted Endocrine Therapy: Design, Synthesis, and 
Proof-of-Principle of 17β-Hydroxysteroid Dehydrogenase 
Type 2 Inhibitors in Bone Fracture Healing 
Ahmed S. Abdelsamie, Steven Herath, Yannik Biskupek, Carsten Borger, Lorenz 
Siebenburger, Mohamed Salah,  Claudia Scheuer, Sandrine Marchais-Oberwinkler, Martin 
Frotscher, Tim Pohlemann, Michael D. Menger, Rolf W. Hartmann, Matthias W. Laschke, 
and Chris J. van Koppen 
 
Reprinted with permission J. Med. Chem. 2019, 62 (3), 1362–1372. 
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Copyright (2019) American Chemical Society 
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Contribution Report 
The author contributed significantly to the in vitro biological evaluation of the synthesized 
compounds. Furthermore, He contributed in the interpretation of the results and writing the 
manuscript. 
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3.2.III First Structure Activity Relationship of 
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Inhibitors and Crystal Structures in Complex with the 
Enzyme 
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3.2.IV Inhibitors of 17β-hydroxysteroid dehydrogenase type 1, 2 
and 14: Structures, biological activities and future 
challenges 
Mohamed Salah*, Ahmed S. Abdelsamie*, and Martin Frotscher 
 
Reprinted with permission Mol. Cell. Endocrinol. 2018. 
DOI: 10.1016/j.mce.2018.10.001 
Copyright (2018) ELSEVIER 
* These authors contributed equally 
Publication F 
Contribution Report 
The author collected the data for all 17β-HSD1 inhibitors from literature, and significantly 
contributed in the selection of the represented candidates of each class. He wrote this part in 
the review and contributed in the other parts. 
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4. Final Discussion 
The superior goal of this thesis was the development of the first dual inhibitors of STS and 
17β-HSD1 (DSHIs) that can be used for in vivo proof-of-principle studies using human 
endometriotic tissues. As previously mentioned in the introduction, STS and 17β-HSD1 
inhibitions play crucial roles in decreasing the local biosynthesis of estrogen inside the 
endometriosis without affecting the circulating ovarian estrogen in premenopausal women. 
This offers a novel therapeutic option for the treatment of endometriosis without the common 
hypo-estrogenic side effects that characterize existing treatment options. In this thesis, two 
different chemical classes of DSHIs have been introduced. The approach leading to their 
design, their biological activities and metabolic stabilities will be discussed and compared -
whenever possible- in the following chapters. This is followed by a discussion of the 
pharmacokinetic profiles of the most interesting candidates of the metabolically stable class. 
For the sake of clarity, compounds mentioned in this section are identified by a capital letter 
which stands for the respective paper, followed by an arabic number referring to the 
compound numbering in the respective paper. 
4.1 Design rationale of DSHIs 
A rational design approach was pursed to imbue STS and 17β-HSD1 dual inhibitory activity 
by taking a potent 17β-HSD1 inhibitor and building the aryl sulfamate pharmacophore which 
is essential for STS inhibition. This designed multiple ligand approach shall be facilitated by 
the fact that both target enzymes have very similar natural ligands, E1-S and E1. This tactic 
was applied successfully on two 17β-HSD1 inhibitor classes (see figure 9). In the first class of 
DSHIs, compound C15 a potent 17β-HSD1 inhibitor was used as a starting point for building 
the STS pharmacophore. Extensive structure activity relationship (SAR) studies have been 
performed on this 17β-HSD1 inhibitor class which is presented in chapter 3.2.I. These SAR 
studies show that the appropriate place to introduce modifications without significantly 
affecting the 17β-HSD1 inhibitory activity is ring A as the other part of the scaffold is 
essential for activity (see figure 9). Therefore, our strategy was to introduce the 
aryl-O-sulfamate to ring A (results of the first class is presented in chapter 3.1.I). Similarly, 
the second class of the DSHIs (results shown in chapter 3.1.II) was developed, in which 
compound B3 was our starting point for the insertion of the sulfamate group on the 
appropriate ring; in this case it was ring B as a consequence of an existing SAR studies. 
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4.2 Biological profiling of DSHIs 
In general, the introduction of the sulfamate group maintained the 17β-HSD1 inhibitory 
activity as anticipated. On the other hand, the STS inhibitory activity was found to be closely 
linked to the position of the sulfamate on the phenyl ring and the substituents on this ring. The 
optimization of the sulfamate position on the aryl ring revealed that this group should be in 
the meta or para position to the attachment point of the ring (position 3 and 4 on ring A and B 
in figure 9). In contrast, compounds with ortho sulfamate group (position 2 on ring A and B in 
figure 9) showed no STS inhibition e.g. compounds A2 and B7. In the first class of DSHIs, 
the presence of an additional group on the phenyl ring was essential for STS inhibitory 
activity. This was manifested by compounds that lack additional substituents on ring A (A1 
and A3), showing no STS inhibition. On the other hand, the presence of electron withdrawing 
groups (Cl or F) on the aryl system led to the most potent STS inhibition manifested in both 
classes of inhibitors. This is probably attributed to the enhanced sulfamoyl transfer potential 
resulting from the increased leaving group ability of the corresponding phenol precursors of 
the sulfamates. The first class of DSHIs (A5, A6, A8 and A9) displayed a 3-20 fold higher 
inhibitory potency against STS when compared to the second class (B10, B11 and B12). In 
the second class, the presence of the methyl group in compounds B5 and B6 resulted in a 
10-25 fold increase in the 17β-HSD1 inhibitory activity while maintaining moderate STS 
inhibitory activity.  
17β-HSD2 has a very beneficial protective role in EDDs by lowering the intracellular levels 
of E2, making its inhibition undesirable. However, this is a challenging characteristic in 
17β-HSD1 inhibitors as the two enzymes have very similar substrates, namely E1 and E2. 
Therefore, the selectivity over 17β-HSD2 of the above mentioned dual inhibitors was 
evaluated. Generally, the second class displayed higher selectivity over 17β-HSD2 than the 
first class. The most selective compounds of the second DSHIs class (B5, B6 and B12) 
showed a 3-7 fold higher selectivity factors in the range of 110-280, compared to A9 the only 
selective compound in the first DSHIs class (SF=33). 
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Figure 9 Design rational of DSHIs classes, with the biological data of the most potent 
representatives  
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The intracellular inhibitory activity of the most potent candidates from both DSHIs classes 
using T47D cells which express both target enzymes revealed that the two classes possess 
good cellular permeability shown by their potent intracellular inhibition for both enzymes. 
The STS enzyme was found to be irreversibly inhibited by the developed DSHIs of both 
classes, similar to other sulfamate-containing STS inhibitors. 
The biological profiles of the developed DSHIs show that A9 is the most potent DSHIs from 
the first class of compounds that poses selectivity over 17β-HSD2. On the other hand, B5, B6 
and B12 are the most potent and selective candidates of the second class of compounds (see 
figure 9). 
4.3 Effect of DSHIs on estrogen-stimulated growth 
After having in hands inhibitors with promising in vitro inhibitory activities towards STS and 
17β-HSD1 even in cellular assays, it was of high interest to evaluate the impact of this 
inhibition in a more complex assay system. Thus, the effect of A9 (DSHIs) on E1-S and E1 
stimulated growth of T47D cells (ER
+
 breast cancer cells) was evaluated in comparison to 
single-target inhibitors A13 and A14 (17β-HSD1 inhibitor and STS inhibitor, respectively). 
A9 was able to decrease the proliferative effect of E1-S/E1 stimulation in a dose-dependent 
manner, reaching control levels at concentration of 400 nM. In contrast, the single-target 
inhibitors did not decrease the stimulated effect of estrogen below 150% and 200% of the 
control (A13 and A14, respectively). These differences in antiproliferative effects between 
DSHIs and single-target inhibitors were attributed to the differences in E1 and E2 levels 
produced in the presence of different inhibitors. It was shown experimentally that in the 
absence of inhibitors the cells convert E1-S and E1 into E2, which strongly stimulates cell 
growth. In case of A9, no significant conversion of E1-S or E1 was detected, while in case of 
single-target inhibitors the residual cell proliferation was in agreement with the amounts of E1 
and/or E2 produced. Moreover, A9 showed no influence on non-stimulated or E2-stimulated 
cell proliferation, indicating that it exerts neither cytotoxic nor estrogenic effects nor estrogen 
receptor antagonism. Therefore, A9 (DSHIs) deploys its antiproliferative effect through the 
inhibition of STS and 17β-HSD1 which results in the blockage of E2 formation. 
4.4 Further in vitro biological evaluation of DSHIs 
An important prerequisite for reaching sufficient plasma concentrations for an adequate time 
interval after in vivo application of the compounds is achieving high in vitro metabolic 
stability. Therefore, the metabolic stabilities of the compounds with the most beneficial 
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biological profiles were evaluated. On one hand, compound A9 the representative of the first 
class of DSHIs was found to be metabolically unstable with t1/2 less than 5 minutes. Upon 
investigation, it was found that phase II metabolism is the major pathway, which can be 
strongly linked to the conjugation of the free hydroxy group. Further development of this 
class was stopped as this hydroxy group is essential for potent 17β-HSD1 inhibition. On the 
other hand, the second class of DSHIs was characterized by significantly higher metabolic 
stability. B5 showed the best metabolic stability profile of any DSHIs or 17β-HSD1 inhibitor 
developed by our group, with t1/2 85 min and 56 min using human and mouse hepatic S9 
fractions, respectively. B6 and B12 showed acceptable metabolic stability. 
Along with their good physiochemical properties and their high safety in cytotoxicity assays 
performed on selected human cell lines (HEK293 and HepG2 cells), these interesting results 
of B5, B6 and B12 constitute important requirements to be eligible for in vivo 
pharmacokinetic profile evaluation. 
4.5 In vivo evaluation of pharmacokinetic profile of 
DSHIs 
In order to select the best candidate from B5, B6 and B12 for a proof-of-principle study in a 
xenograft mouse model for endometriosis, their PK profiles had to be evaluated. The plasma 
levels of the three compounds after single subcutaneous dosing revealed that B5 had high 
AUC value (11619 ng.h/mL) which was a 6 fold higher than that’s of B6 and B12. Moreover, 
the plasma concentration of B5 remained higher than the cellular IC80 values of both target 
enzymes up to 24 h. After oral application, B5 showed high plasma levels in first 8 h of the 
study sufficient for both target enzymes. However, in the following intervals the 
concentration of B5 continued declining to reach very low levels that were not sufficient for 
the inhibition of any of the target enzymes at 24 h. A multiple dose PK study was performed 
with B5 in which the compound was administered subcutaneously every day or every second 
day. After 24 h, the plasma levels were sufficient for inhibition of both target enzymes. The 
plasma concentrations of B5 48 h post-dosing was sufficient for 17β-HSD1 inhibition but not 
STS inhibition. However, taking in consideration the irreversible mode of inhibition of STS, 
these levels could be sufficient but this has to be clinically evaluated. Additionally, a steady 
state behavior in the plasma level of B5 was observed which strongly suggest that CYP 
metabolizing enzymes aren’t altered by inhibition or by induction. 




Taken together, a successful design approach for the first DSHIs was implemented, followed 
by good biological results which demonstrated that the in vitro inhibition of STS and 
17β-HSD1 can be translated into significant anti-proliferative effect for estrogen stimulated 
cell growth. Additionally, the second class of DSHIs especially compound B5, showed very 
strong inhibition of STS and 17β-HSD1 in cellular assays along with high selectivity over 
17β-HSD2. The high metabolic stability of B5 in human and mouse hepatic S9 fractions, 
besides its good physiochemical properties resulted in admirable PK profile. These findings 
obviously reflect the suitability of B5 for future proof-of-principle studies. 
As previously shown in the introduction, the HSD enzyme family has a wide range of 
physiological roles and it is often associated with diseases. In chapter 3.2.II, a novel targeted 
intracrine therapy for bone fracture was successfully introduced in a proof-of-principle study 
using a potent and selective 17β-HSD2 inhibitor (compound D15) in mouse bone fracture 
model. Moreover, in chapter 3.2.III the first SAR of 17β-HSD14 non-steroidal inhibitors was 
introduced. This will provide the basis for future development of highly potent and selective 
17β-HSD14 inhibitor that could serve as a chemical tool for proper understanding of the 
enzyme physiological role upon in vivo administration. In this context, a comprehensive 
review on the inhibitors of 17β-HSD1, 2 and 14 is included in chapter 3.2.IV. 
  
  




The results of the potent dual inhibitor of STS and 17β-HSD1 B5, pave the way for its 
rational use in future studies to evaluate the efficacy of the DSHIs in proof-of-principle 
studies for the treatment of endometriosis. In the initial phase, the efficacy of B5 can be 
evaluated in vivo using nude mice with xenograft endometrium tissue from endometriotic 
patients. The parameters to be studied should include: 
 Determination of lesion size by ultrasound  
 Histological examination of the lesions (incl. neovascularization) 
 Determination of STS and 17β-HSD1 activity in the lesions 
 Quantification of plasma steroid hormones (E1-S) and cellular E1-S, E1 
and E2 in the lesions 
In parallel, an ex vivo study can be performed to compare between the efficacy of the DSHIs 
(B5) and the single inhibitors using human endometriotic tissues. In which the same 
parameters mentioned in the previous experiment should be monitored.  
In case B5 turned out to be effective in the abovementioned proof-of-principle studies, it 
could be used as a tool for safety profiling of DSHIs in non-human primate (monkey). Among 
the parameters that should be monitored: 
 Plasma E1-S, E1 and E2 
 Ovulation and menstrual cycle disrubtion 
 Bone formation and resorption 
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5. Supporting information 
This section contains the supporting information of the studies presented in chapter 3.1. It 
contains further experimental details, as well as additional figures and results. 
5.1. Supporting information for publication A 
5.1.I Chemistry 
5.1.I.1 Chemical methods 
Chemical names follow IUPAC nomenclature. 
Starting materials were purchased from Acros Organics, Alfa Aesar, Combi-Blocks, 
Fluorochem and Sigma Aldrich. Column chromatography was performed on silica gel (0.04-
0.063 mm, Macherey-Nagel) and reaction progress was monitored by TLC on aluminum 





C NMR spectra were measured on a Bruker-500 (at 500 MHz and 125 MHz, 
respectively) or Bruker-300 (at 300 MHz). Chemical shifts are reported in δ (parts per 
million: ppm), using residual peaks of the deuterated solvents as internal standard: (CD3)2SO 
(DMSO-d6): 2.50 ppm (
1
H NMR), 39.52 ppm (
13
C NMR); (CD3)2CO (acetone-d6): 2.05 ppm 
(
1
H NMR), 29.84 ppm and 206.26 ppm (
13
C NMR). Signals are described as s, d, t, dd, ddd, 
dt, td and m for singlet, doublet, triplet, doublet of doublets, doublet of doublet of doublets, 
doublet of triplets, triplets of doublets and multiplet, respectively. All coupling constants (J) 
are given in Hertz (Hz). 
All tested compounds have ≥ 95% chemical purity as evaluated by HPLC. The purity of the 
compounds was evaluated by LC/MS. The Surveyor®-LC-system consisted of a pump, an 
auto sampler, and a PDA detector. Mass spectrometry was performed by a TSQ® Quantum 
(ThermoFisher, Dreieich, Germany). The triple quadrupole mass spectrometer was equipped 
with an electrospray interface (ESI). The system was operated by the standard software 
Xcalibur®. A RP C18 NUCLEODUR® 100-5 (3 mm) column (Macherey-Nagel GmbH, 
Dühren, Germany) was used as stationary phase. All solvents were HPLC grade. In a gradient 
run the percentage of acetonitrile (containing 0.1 % trifluoroacetic acid) was increased from 
an initial concentration of 30% at 0 min to 100 % at 12 min and kept at 100 % for 3 min. The 
injection volume was 25 µL and flow rate was set to 700 µL/min. MS analysis was carried out 
at a needle voltage of 3000 V and a capillary temperature of 350 °C. Mass spectra were 
acquired in positive mode from 100 to 1000 m/z and UV spectra were recorded at the wave 
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length of 254 nm. The melting points were measured using Stuart™ melting point apparatus 
SMP3. 
5.1.I.2 General procedures 
General procedure for Friedel-Crafts acylation (Method A) 
An ice-cooled mixture of monosubstituted thiophene derivate (1.5 equiv), 2,6-difluoro-3-
methoxybenzoyl chloride (1 equiv), and anhydrous aluminum trichloride (2 equiv) in 
anhydrous dichloromethane was left for 0.5 h, warmed to room temperature and stirred for 2-
4 h, then quenched with 1 M HCl. The aqueous layer was extracted with ethyl acetate. The 
organic layers were combined, dried over magnesium sulfate and concentrated to dryness 
under reduced pressure. The product was purified by column chromatography.  
General procedure for Suzuki coupling (Method B) 
Arylbromide (1 equiv), boronic acid derivative (1.2 equiv), cesium carbonate (4 equiv) and 
tetrakis(triphenylphosphine) palladium (0.05 equiv) were added to an oxygen-free 
DME/water (1:1) and refluxed under nitrogen atmosphere for 4 h. The reaction mixture was 
cooled to room temperature. The aqueous layer was extracted with ethyl acetate. The organic 
layers were combined, dried over magnesium sulfate and concentrated to dryness under 
reduced pressure.  The product was purified by column chromatography.  
General procedure for ether cleavage (Method C) 
To a solution of methoxybenzene derivative (1 equiv) in anhydrous dichloromethane at -78 
o
C 
(dry ice/acetone bath), boron tribromide in dichloromethane (1 M, 3 equiv per methoxy 
function) was added dropwise. The reaction mixture was stirred overnight at room 
temperature under nitrogen atmosphere. The reaction was quenched with water, then the 
aqueous layer was extracted with ethyl acetate and the combined organic layer was washed 
with brine, dried over magnesium sulfate, filtered and concentrated to dryness under reduced 
pressure. The product was purified by column chromatography. 
General procedure for Sulfamoylation (Method D) 
A solution of phenol derivative (1.0 equiv) in DMA was cooled to 0 
o
C. A freshly prepared 
sulfamoyl chloride (5 equiv) was subsequently added over 5 min and the reaction mixture was 
warmed to room temperature overnight. The reaction was quenched with water, then the 
aqueous layer was extracted with ethyl acetate. The organic layers were combined, dried over 
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magnesium sulfate and concentrated to dryness under reduced pressure. The product was 
purified by column chromatography.  
Preparation of sulfamoyl chloride (Method E) 
A fresh solution was prepared for each reaction. Chlorosulfonyl isocyanate (1 equiv) was 
cooled to 0 
o
C. Then formic acid 99% (1 equiv) was then added dropwise to the isocyanate 
slowly over 10 min. Slow, steady evolution of CO2 was observed; eventually a white solid 
was formed. After 10 min, the ice bath was removed and the reaction mixture was warmed to 
room temperature and then used in the next reaction without further workup.  
5.1.I.3 Detailed synthesis procedure and compound characterization 
(5-Bromothiophen-2-yl)(2,6-difluoro-3-methoxyphenyl)methanone (1a). 
 
The title compound was prepared according to method A by the reaction of 2,6-difluoro-3-
methoxybenzoyl chloride (1.03 g, 5.00 mmol, 1 equiv) and 2-bromothiophene (1.22 g, 
7.50 mmol, 1.5 equiv) in the presence of anhydrous aluminium chloride (1.33 g, 10.00 mmol, 
2 equiv) in anhydrous dichloromethane (20 ml). The product was purified by column 
chromatography (cyclohexane/ethylacetate 4:1) to give 1.24 g (3.77 mmol/ 75%) of the 
analytically pure compound. C12H7BrF2O2S; MW 333;
 1
H NMR (300 MHz, (CD3)2SO) δ 7.52 
(dt, J = 4.1, 1.0 Hz, 1H), 7.47 – 7.37 (m, 2H), 7.25 (ddd, J = 9.3, 8.8, 1.9 Hz, 1H), 3.89 (s, 





The title compound was prepared according to method B by the reaction of 1a (0.45 g, 
1.50 mmol, 1 equiv) and (4-hydroxyphenyl)boronic acid (0.24 g, 1.80 mmol, 1.2 equiv) in the 
presence of ceasium carbonate (1.95 g, 6.00 mmol, 4 equiv) and tetrakis(triphenylphosphine) 
palladium (87.00 mg, 0.08 mmol, 0.05 equiv)  in DME/water 1:1 (20 ml). The product was 
purified by column chromatography (dichloromethane) to give 0.39 g (1.12 mmol/ 75%) of 
the analytically pure compound. C18H12F2O3S; MW 346; 
1
H NMR (300 MHz, (CD3)2SO) δ 
9.79 (s, 1H), 7.69 – 7.58 (m, 2H), 7.42 (td, J = 9.5, 5.3 Hz, 1H), 7.35 – 7.21 (m, 3H), 7.17 (dd, 
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4-(5-(2,6-Difluoro-3-methoxybenzoyl)thiophen-2-yl)phenyl sulfamate (1c). 
 
The title compound was prepared according to Method D by the reaction of 1b (0.34 g, 
1.00 mmol, 1 equiv) and sulfamoyl chloride (0.58 g, 5.00 mmol, 5 equiv) in DMA (10 ml). 
The product was purified by column chromatography (cyclohexane/ethylacetate 1:1) to give 
0.33 g (0.78 mmol/ 78%) of the analytically pure compound. C18H13F2NO5S2; MW 425;
 1H 
NMR (300 MHz, (CD3)2SO) δ 8.11 (s, 2H), 7.87 – 7.73 (m, 2H), 7.72 (dd, J = 3.7, 1.5 Hz, 
2H), 7.61 (t, J = 8.0 Hz, 1H), 7.45 (dt, J = 9.5, 4.8 Hz, 1H), 7.39 (ddd, J = 8.2, 2.3, 1.0 Hz, 
1H), 7.28 (td, J = 9.0, 1.9 Hz, 1H), 3.92 (s, 3H); MS (ESI): 426.03 (M+H)
+
. 
4-(5-(2,6-Difluoro-3-hydroxybenzoyl)thiophen-2-yl)phenyl sulfamate (1). 
 
The title compound was prepared according to Method C by the reaction of 1c (0.21 g, 
0.50 mmol, 1 equiv) and boron tribromide (1 M) in dichloromethane (1.50 ml, 1.50 mmol, 
3 equiv) in anhydrous dichloromethane (10 ml). The product was purified by column 
chromatography (dichloromethane/methanol 98.5:1.5) to give 0.10 g (0.25 mmol/ 50%) of the 
analytically pure compound. C17H11F2NO5S2; MW 411; mp: 176-177;
 1
H NMR (500 MHz, 
(CD3)2CO) δ 9.02 (s, 1H), 7.78 (ddd, J = 7.8, 1.8, 1.0 Hz, 1H), 7.75 (ddd, J = 2.2, 1.8, 0.4 Hz, 
1H), 7.67 (dt, J = 4.1, 0.8 Hz, 1H), 7.66 (d, J = 4.0 Hz, 1H), 7.61 – 7.56 (m, 1H), 7.41 (ddd, J 
= 8.2, 2.3, 1.0 Hz, 1H), 7.25 (s, 2H), 7.23 – 7.18 (m, 1H), 7.04 (ddd, J = 9.1, 8.6, 1.9 Hz, 1H);
 
13
C NMR (126 MHz, (CD3)2CO) δ 180.73, 153.68, 152.53 (dd, J = 240.6, 5.7 Hz), 148.40 
(dd, J = 245.8, 7.7 Hz), 152.18, 143.75, 142.64 (dd, J = 12.9, 3.2 Hz), 138.13, 135.45, 131.66, 
126.76, 125.46, 124.29, 121.02, 120.40 (dd, J = 9.1, 3.9 Hz), 117.95 (dd, J = 23.8, 19.6 Hz), 





The title compound was prepared according to method B by the reaction of 1a (0.45 g, 
1.50 mmol, 1 equiv) and (2-hydroxyphenyl)boronic acid (0.24 g, 1.80 mmol, 1.2 equiv) in the 
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presence of ceasium carbonate (1.95 g, 6.00 mmol, 4 equiv) and tetrakis(triphenylphosphine) 
palladium (87 mg, 0.08 mmol, 0.05 equiv)  in DME/water 1:1 (20 ml). The product was 
purified by column chromatography (cyclohexane/ethylacetate 2:1) to give 0.44 g (1.29 
mmol/ 86%) of the analytically pure compound. C18H12F2O3S; MW 346;
 1
H NMR (500 MHz, 
(CD3)2SO) δ 10.89 (s, 1H), 7.84 (dd, J = 8.0, 1.6 Hz, 1H), 7.77 (d, J = 4.3 Hz, 1H), 7.59 (dd, J 
= 4.2, 0.9 Hz, 1H), 7.40 (td, J = 9.5, 5.3 Hz, 1H), 7.30 – 7.21 (m, 2H), 7.02 (dd, J = 8.2, 1.2 
Hz, 1H), 6.93 (ddd, J = 8.3, 7.2, 1.2 Hz, 1H), 3.90 (s, 3H); MS (ESI): 347.01 (M+H)
+
. 
2-(5-(2,6-Difluoro-3-methoxybenzoyl)thiophen-2-yl)phenyl sulfamate (2c). 
 
The title compound was prepared according to Method D by the reaction of 2b (0.34 g, 
1.00 mmol, 1 equiv) and sulfamoyl chloride (0.58 g, 5.00 mmol, 5 equiv) in DMA (10 ml). 
The product was purified by column chromatography (cyclohexane/ethylacetate 3:2) to give 
0.38 g (0.90 mmol/ 90%) of the analytically pure compound. C18H13F2NO5S2; MW 425;
 1
H 
NMR (500 MHz, (CD3)2SO) δ 8.37 (s, 2H), 7.93 (dd, J = 7.9, 1.6 Hz, 1H), 7.72 (d, J = 4.2 
Hz, 1H), 7.64 (dt, J = 4.3, 0.9 Hz, 1H), 7.61 (dd, J = 8.3, 1.3 Hz, 1H), 7.54 (ddd, J = 8.2, 7.3, 




2-(5-(2,6-Difluoro-3-hydroxybenzoyl)thiophen-2-yl)phenyl sulfamate (2). 
 
The title compound was prepared according to Method C by the reaction of 2c (0.21 g, 
0.50 mmol, 1 equiv) and boron tribromide (1 M) in dichloromethane (1.50 ml, 1.50 mmol, 
3 equiv) in anhydrous dichloromethane (10 ml). The product was purified by column 
chromatography (dichloromethane/methanol 98.5:1.5) to give 61.00 mg (0.15 mmol/ 30%) of 
the analytically pure compound. C17H11F2NO5S2; MW 411; mp: 164-165;
  1
H NMR (500 
MHz, (CD3)2CO) δ 9.06 (d, J = 1.1 Hz, 1H), 7.89 (dd, J = 7.8, 1.7 Hz, 1H), 7.70 (d, J = 4.1 
Hz, 1H), 7.68 (dd, J = 8.3, 1.3 Hz, 1H), 7.61 (dt, J = 4.1, 1.0 Hz, 1H), 7.52 (ddd, J = 8.2, 7.4, 
1.7 Hz, 1H), 7.48 (s, 2H), 7.44 (td, J = 7.6, 1.3 Hz, 1H), 7.21 (ddd, J = 9.7, 9.1, 5.5 Hz, 1H), 
7.04 (ddd, J = 9.1, 8.6, 1.9 Hz, 1H); 
13
C NMR (126 MHz, (CD3)2CO) δ 180.99, 152.52 (dd, J 
= 240.4, 5.9 Hz), 148.40 (dd, J = 245.7, 7.9 Hz), 149.65, 148.28, 144.30, 142.64 (dd, J = 12.9, 
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3.2 Hz), 137.32, 131.32, 130.80, 129.13, 127.91, 127.24, 123.56, 120.28 (dd, J = 9.1, 3.9 Hz), 





The title compound was prepared according to method B by the reaction of 2-bromothiophene 
(0.82 g, 5.00 mmol, 1 equiv) and (3-methoxyphenyl)boronic acid (0.91 g, 6.00 mmol, 1.2 
equiv) in the presence of ceasium carbonate (6.50 g, 20.00 mmol, 4 equiv) and 
tetrakis(triphenylphosphine) palladium (0.29 g, 0.25 mmol, 0.05 equiv)  in DME/water 1:1 
(50 ml). The product was purified by column chromatography (cyclohexane/dichloromethane 
5:1) to give 0.87 g (4.60 mmol/ 92%) of the analytically pure compound. C11H10OS; MW 
190; 
1
H NMR (300 MHz, (CD3)2SO) δ 7.57 – 7.53 (m, 1H), 7.53 – 7.51 (m, 1H), 7.33 (t, J = 
7.9 Hz, 1H), 7.24 – 7.20 (m, 1H), 7.19 – 7.17 (m, 1H), 7.13 (dd, J = 5.0, 3.7 Hz, 1H), 6.89 





The title compound was prepared according to Method C by the reaction of 3a (0.76 g, 
4.00 mmol, 1 equiv) and boron tribromide (1 M) in dichloromethane (12.00 ml, 12.00 mmol, 
3 equiv) in anhydrous dichloromethane (20 ml). The product was purified by column 
chromatography (cyclohexane/dichloromethane 4:1) to give 0.56 g (3.20 mmol/ 80%) of the 
analytically pure compound. C10H8OS; MW 176; 
1
H NMR (300 MHz(CD3)2SO) δ 9.55 (s, 
1H), 7.51 (dd, J = 5.1, 1.2 Hz, 1H), 7.42 (dd, J = 3.6, 1.2 Hz, 1H), 7.20 (t, J = 7.8 Hz, 1H), 
7.11 (dd, J = 5.1, 3.6 Hz, 1H), 7.10 – 7.05 (m, 1H), 7.04 – 7.00 (m, 1H), 6.71 (ddd, J = 8.0, 
2.4, 1.0 Hz, 1H); MS (ESI): 176.98 (M+H)
+
. 
3-(Thiophen-2-yl)phenyl sulfamate (3c). 
 
The title compound was prepared according to Method D by the reaction of 3b (0.53 g, 
3.00 mmol, 1 equiv) and sulfamoyl chloride (1.73 g, 15.00 mmol, 5 equiv) in DMA (20 ml). 
The product was purified by column chromatography (cyclohexane/ethylacetate 3:2) to give 
0.61 g (2.40 mmol/ 80%) of the analytically pure compound. C10H9NO3S2; MW 255; 
1
H 
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NMR (300 MHz, (CD3)2SO) δ 8.05 (s, 2H), 7.65 – 7.58 (m, 2H), 7.56 (dd, J = 3.6, 1.2 Hz, 
1H), 7.54 – 7.46 (m, 2H), 7.22 (ddd, J = 8.1, 2.3, 1.0 Hz, 1H), 7.17 (dd, J = 5.1, 3.6 Hz, 1H); 
MS (ESI): 256.01 (M+H)
+
. 
3-(5-(2,6-Difluoro-3-methoxybenzoyl)thiophen-2-yl)phenyl sulfamate (3d). 
      
The title compound was prepared according to method by the reaction of 2,6-difluoro-3-
methoxybenzoyl chloride (0.41 g, 2.00 mmol, 1 equiv) and 3c (0.76 g, 3.00 mmol, 1.5 equiv) 
in the presence of anhydrous aluminium chloride (0.53 g, 4.00 mmol, 2 equiv) in anhydrous 
dichloromethane (10 ml). The product was purified by column chromatography 
(cyclohexane/ethylacetate 3:2) to give 0.49 g (1.16 mmol/ 58%) of the analytically pure 
compound. C18H13F2NO5S2; MW 425;
 1
H NMR (300 MHz, (CD3)2SO) δ 8.10 (s, 2H), 7.85 – 
7.76 (m, 1H), 7.76 – 7.68 (m, 3H), 7.60 (t, J = 8.0 Hz, 1H), 7.44 (dt, J = 9.5, 4.7 Hz, 1H), 7.40 
– 7.34 (m, 1H), 7.27 (td, J = 9.0, 1.9 Hz, 1H), 3.91 (s, 3H); MS (ESI): 426.00 (M+H)
+
. 
3-(5-(2,6-Difluoro-3-hydroxybenzoyl)thiophen-2-yl)phenyl sulfamate (3).  
 
The title compound was prepared according to Method C by the reaction of 3d (0.21 g, 
0.50 mmol, 1 equiv) and boron tribromide (1 M) in dichloromethane (1.50 ml, 1.50 mmol, 
3 equiv) in anhydrous dichloromethane (10 ml). The product was purified by column 
chromatography (dichloromethane/methanol 98.5:1.5) to give 123.00 mg (0.29 mmol/ 58%) 




H NMR (500 
MHz, (CD3)2CO) δ 9.01 (s, 1H), 7.78 (ddd, J = 7.8, 1.8, 1.0 Hz, 1H), 7.76 – 7.74 (m, 1H), 
7.68 – 7.64 (m, 2H), 7.58 (t, J = 8.0 Hz, 1H), 7.41 (ddd, J = 8.2, 2.3, 1.0 Hz, 1H), 7.25 (s, 
2H), 7.23 – 7.18 (m, 1H), 7.04 (td, J = 8.9, 1.9 Hz, 1H); 
13
C NMR (126 MHz, (CD3)2CO) δ 
180.74, 153.69, 152.54 (dd, J = 240.5, 5.8 Hz), 152.20, 148.41 (dd, J = 246.0, 7.7 Hz), 
143.77, 142.66 (dd, J = 12.8, 3.2 Hz),  138.14, 135.46, 131.67, 126.78, 125.48, 124.30, 
121.04, 120.41 (dd, J = 9.1, 3.9 Hz), 117.97 (dd, J = 23.9, 19.7 Hz), 112.45 (dd, J = 22.8, 3.9 








The title compound was prepared according to method B the reaction of 2-bromothiophene 
(0.82 g, 5.00 mmol, 1 equiv) and (2-fluoro-3-methoxyphenyl)boronic acid (1.02 g, 
6.00 mmol, 1.2 equiv) in the presence of ceasium carbonate (6.50 g, 20.00 mmol, 4 equiv) and 
tetrakis(triphenylphosphine) palladium (0.29 g, 0.25 mmol, 0.05 equiv)  in DME/water 1:1 
(50 ml). The product was purified by column chromatography 
(cyclohexane/dichloromethane 7:1) to give 1.00 g (4.80 mmol/ 96%) of the analytically pure 
compound. C11H9FOS; MW 208;
 1
H NMR (300 MHz, (CD3)2SO) δ 7.32 – 7.20 (m, 2H), 7.16 
(dt, J = 3.7, 1.2 Hz, 1H), 6.94 (ddd, J = 8.0, 7.1, 1.9 Hz, 1H), 6.86 (td, J = 8.0, 1.1 Hz, 1H), 





The title compound was prepared according to Method C by the reaction of 4a (0.83 g, 
4.00 mmol, 1 equiv) and boron tribromide (1 M) in dichloromethane (12.00 ml, 12.00 mmol, 
3 equiv) in anhydrous dichloromethane (20 ml). The product was purified by column 
chromatography (cyclohexane/dichloromethane 4:1) to give 0.73 g (3.76 mmol/ 97%) of the 
analytically pure compound. C10H7FOS; MW 194;
 1
H NMR (300 MHz, (CD3)2SO) δ 10.36 (s, 
1H), 7.33 – 7.22 (m, 2H), 7.17 (dt, J = 3.7, 1.1 Hz, 1H), 6.95 (ddd, J = 8.0, 7.1, 1.7 Hz, 1H), 
6.87 (td, J = 7.9, 1.1 Hz, 1H), 6.77 (ddd, J = 5.1, 3.8, 1.1 Hz, 1H); MS (ESI): 195.01 (M+H)
+
. 
2-Fluoro-3-(thiophen-2-yl)phenyl sulfamate (4c). 
 
The title compound was prepared according to Method D by the reaction of 4b (0.58 g, 
3.00 mmol, 1 equiv) and sulfamoyl chloride (1.73 g, 15.00 mmol, 5 equiv) in DMA (20 ml). 
The product was purified by column chromatography (cyclohexane/ethylacetate 3:1) to give 
0.44 g (1.60 mmol/ 53%) of the analytically pure compound. C10H8FNO3S2; MW 273;
 1
H 
NMR (300 MHz, (CD3)2SO) δ 8.30 (s, 2H), 7.78 – 7.66 (m, 2H), 7.61 (dt, J = 3.7, 1.1 Hz, 
1H), 7.39 (ddd, J = 8.1, 7.1, 1.8 Hz, 1H), 7.32 (td, J = 7.9, 1.1 Hz, 1H), 7.22 (ddd, J = 5.0, 3.7, 
1.2 Hz, 1H); MS (ESI): 274.00 (M+H)
+
. 
3-(5-(2,6-Difluoro-3-methoxybenzoyl)thiophen-2-yl)-2-fluorophenyl sulfamate (4d). 




The title compound was prepared according to method A by the reaction of 2,6-difluoro-3-
methoxybenzoyl chloride (0.41 g, 2.00 mmol, 1 equiv) and 4c (0.82 g, 3.00 mmol, 1.5 equiv) 
in the presence of anhydrous aluminium chloride (0.53 g, 4.00 mmol, 2 equiv) in anhydrous 
dichloromethane (10 ml). The product was purified by column chromatography 
(cyclohexane/ethylacetate 3:2) to give 0.60 g (1.35 mmol/ 67%) of the analytically pure 
compound. C18H12F3NO5S2; MW 443; 
1
H NMR (500 MHz, (CD3)2CO) δ 8.37 (s, 2H), 7.85 
(ddd, J = 8.2, 6.7, 1.6 Hz, 1H), 7.76 – 7.69 (m, 2H), 7.57 (ddd, J = 8.2, 7.4, 1.6 Hz, 1H), 7.40 
(td, J = 8.1, 1.4 Hz, 1H), 7.28 – 7.17 (m, 1H), 7.06 (ddd, J = 9.1, 8.5, 1.9 Hz, 1H), 3.91 (s, 
3H); MS (ESI): 444.08 (M+H)
+
. 
3-(5-(2,6-Difluoro-3-hydroxybenzoyl)thiophen-2-yl)-2-fluorophenyl sulfamate (4). 
 
The title compound was prepared according to Method C by the reaction of 4d (0.22 g, 
0.50 mmol, 1 equiv) and boron tribromide (1 M) in dichloromethane (1.50 ml, 1.50 mmol, 
3 equiv) in anhydrous dichloromethane (10 ml). The product was purified by column 
chromatography (dichloromethane/methanol 98.5:1.5) to give 140.00 mg (0.33 mmol/ 66%) 




H NMR (500 
MHz, (CD3)2CO) δ 9.14 (s, 1H), 7.84 (ddd, J = 8.2, 6.7, 1.6 Hz, 1H), 7.75 – 7.68 (m, 2H), 
7.56 (ddd, J = 8.2, 7.4, 1.6 Hz, 1H), 7.52 (s, 2H), 7.39 (td, J = 8.1, 1.4 Hz, 1H), 7.22 (ddd, J = 
9.7, 9.2, 5.4 Hz, 1H), 7.05 (ddd, J = 9.1, 8.5, 1.9 Hz, 1H);
 13
C NMR (126 MHz, (CD3)2CO) δ 
180.99, 152.76 (d, J = 256.1 Hz), 152.51 (dd, J = 240.7, 5.7 Hz), 148.41 (dd, J = 245.9, 7.7 
Hz), 146.60 (d, J = 3.5 Hz), 144.54 (d, J = 4.5 Hz), 142.70 (dd, J = 12.8, 3.2 Hz), 139.72 (d, J 
= 12.8 Hz), 137.37, 129.42 (d, J = 5.3 Hz), 127.84 (d, J = 2.1 Hz), 126.55, 126.04 (d, J = 4.7 
Hz), 123.43 (d, J = 10.6 Hz), 120.50 (dd, J = 9.1, 4.0 Hz), 117.94 (dd, J = 23.8, 19.6 Hz), 
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The title compound was prepared according to method B by the reaction of 2-bromothiophene 
(0.82 g, 5.00 mmol, 1 equiv) and (2-fluoro-4-methoxyphenyl)boronic acid (1.02 g, 
6.00 mmol, 1.2 equiv) in the presence of ceasium carbonate (6.50 g, 20.00 mmol, 4 equiv) and 
tetrakis(triphenylphosphine) palladium (0.29 g, 0.25 mmol, 0.05 equiv)  in DME/water 1:1 
(50 ml). The product was purified by column chromatography 
(cyclohexane/dichloromethane 7:1) to give 0.84 g (4.05 mmol/ 81%) of the analytically pure 
compound. C11H9FOS; MW 208;
 1
H NMR (300 MHz, CD3)2SO) δ 7.11 (dd, J = 12.8, 2.4 Hz, 
1H), 7.06 (dd, J = 5.2, 1.1 Hz, 1H), 7.01 (dd, J = 3.7, 1.1 Hz, 1H), 6.99 – 6.93 (m, 1H), 6.75 





The title compound was prepared according to Method C by the reaction of 5a (0.83 g, 
4.00 mmol, 1 equiv) and boron tribromide (1 M) in dichloromethane (12.00 ml, 12.00 mmol, 
3 equiv) in anhydrous dichloromethane (20 ml). The product was purified by column 
chromatography (cyclohexane/dichloromethane 4:1) to give 0.73 g (3.76 mmol/ 94%) of the 
analytically pure compound. C10H7FOS; MW 194;
 1
H NMR (300 MHz, CD3)2SO) δ 9.55 (s, 
1H), 7.13 (dd, J = 12.6, 2.3 Hz, 1H), 7.07 (dd, J = 5.1, 1.2 Hz, 1H), 7.03 (dd, J = 3.8, 1.2 Hz, 




3-Fluoro-4-(thiophen-2-yl)phenyl sulfamate (5c). 
 
The title compound was prepared according to Method D by the reaction of 5b (0.58 g, 
3.00 mmol, 1 equiv) and sulfamoyl chloride (1.73 g, 15.00 mmol, 5 equiv) in DMA (20 ml). 
The product was used in the next step without further purification. C10H8FNO3S2; MW 273; 
MS (ESI): 274.01 (M+H)
+
. 
4-(5-(2,6-Difluoro-3-methoxybenzoyl)thiophen-2-yl)-3-fluorophenyl sulfamate (5d). 
 
The title compound was prepared according to method A by the reaction of 2,6-difluoro-3-
methoxybenzoyl chloride (0.41 g, 2.00 mmol, 1 equiv) and 5c (0.82 g, 3.00 mmol, 1.5 equiv) 
in the presence of anhydrous aluminium chloride (0.53 g, 4.00 mmol, 2 equiv) in anhydrous 
dichloromethane (10 ml). The product was purified by column chromatography 
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(cyclohexane/ethylacetate 3:2) to give 0.68 g (1.54 mmol/ 77%) of the analytically pure 
compound. C18H12F3NO5S2; MW 443; 
1
H NMR (500 MHz, (CD3)2CO) δ 7.99 (t, J = 8.6 Hz, 
1H), 7.71 – 7.66 (m, 2H), 7.40 (s, 2H), 7.37 – 7.33 (m, 2H), 7.32 – 7.30 (m, 1H), 7.15 (ddd, J 
= 9.13, 8.6, 2.0 Hz, 1H), 3.92 (s, 3H); MS (ESI): 444.10 (M+H)
+
. 
4-(5-(2,6-Difluoro-3-hydroxybenzoyl)thiophen-2-yl)-3-fluorophenyl sulfamate (5). 
 
The title compound was prepared according to Method C by the reaction of 5d (0.22 g, 
0.50 mmol, 1 equiv) and boron tribromide (1 M) in dichloromethane (1.50 ml, 1.50 mmol, 
3 equiv) in anhydrous dichloromethane (10 ml). The product was purified by column 
chromatography (dichloromethane/methanol 98.5:1.5) to give 94.00 mg (0.22 mmol/ 44%) of 




H NMR (500 
MHz, (CD3)2CO) δ 9.06 (d, J = 1.3 Hz, 1H), 8.00 (t, J = 8.6 Hz, 1H), 7.73 – 7.67 (m, 2H), 
7.42 (s, 2H), 7.37 – 7.31 (m, 2H), 7.25 – 7.18 (m, 1H), 7.05 (ddd, J = 9.1, 8.6, 1.9 Hz, 1H);
 
13
C NMR (126 MHz, (CD3)2CO) δ 180.91, 159.94 (d, J = 252.6 Hz),  152.63 (d, J = 11.4 Hz),  
152.51 (dd, J = 240.7, 5.7 Hz), 148.38 (dd, J = 246.0, 7.8 Hz), 146.70 (d, J = 4.2 Hz), 144.26 
(d, J = 4.6 Hz), 142.64 (dd, J = 12.9, 3.2 Hz), 137.45, 130.88 (d, J = 4.0 Hz), 128.90 (d, J = 
5.0 Hz), 120.43 (dd, J = 9.1, 3.9 Hz), 120.18 (d, J = 3.7 Hz), 120.05, 117.95 (dd, J = 23.9, 




                     
The title compound was prepared according to method B by the reaction of 2-bromothiophene 
(0.82 g, 5.00 mmol, 1 equiv) and (2-chloro-4-methoxyphenyl)boronic acid (1.11 g, 
6.00 mmol, 1.2 equiv) in the presence of ceasium carbonate (6.50 g, 20.00 mmol, 4 equiv) and 
tetrakis(triphenylphosphine) palladium (0.29 g, 0.25 mmol, 0.05 equiv)  in DME/water 1:1 
(50 ml). The product was purified by column chromatography 
(cyclohexane/dichloromethane 7:1) to give 1.01 g (4.55 mmol/ 91%) of the analytically pure 
compound. C11H9ClOS; MW 224;
 1
H NMR (300 MHz, (CD3)2SO) δ 7.28 (d, J = 2.4 Hz, 1H), 
7.15 (dd, J = 8.7, 2.4 Hz, 1H), 7.08 (dd, J = 5.1, 1.1 Hz, 1H), 7.03 (dd, J = 3.7, 1.1 Hz, 1H), 
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The title compound was prepared according to Method C by the reaction of 6a (0.90 g, 
4.00 mmol, 1 equiv) and boron tribromide (1 M) in dichloromethane (12.00 ml, 12.00 mmol, 
3 equiv) in anhydrous dichloromethane (20 ml). The product was purified by column 
chromatography (cyclohexane/dichloromethane 4:1) to give 0.66 g (3.16 mmol/ 79%) of the 
analytically pure compound. C10H7ClOS; MW 210;
 1
H NMR (300 MHz, (CD3)2SO) δ 9.59 (s, 
1H), 7.63 (d, J = 2.3 Hz, 1H), 7.47 (dd, J = 5.1, 1.2 Hz, 1H), 7.43 (dd, J = 8.4, 2.3 Hz, 1H), 




3-Chloro-4-(thiophen-2-yl)phenyl sulfamate (6c). 
           
The title compound was prepared according to Method D by the reaction of 6b (0.63 g, 
3.00 mmol, 1 equiv) and sulfamoyl chloride (1.73 g, 15.00 mmol, 5 equiv) in DMA (20 ml). 
The product was used in the next step without further purification. C10H8ClNO3S2; MW 289; 
MS (ESI): 290.03 (M+H)
+
. 
3-Chloro-4-(5-(2,6-difluoro-3-methoxybenzoyl)thiophen-2-yl)phenyl sulfamate (6d). 
 
The title compound was prepared according to method A by the reaction of 2,6-difluoro-3-
methoxybenzoyl chloride (0.41 g, 2.00 mmol, 1 equiv) and 6c (0.87 g, 3.00 mmol, 1.5 equiv) 
in the presence of anhydrous aluminium chloride (0.53 g, 4.00 mmol, 2 equiv) in anhydrous 
dichloromethane (10 ml). The product was purified by column chromatography 
(cyclohexane/ethylacetate 1:1) to give 0.62 g (1.36 mmol/ 68%) of the analytically pure 
compound. C18H12ClF2NO5S2; MW 459; 
1
H NMR (500 MHz, (CD3)2CO) δ 7.84 (d, J = 8.5 
Hz, 1H), 7.68 (dt, J = 4.1, 1.0 Hz, 1H), 7.59 (d, J = 2.4 Hz, 1H), 7.57 (d, J = 4.1 Hz, 1H), 7.45 
(dd, J = 8.6, 2.4 Hz, 1H), 7.43 (s, 2H), 7.38 (td, J = 9.4, 5.2 Hz, 1H), 7.16 (ddd, J = 9.2, 8.6, 
2.0 Hz, 1H), 3.96 (s, 3H); MS (ESI): 460.01 (M+H)
+
. 
3-Chloro-4-(5-(2,6-difluoro-3-hydroxybenzoyl)thiophen-2-yl)phenyl sulfamate (6). 
               
The title compound was prepared according to Method C by the reaction of 6d (0.23 g, 
0.50 mmol, 1 equiv) and boron tribromide (1 M) in dichloromethane (1.50 ml, 1.50 mmol, 
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3 equiv) in anhydrous dichloromethane (10 ml). The product was purified by column 
chromatography (dichloromethane/methanol 98.5:1.5) to give 71.00 mg (0.16 mmol/ 32%) of 




H NMR (500 
MHz, (CD3)2CO) δ 9.07 (s, 1H), 7.84 (d, J = 8.5 Hz, 1H), 7.69 (dt, J = 4.0, 1.0 Hz, 1H), 7.59 
(d, J = 2.4 Hz, 1H), 7.57 (d, J = 4.1 Hz, 1H), 7.45 (dd, J = 8.6, 2.4 Hz, 1H), 7.43 (s, 2H), 7.22 
(ddd, J = 9.7, 9.1, 5.4 Hz, 1H), 7.05 (td, J = 8.9, 1.9 Hz, 1H);
 13
C NMR (126 MHz, (CD3)2CO) 
δ 181.03, 152.50 (dd, J = 240.8, 5.8 Hz), 152.10, 149.86, 148.39 (dd, J = 246.0, 7.8 Hz), 
144.89, 142.68 (dd, J = 12.9, 3.4 Hz), 136.99, 133.47, 133.29, 131.04, 130.78, 125.29, 
122.74, 120.44 (dd, J = 9.1, 3.9 Hz), 117.89 (dd, J = 23.8, 19.8 Hz), 112.46 (dd, J = 22.8, 4.0 





The title compound was prepared according to method B by the reaction of 2-bromothiophene 
(0.82 g, 5.00 mmol, 1 equiv) and (4-methoxy-2-methylphenyl)boronic acid (0.99 g, 
6.00 mmol, 1.2 equiv) in the presence of ceasium carbonate (6.50 g, 20.00 mmol, 4 equiv) and 
tetrakis(triphenylphosphine) palladium (0.29 g, 0.25 mmol, 0.05 equiv)  in DME/water 1:1 
(50 ml). The product was purified by column chromatography 
(cyclohexane/dichloromethane 7:1) to give 0.92 g (4.50 mmol/ 90%) of the analytically pure 
compound. C12H12OS; MW 204; 
1
H NMR (500 MHz, (CD3)2CO) δ 7.43 (dd, J = 5.2, 1.2 Hz, 
1H), 7.30 (d, J = 8.4 Hz, 1H), 7.10 (dd, J = 5.2, 3.5 Hz, 1H), 7.05 (dd, J = 3.5, 1.2 Hz, 1H), 






The title compound was prepared according to Method C by the reaction of 7a (0.82 g, 
4.00 mmol, 1 equiv) and boron tribromide (1 M) in dichloromethane (12.00 ml, 12.00 mmol, 
3 equiv) in anhydrous dichloromethane (20 ml). The product was purified by column 
chromatography (cyclohexane/dichloromethane 4:1) to give 0.61 g (3.24 mmol/ 81%) of the 
analytically pure compound. C11H10OS; MW 190; 
1
H NMR (500 MHz, (CD3)2CO) δ 8.45 (s, 
1H), 7.41 (dd, J = 5.2, 1.2 Hz, 1H), 7.21 (d, J = 8.3 Hz, 1H), 7.08 (dd, J = 5.2, 3.5 Hz, 1H), 
7.02 (dd, J = 3.5, 1.2 Hz, 1H), 6.79 (d, J = 2.5 Hz, 1H), 6.72 (dd, J = 8.3, 2.6 Hz, 1H), 2.32 (s, 
3H); MS (ESI): 191.10 (M+H)
+
. 
3-Methyl-4-(thiophen-2-yl)phenyl sulfamate (7c). 
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The title compound was prepared according to Method D by the reaction of 7b (0.57 g, 
3.00 mmol, 1 equiv) and sulfamoyl chloride (1.73 g, 15.00 mmol, 5 equiv) in DMA (20 ml). 
The product was used in the next step without further purification. C11H11NO3S2; MW 269; 
MS (ESI): 270.05 (M+H)
+
. 
4-(5-(2,6-Difluoro-3-methoxybenzoyl)thiophen-2-yl)-3-methylphenyl sulfamate (7d). 
 
The title compound was prepared according to method A by the reaction of 2,6-difluoro-3-
methoxybenzoyl chloride (0.41 g, 2.00 mmol, 1 equiv) and 7c (0.81 g, 3.00 mmol, 1.5 equiv) 
in the presence of anhydrous aluminium chloride (0.53 g, 4.00 mmol, 2 equiv) in anhydrous 
dichloromethane (10 ml). The product was purified by column chromatography 
(cyclohexane/ethylacetate 2:1) to give 0.65 g (1.48 mmol/ 74%) of the analytically pure 
compound. C19H15F2NO5S2; MW 439;
 1
H NMR (500 MHz, (CD3)2SO) δ 8.18 (s, 2H), 7.79 
(dd, J = 2.5, 0.9 Hz, 1H), 7.71 (ddd, J = 8.5, 2.5, 0.6 Hz, 1H), 7.65 (d, J = 4.1 Hz, 1H), 7.62 
(d, J = 4.1 Hz, 1H), 7.49 (d, J = 8.5 Hz, 1H), 7.26 – 7.18 (m, 1H), 7.05 (td, J = 8.9, 1.9 Hz, 
1H), 3.89 (s, 3H),  2.43 (s, 3H); MS (ESI): 440.03 (M+H)
+
. 
4-(5-(2,6-Difluoro-3-hydroxybenzoyl)thiophen-2-yl)-3-methylphenyl sulfamate (7). 
 
The title compound was prepared according to Method C by the reaction of 7d (0.22 g, 
0.50 mmol, 1 equiv) and boron tribromide (1 M) in dichloromethane (1.50 ml, 1.50 mmol, 
3 equiv) in anhydrous dichloromethane (10 ml). The product was purified by column 
chromatography (dichloromethane/methanol 98.5:1.5) to give 93.00 mg (0.22 mmol/ 44%) of 
the analytically pure compound. C18H13F2NO5S2; MW 425; mp: 166-167;
  1
H NMR (500 
MHz, (CD3)2SO) δ 10.29 (s, 1H), 8.12 (s, 2H), 7.66 (d, J = 4.0 Hz, 1H), 7.62 (d, J = 8.5 Hz, 
1H), 7.40 (d, J = 4.0 Hz, 1H), 7.31 (d, J = 2.4 Hz, 1H), 7.24 (ddd, J = 8.5, 2.5, 0.6 Hz, 1H), 
7.20 – 7.13 (m, 1H), 7.13 – 7.07 (m, 1H), 2.45 (s, 3H);
 13
C NMR (126 MHz, (CD3)2SO) δ 
180.14, 152.44, 150.56, 150.54 (dd, J = 239.4, 5.6 Hz), 146.92 (dd, J = 246.3, 7.7 Hz), 
142.30, 141.91 (dd, J = 11.9, 2.8 Hz),  137.86, 137.25, 131.52, 130.50, 129.34, 124.51, 
120.14, 119.56 (dd, J = 9.2, 3.8 Hz), 116.58 (dd, J = 23.6, 19.5 Hz), 111.73 (dd, J = 22.4, 3.7 
Hz), 20.85; MS (ESI): 426.01 (M+H)
+
. 





The title compound was prepared according to method B by the reaction of 2-bromothiophene 
(0.82 g, 5.00 mmol, 1 equiv) and (3-fluoro-4-methoxyphenyl)boronic acid (1.02 g, 
6.00 mmol, 1.2 equiv) in the presence of ceasium carbonate (6.50 g, 20.00 mmol, 4 equiv) and 
tetrakis(triphenylphosphine) palladium (0.29 g, 0.25 mmol, 0.05 equiv)  in DME/water 1:1 
(50 ml). The product was purified by column chromatography 
(cyclohexane/dichloromethane 7:1) to give 0.94 g (4.50 mmol/ 90%) of the analytically pure 
compound. C11H9FOS; MW 208; 
1
H NMR (300 MHz, (CD3)2SO) δ 7.55 (dd, J = 12.7, 2.3 
Hz, 1H), 7.49 (dd, J = 5.1, 1.2 Hz, 1H), 7.45 (dd, J = 3.6, 1.2 Hz, 1H), 7.43 – 7.37 (m, 1H), 






The title compound was prepared according to Method C by the reaction of 8a (0.83 g, 
4.00 mmol, 1 equiv) and boron tribromide (1 M) in dichloromethane (12.00 ml, 12.00 mmol, 
3 equiv) in anhydrous dichloromethane (20 ml). The product was purified by column 
chromatography (cyclohexane/dichloromethane 4:1) to give 0.60 g (3.12 mmol/ 78%) of the 
analytically pure compound. C10H7FOS; MW 194;
 1
H NMR (300 MHz, (CD3)2SO) δ 10.32 (s, 
1H), 7.56 (dd, J = 12.8, 2.4 Hz, 1H), 7.51 (dd, J = 5.2, 1.3 Hz, 1H), 7.46 (dd, J = 3.6, 1.3 Hz, 




2-Fluoro-4-(thiophen-2-yl)phenyl sulfamate (8c). 
 
The title compound was prepared according to Method D by the reaction of 8b (0.58 g, 
3.00 mmol, 1 equiv) and sulfamoyl chloride (1.73 g, 15.00 mmol, 5 equiv) in DMA (20 ml). 
The product was purified by column chromatography (cyclohexane/dichloromethane 1:1) to 
give 0.49 g (1.8 mmol/ 60%) of the analytically pure compound. C10H8FNO3S2; MW 273; 
1
H 
NMR (300 MHz, (CD3)2SO) δ 8.27 (s, 2H), 7.74 (dd, J = 11.6, 2.1 Hz, 1H), 7.66 – 7.59 (m, 




4-(5-(2,6-Difluoro-3-methoxybenzoyl)thiophen-2-yl)-2-fluorophenyl sulfamate (8d). 




The title compound was prepared according to method A by the reaction of 2,6-difluoro-3-
methoxybenzoyl chloride (0.41 g, 2.00 mmol, 1 equiv) and 8c (0.82 g, 3.00 mmol, 1.5 equiv) 
in the presence of anhydrous aluminium chloride (0.53 g, 4.00 mmol, 2 equiv) in anhydrous 
dichloromethane (10 ml). The product was purified by column chromatography 
(cyclohexane/ethylacetate 1:1) to give 0.69 g (1.56 mmol/ 78%) of the analytically pure 
compound. C18H12F3NO5S2; MW 443; 
1
H NMR (300 MHz, (CD3)2SO) δ 8.35 (s, 2H), 7.97 
(dd, J = 11.3, 2.2 Hz, 1H), 7.81 – 7.68 (m, 3H), 7.54 (t, J = 8.3 Hz, 1H), 7.43 (td, J = 9.5, 5.3 
Hz, 1H), 7.26 (td, J = 9.1, 1.9 Hz, 1H), 3.90 (s, 3H); MS (ESI): 444.09 (M+H)
+
. 
4-(5-(2,6-Difluoro-3-hydroxybenzoyl)thiophen-2-yl)-2-fluorophenyl sulfamate (8). 
 
The title compound was prepared according to Method C by the reaction of 8d (0.22 g, 
0.50 mmol, 1 equiv) and boron tribromide (1 M) in dichloromethane (1.50 ml, 1.50 mmol, 
3 equiv) in anhydrous dichloromethane (10 ml). The product was purified by column 
chromatography (dichloromethane/methanol 98.5:1.5) to give 124.00 mg (0.29 mmol/ 56%) 




H NMR (500 
MHz, (CD3)2CO) δ 9.00 (d, J = 1.4 Hz, 1H), 7.80 (dd, J = 11.1, 2.2 Hz, 1H), 7.72 – 7.68 (m, 
2H), 7.67 (dt, J = 4.1, 0.9 Hz, 1H), 7.60 (t, J = 8.2 Hz, 1H), 7.48 (s, 2H), 7.21 (ddd, J = 9.6, 
9.2, 5.4 Hz, 1H), 7.07 – 7.01 (m, 1H);
 13
C NMR (126 MHz, (CD3)2CO) δ 180.77, 155.96 (d, J 
= 251.3 Hz), 152.58 (d, J = 2.4 Hz), 152.54 (dd, J = 240.6, 5.8 Hz), 148.41 (dd, J = 245.9, 7.6 
Hz), 144.12, 142.65 (dd, J = 13.0, 3.2 Hz), 139.36 (d, J = 12.4 Hz),  138.18, 133.84 (d, J = 7.4 
Hz), 127.23, 126.64, 123.73 (d, J = 3.6 Hz), 120.45 (dd, J = 9.1, 3.9 Hz), 117.89 (dd, J = 23.9, 





The title compound was prepared according to method B by the reaction of 2-bromothiophene 
(0.82 g, 5 mmol, 1 equiv) and (3-chloro-4-methoxyphenyl)boronic acid (1.11 g, 6.00 mmol, 
1.2 equiv) in the presence of ceasium carbonate (6.50 g, 20.00 mmol, 4 equiv) and 
tetrakis(triphenylphosphine) palladium (0.29 g, 0.25 mmol, 0.05 equiv)  in DME/water 1:1 
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(50 ml). The product was purified by column chromatography 
(cyclohexane/dichloromethane 7:1) to give 1.01 g (4.50 mmol/ 90%) of the analytically pure 
compound. C11H9ClOS; MW 224; 
1
H NMR (300 MHz, (CD3)2SO) δ 7.72 (d, J = 2.3 Hz, 1H), 
7.57 (dd, J = 8.6, 2.3 Hz, 1H), 7.50 (dd, J = 5.1, 1.2 Hz, 1H), 7.47 (dd, J = 3.6, 1.2 Hz, 1H), 






The title compound was prepared according to Method C by the reaction of 9a (0.90 g, 
4.00 mmol, 1 equiv) and boron tribromide (1 M) in dichloromethane (12.00 ml, 12.00 mmol, 
3 equiv) in anhydrous dichloromethane (20 ml). The product was purified by column 
chromatography (cyclohexane/dichloromethane 4:1) to give 0.65 g (3.08 mmol/ 77%) of the 
analytically pure compound. C10H7ClOS; MW 210; 
1
H NMR (300 MHz, (CD3)2SO) δ 10.36 
(s, 1H), 7.62 (d, J = 2.3 Hz, 1H), 7.46 (dd, J = 5.1, 1.2 Hz, 1H), 7.44 – 7.35 (m, 2H), 7.09 (dd, 
J = 5.1, 3.6 Hz, 1H), 7.00 (d, J = 8.4 Hz, 1H); MS (ESI): 211.03 (M+H)
+
. 
2-Chloro-4-(thiophen-2-yl)phenyl sulfamate (9c). 
 
The title compound was prepared according to Method D by the reaction of 9b (0.63 g, 
3.00 mmol, 1 equiv) and sulfamoyl chloride (1.73 g, 15.00 mmol, 5 equiv) in DMA (20 ml). 
The product was purified by column chromatography (cyclohexane/ethylacetate 2:1) to give 
0.45 g (1.56 mmol/ 52%) of the analytically pure compound. C10H8ClNO3S2; MW 289; 
1
H 
NMR (300 MHz, (CD3)2SO) δ 8.29 (s, 2H), 7.88 (d, J = 2.2 Hz, 1H), 7.69 (dd, J = 8.6, 2.3 




2-Chloro-4-(5-(2,6-difluoro-3-methoxybenzoyl)thiophen-2-yl)phenyl sulfamate (9d). 
 
The title compound was prepared according to method A by the reaction of 2,6-difluoro-3-
methoxybenzoyl chloride (0.41 g, 2.00 mmol, 1 equiv) and 9c (0.87 g, 3.00 mmol, 1.5 equiv) 
in the presence of anhydrous aluminium chloride (0.53 g, 4.00 mmol, 2 equiv) in anhydrous 
dichloromethane (10 ml). The product was purified by column chromatography 
(cyclohexane/ethylacetate 1:1) to give 0.59 g (1.30 mmol/ 65%) of the analytically pure 
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compound. C18H12ClF2NO5S2; MW 459; 
1
H NMR (300 MHz, (CD3)2SO) δ 8.37 (s, 2H), 8.11 
(d, J = 2.3 Hz, 1H), 7.88 (dd, J = 8.6, 2.3 Hz, 1H), 7.79 (d, J = 4.1 Hz, 1H), 7.70 (d, J = 4.1 




2-Chloro-4-(5-(2,6-difluoro-3-hydroxybenzoyl)thiophen-2-yl)phenyl sulfamate (9). 
 
The title compound was prepared according to Method C by the reaction of 9d (0.23 g, 
0.50 mmol, 1 equiv) and boron tribromide (1 M) in dichloromethane (1.50 ml, 1.50 mmol, 
3 equiv) in anhydrous dichloromethane (10 ml). The product was purified by column 
chromatography (dichloromethane/methanol 98.5:1.5) to give 60.00 mg (0.13 mmol/ 27%) of 




H NMR (500 
MHz, (CD3)2CO) δ 9.00 (s, 1H), 7.97 (d, J = 2.3 Hz, 1H), 7.80 (dd, J = 8.6, 2.3 Hz, 1H), 7.67 
(d, J = 4.1 Hz, 1H), 7.64 – 7.62 (m, 1H), 7.62 (d, J = 8.5 Hz, 1H), 7.47 (s, 2H), 7.21 – 7.14 
(m, 1H), 7.03 – 6.96 (m, 1H);
 13
C NMR (126 MHz, (CD3)2CO) δ 180.76, 152.52 (dd, J = 
240.6, 5.9 Hz), 152.31, 148.41 (dd, J = 246.0, 7.6 Hz), 148.06, 144.15, 142.67 (dd, J = 12.8, 
3.2 Hz), 138.18, 133.45, 129.05, 129.03, 127.25, 127.04, 125.62, 120.44 (dd, J = 9.1, 3.9 Hz), 





The title compound was prepared according to method B by the reaction of 2-bromothiophene 
(0.82 g, 5 mmol, 1 equiv) and (4-methoxy-3-methylphenyl)boronic acid (0.99 g, 6 mmol, 
1.2 equiv) in the presence of ceasium carbonate (6.5 g, 20 mmol, 4 equiv) and 
tetrakis(triphenylphosphine) palladium (0.29 g, 0.25 mmol, 0.05 equiv)  in DME/water 1:1 
(50 ml). The product was purified by column chromatography 
(cyclohexane/dichloromethane 7:1) to give 0.99 g (4.85 mmol/ 97%) of the analytically pure 
compound. C12H12OS; MW 204;
 1H NMR (500 MHz, (CD3)2CO) δ 7.46 – 7.43 (m, 2H), 7.34 
(dd, J = 5.1, 1.2 Hz, 1H), 7.30 (dd, J = 3.6, 1.1 Hz, 1H), 7.06 (dd, J = 5.1, 3.6 Hz, 1H), 6.95 – 





Supporting information  144 
 
 
The title compound was prepared according to Method C by the reaction of 10a (0.82 g, 
4.00 mmol, 1 equiv) and boron tribromide (1 M) in dichloromethane (12.00 ml, 12.00 mmol, 
3 equiv) in anhydrous dichloromethane (20 ml). The product was purified by column 
chromatography (cyclohexane/dichloromethane 4:1) to give 0.66 g (3.48 mmol/ 87%) of the 
analytically pure compound. C11H10OS; MW 190; 
1
H NMR (500 MHz, (CD3)2CO) δ 8.41 (s, 
1H), 7.41 (d, J = 2.3 Hz, 1H), 7.33 – 7.29 (m, 2H), 7.25 (dd, J = 3.6, 1.2 Hz, 1H), 7.05 (dd, J 
= 5.1, 3.6 Hz, 1H), 6.86 (d, J = 8.3 Hz, 1H), 2.24 (s, 3H); MS (ESI): 191.08 (M+H)
+
. 
2-Methyl-4-(thiophen-2-yl)phenyl sulfamate (10c). 
 
The title compound was prepared according to Method D by the reaction of 10b (0.57 g, 
3.00 mmol, 1 equiv) and sulfamoyl chloride (1.73 g, 15.00 mmol, 5 equiv) in DMA (20 ml). 
The product was purified by column chromatography (cyclohexane/ethylacetate 4:1) to give 
0.72 g (2.67 mmol/ 89%) of the analytically pure compound. C11H11NO3S2; MW 269; 
1
H 
NMR (500 MHz, (CD3)2CO) δ 7.61 (d, J = 2.4 Hz, 1H), 7.53 (dd, J = 8.4, 2.4 Hz, 1H), 7.49 – 
7.44 (m, 2H), 7.40 (d, J = 8.4 Hz, 1H), 7.26 (s, 2H), 7.13 (dd, J = 5.1, 3.6 Hz, 1H), 2.38 (s, 
3H); MS (ESI): 270.09 (M+H)
+
. 
4-(5-(2,6-Difluoro-3-methoxybenzoyl)thiophen-2-yl)-2-methylphenyl sulfamate (10d). 
 
The title compound was prepared according to method A by the reaction of 2,6-difluoro-3-
methoxybenzoyl chloride (0.41 g, 2.00 mmol, 1 equiv) and 10c (0.81 g, 3.00 mmol, 1.5 equiv) 
in the presence of anhydrous aluminium chloride (0.53 g, 4.00 mmol, 2 equiv) in anhydrous 
dichloromethane (10 ml). The product was used in the next step without further 
purification.C19H15F2NO5S2; MW 439; MS (ESI): 440.04 (M+H)
+
. 
4-(5-(2,6-Difluoro-3-hydroxybenzoyl)thiophen-2-yl)-2-methylphenyl sulfamate (10). 
 
The title compound was prepared according to Method C by the reaction of 10d (0.22 g, 
0.50 mmol, 1 equiv) and boron tribromide (1 M) in dichloromethane (1.50 ml, 1.50 mmol, 
3 equiv) in anhydrous dichloromethane (10 ml). The product was purified by column 
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chromatography (dichloromethane/methanol 98.5:1.5) to give 72.00 mg (0.17 mmol/ 34%) of 




H NMR (500 
MHz, (CD3)2CO) δ 9.03 (s, 1H), 7.78 (dd, J = 2.5, 0.9 Hz, 1H), 7.70 (ddd, J = 8.5, 2.5, 0.6 
Hz, 1H), 7.64 (d, J = 4.1 Hz, 1H), 7.61 (d, J = 4.1 Hz, 1H), 7.49 (d, J = 8.5 Hz, 1H), 7.34 (s, 
2H), 7.25 – 7.17 (m, 1H), 7.04 (td, J = 8.9, 1.9 Hz, 1H), 2.42 (s, 3H);
 13
C NMR (126 MHz, 
(CD3)2CO) δ 180.63, 154.35, 152.49 (dd, J = 240.3, 5.8 Hz),  150.93, 148.36 (dd, J = 245.6, 
7.8 Hz), 143.34, 142.61 (dd, J = 13.0, 3.4 Hz), 138.27, 133.68, 132.08, 130.21, 126.25, 
125.90, 123.97, 120.28 (dd, J = 9.1, 3.9 Hz), 118.02 (dd, J = 24.2, 19.7 Hz), 112.41 (dd, J = 





The title compound was prepared according to method B by the reaction of 2-bromothiophene 
(0.82 g, 5.00 mmol, 1 equiv) and (2,3-difluoro-4-methoxyphenyl)boronic acid (1.13 g, 
6.00 mmol, 1.2 equiv) in the presence of ceasium carbonate (6.50 g, 20.00 mmol, 4 equiv) and 
tetrakis(triphenylphosphine) palladium (0.29 g, 0.25 mmol, 0.05 equiv)  in DME/water 1:1 
(50 ml). The product was used in the next step without further purification. C11H8F2OS; MW 
226; MS (ESI): 227.01 (M+H)+. 
2,3-Difluoro-4-(thiophen-2-yl)phenol (11b). 
 
The title compound was prepared according to Method C by the reaction of 11a (0.80 g, 
3.50 mmol, 1 equiv) and boron tribromide (1 M) in dichloromethane (10.50 ml, 10.50 mmol, 
3 equiv) in anhydrous dichloromethane (20 ml). The product was purified by column 
chromatography (cyclohexane/dichloromethane 4:1) to give 0.66 g (3.15 mmol/ 90%) of the 
analytically pure compound. C10H6F2OS; MW 212;
 1
H NMR (300 MHz, (CD3)2CO) δ 9.46 (s, 
1H), 7.58 – 7.49 (m, 2H), 7.46 – 7.40 (m, 1H), 7.19 – 7.12 (m, 1H), 6.96 (dd, J = 8.8, 1.7 Hz, 
1H); MS (ESI): 213.04 (M+H)
+
. 
2,3-Difluoro-4-(thiophen-2-yl)phenyl sulfamate (11c). 
 
The title compound was prepared according to Method D by the reaction of 11b (0.64 g, 
3.00 mmol, 1 equiv) and sulfamoyl chloride (1.73 g, 15.00 mmol, 5 equiv) in DMA (20 ml). 
The product was purified by column chromatography (cyclohexane/ethylacetate 4:1) to give 
Supporting information  146 
 
 
0.50 g (1.74 mmol/ 58%) of the analytically pure compound. C10H7F2NO3S2; MW 291;
 1
H 
NMR (300 MHz, (CD3)2SO) δ 8.42 (s, 2H), 7.89 (t, J = 8.6 Hz, 1H), 7.74 (dd, J = 5.0, 1.2 Hz, 
1H), 7.63 (dt, J = 3.7, 1.2 Hz, 1H), 7.44 (dd, J = 8.6, 1.2 Hz, 1H), 7.24 (ddd, J = 5.0, 3.7, 1.2 
Hz, 1H); MS (ESI): 292.05 (M+H)
+
. 
4-(5-(2,6-Difluoro-3-methoxybenzoyl)thiophen-2-yl)-2,3-difluorophenyl sulfamate (11d). 
 
The title compound was prepared according to method A by the reaction of 2,6-difluoro-3-
methoxybenzoyl chloride (0.41 g, 2.00 mmol, 1 equiv) and 11c (0.87 g, 3.00 mmol, 1.5 equiv) 
in the presence of anhydrous aluminium chloride (0.53 g, 4.00 mmol, 2 equiv) in anhydrous 
dichloromethane (10 ml). The product was used in the next step without further purification. 
C18H11F4NO5S2; MW 461; MS (ESI): 462.03 (M+H)
+
. 
4-(5-(2,6-Difluoro-3-hydroxybenzoyl)thiophen-2-yl)-2,3-difluorophenyl sulfamate (11). 
             
The title compound was prepared according to Method C by the reaction of 11d (0.23 g, 
0.50 mmol, 1 equiv) and boron tribromide (1 M) in dichloromethane (1.50 ml, 1.50 mmol, 
3 equiv) in anhydrous dichloromethane (10 ml). The product was purified by column 
chromatography (dichloromethane/methanol 98.5:1.5) to give 62.00 mg (0.14 mmol/ 28%) of 




H NMR (500 MHz, 
(CD3)2CO) δ 9.15 (s, 1H), 7.77 (ddd, J = 8.9, 7.8, 2.4 Hz, 1H), 7.74 – 7.71 (m, 2H), 7.66 (s, 
2H), 7.45 (ddd, J = 9.0, 7.1, 2.1 Hz, 1H), 7.22 (ddd, J = 9.7, 9.1, 5.4 Hz, 1H), 7.04 (ddd, J = 
9.1, 8.5, 1.8 Hz, 1H);
 13
C NMR (126 MHz, (CD3)2CO) δ 
13
C NMR (126 MHz, (CD3)2CO) δ 
180.99 , 152.47 (dd, J = 240.8, 5.7 Hz), 148.37 (dd, J = 246.1, 7.7 Hz), 149.10 (dd, J = 253.6, 
12.4 Hz), 145.50, 145.41 (dd, J = 252.9, 14.6 Hz), 144.78 (d, J = 4.2 Hz), 142.67 (dd, J = 
12.6, 3.3 Hz), 140.16 (dd, J = 9.7, 2.2 Hz), 137.42 , 129.60 (d, J = 5.3 Hz), 124.00 (dd, J = 
7.1, 2.4 Hz), 121.84 (d, J = 9.6 Hz), 121.32 (d, J = 3.7 Hz), 120.52 (dd, J = 9.2, 3.9 Hz), 








The title compound was prepared according to method B by the reaction of 2-bromothiophene 
(0.82 g, 5.00 mmol, 1 equiv) and (3-chloro-2-fluoro-4-methoxyphenyl)boronic acid (1.22 g, 
6.00 mmol, 1.2 equiv) in the presence of ceasium carbonate (6.50 g, 20.00 mmol, 4 equiv) and 
tetrakis(triphenylphosphine) palladium (0.29 g, 0.25 mmol, 0.05 equiv)  in DME/water 1:1 
(50 ml). The product was purified by column chromatography 
(cyclohexane/dichloromethane 7:1) to give 1.10 g (4.55 mmol/ 91%) of the analytically pure 
compound. C11H8ClFOS; MW 242; 
1
H NMR (300 MHz, (CD3)2CO) δ 7.62 (t, J = 8.8 Hz, 
1H), 7.53 (dd, J = 5.2, 1.2 Hz, 1H), 7.48 – 7.42 (m, 1H), 7.16 (ddd, J = 5.2, 3.7, 1.0 Hz, 1H), 





The title compound was prepared according to Method C by the reaction of 12a (1.00 g, 
4.00 mmol, 1 equiv) and boron tribromide (1 M) in dichloromethane (12.00 ml, 12.00 mmol, 
3 equiv) in anhydrous dichloromethane (20 ml). The product was purified by column 
chromatography (cyclohexane/dichloromethane 4:1) to give 0.87 g (3.80 mmol/ 95%) of the 
analytically pure compound. C10H6ClFOS; MW 228; 
1
H NMR (300 MHz, (CD3)2CO) δ 9.44 
(s, 1H), 7.56 – 7.47 (m, 2H), 7.44 – 7.40 (m, 1H), 7.14 (ddd, J = 5.2, 3.7, 1.0 Hz, 1H), 6.94 
(dd, J = 8.8, 1.7 Hz, 1H); MS (ESI): 229.05 (M+H)
+
. 
2-Chloro-3-fluoro-4-(thiophen-2-yl)phenyl sulfamate (12c). 
 
The title compound was prepared according to Method D by the reaction of 12b (0.68 g, 
3.00 mmol, 1 equiv) and sulfamoyl chloride (1.73 g, 15.00 mmol, 5 equiv) in DMA (20 ml). 
The product was purified by column chromatography (cyclohexane/ethylacetate 4:1) to give 
0.90 g (2.94 mmol/ 98%) of the analytically pure compound. C10H7ClFNO3S2; MW 307;
 1
H 
NMR (300 MHz, (CD3)2SO) δ 8.44 (s, 2H), 7.86 (t, J = 8.7 Hz, 1H), 7.76 (dd, J = 5.1, 1.2 Hz, 
1H), 7.64 (dt, J = 3.7, 1.1 Hz, 1H), 7.43 (dd, J = 8.9, 1.7 Hz, 1H), 7.23 (ddd, J = 5.0, 3.7, 1.2 




sulfamate (12d).     




The title compound was prepared according to method A by the reaction of 2,6-difluoro-3-
methoxybenzoyl chloride (0.41 g, 2.00 mmol, 1 equiv) and 12c (0.92 g, 3.00 mmol, 1.5 equiv) 
in the presence of anhydrous aluminium chloride (0.53 g, 4.00 mmol, 2 equiv) in anhydrous 
dichloromethane (10 ml). The product was purified by column chromatography 
(cyclohexane/ethylacetate 3:2) to give 0.89 g (1.88 mmol/ 94%) of the analytically pure 
compound. C18H11ClF3NO5S2; MW 477; 
1
H NMR (300 MHz, (CD3)2CO) δ 7.94 (t, J = 
8.8 Hz, 1H), 7.77 – 7.68 (m, 2H), 7.61 (s, 2H), 7.55 (dd, J = 8.9, 1.8 Hz, 1H), 7.38 (td, J = 





    
The title compound was prepared according to Method C by the reaction of 12d (0.24 g, 
0.50 mmol, 1 equiv) and boron tribromide (1 M) in dichloromethane (1.50 ml, 1.50 mmol, 
3 equiv) in anhydrous dichloromethane (10 ml). The product was purified by column 
chromatography (dichloromethane/methanol 98.5:1.5) to give 122.00 mg (0.26 mmol/ 53%) 




H NMR (500 
MHz, (CD3)2CO) δ 9.11 (s, 1H), 7.94 (t, 8.8 Hz, 1H), 7.77 – 7.70 (m, 2H), 7.66 (s, 2H), 7.55 
(dd, J = 8.9, 1.8 Hz, 1H), 7.27 – 7.18 (m, 1H), 7.05 (td, J = 8.9, 1.9 Hz, 1H);
 13
C NMR (126 
MHz, (CD3)2CO) δ 181.02 , 156.17 (d, J = 253.5 Hz), 152.51 (dd, J = 240.7, 5.7 Hz), 148.91 
(d, J = 1.8 Hz), 148.40 (dd, J = 246.1, 7.7 Hz), 145.77 (d, J = 4.4 Hz), 144.75 (d, J = 4.4 Hz), 
142.70 (dd, J = 12.8, 3.2 Hz), 137.46 , 129.64 (d, J = 5.2 Hz), 128.21 (d, J = 3.7 Hz), 121.18 
(d, J = 12.9 Hz), 120.77 (d, J = 3.8 Hz), 120.54 (dd, J = 9.1, 3.8 Hz), 117.84 (dd, J = 23.7, 
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Table S1. Purity of final compounds as evaluated by HPLC  
 
Compound Rt (min) Purity (%) 
1 7.49 99.5 
2 7.51 96.5 
3 7.52 97.5 
4 7.63 98.5 
5 8.14 99.0 
6 8.32 99.4 
7 7.51 99.2 
8 8.11 96.6 
9 8.32 95.8 
10 7.52 99.2 
11 7.95 96.7 
12 8.01 98.6 
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5.1.I.4 Representative 1HNMR and 13CNMR spectra
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5.1.II Biological methods 
5.1.II.1 Chemicals 





H]-E1 (50-100 Ci/mmol) and [2,4,6,7-
3
H]-E2 ( >110 Ci/mmol) 
were obtained from Perkin Elmer, Boston. Quickszint Flow 302 scintillator fluid was bought 
from Zinsser Analytic, Frankfurt. Charcoal-stripped FCS was received from Biowest. Other 
chemicals were purchased from Sigma, Merck or Gibco. 
5.1.II.2 hSTS cell free inhibition assay 
The human enzyme was partially purified from the microsomal fraction of freshly 
homogenized human placental tissue according to previously described procedures.
s1
 The 
enzyme preparation was pre-incubated in Tris-HCl buffer (20 mM, pH= 7.4) for 30 min at 
37 °C with DMSO stocks of potential inhibitors (final DMSO concentration in the assay was 
1%). Negative and positive controls (vehicle only and 14 at 2 µM, resp.) were present in each 
assay. Incubation was started by the addition of E1-S (final concentration: 300 nM) for 20 
min at 37 °C. Compounds 8 or 14 was added (final concentration: 2 µM) to quench the 
reaction. The amount of E1 produced was quantified using the competitive Estrone ELISA 
Kit from DRG Instruments GmbH (Marburg, Germany) according to the instructions of the 
manufacturer.
s2
 The assay did not show cross-sensitivity for E1-S and E2 in the relevant 
concentration range. Optical densities were measured with a Polarstar Omega plate reader 
(BMG Labtech, Ortenberg, Germany) at 450 nm.
s3
 For IC50 determinations, at least two 
independent measurements were carried out using three different inhibitor concentrations 
(leading to inhibitions in the range from 30-70%, relative to the uninhibited control). In this 
assay, the reference compound 14 shows an IC50 value of 15.1 nM, comparable to the value 
reported in the literature 8 nM.
s4 
5.1.II.3 h17β-HSD1 and h17β-HSD2 cell free inhibition assays 
The human enzymes were partially purified from human placental tissue according to 
previously described procedures.
s1
 Fresh human placenta was homogenized and by fractional 
centrifugation the cytosolic and microsomal fractions were separated. In case of the h17β-
HSD1 assay the cytosolic fraction was incubated with NADH (500 µM), while in the case of 
the h17β-HSD2 assay the microsomal fraction was incubated with NAD
+
 (1500 µM) at 37 °C 
in a phosphate buffer (50 mM) with 20% of glycerol and EDTA (1 mM) in the presence of 
potential inhibitors which were prepared in DMSO (final DMSO concentration in the assay 
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was 1%). The enzymatic reaction was started by the addition of a mixture of unlabeled and 
radiolabeled substrate (final concentration: 500 nM), [
3
H]-E1 in the case of h17β-HSD1 assay 
for 10 min or with [
3
H]-E2 in the case of h17β-HSD2 assay for 20 min.
s1
 HgCl2 (10mM) was 
used to stop the enzymatic reactions and the steroids were extracted with diethylether. After 
evaporation, they were dissolved in acetonitrile/water (45:55). E1 and E2 were separated on a 
C18 reverse phase chromatography column (Nucleodur C18 Isis, Macherey-Nagel) connected 
to an Agilent 1200 Series (Agilent Technologies) HPLC-system using acetonitrile/water 
(45:55) as mobile phase. A radioflow detector (Ramona, raytest) was coupled to the HPLC-
system for the detection and quantification of the steroids. After the analysis of the resulting 
chromatograms, the conversion rates were calculated according to the following equation: 
%𝑐𝑜𝑛𝑣𝑒𝑟𝑠𝑖𝑜𝑛 = [
%𝑝𝑟𝑜𝑑𝑢𝑐𝑡
%𝑝𝑟𝑜𝑑𝑢𝑐𝑡 + % 𝑆𝑢𝑏𝑠𝑡𝑟𝑎𝑡𝑒
] ∗ 100 
Each value was calculated from at least two independent experiments. 
Then the percentage inhibition corresponding to each inhibitor concentration was calculated 
according to the following equation: 
%𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 = [1 − (
%𝑐𝑜𝑛𝑣𝑒𝑟𝑠𝑖𝑜𝑛 𝑜𝑓 𝑡ℎ𝑒 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟
%𝑐𝑜𝑛𝑣𝑒𝑟𝑠𝑖𝑜𝑛 𝑜𝑓 𝑡ℎ𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 (𝐷𝑀𝑆𝑂)
)] ∗ 100 
At least three different concentrations of each inhibitor leading to inhibitions ranging from 
30% to 80% were chosen to deduce the IC50 of each inhibitor. The IC50 of each inhibitor was 
calculated from at least two independent experiments.  
5.1.II.4 Cell culture 
T47D human mammary cancer cell line was purchased from ECACC, Salisburry. The cells 
were routinely cultivated in DMEM (Sigma) supplemented with 10% FCS (Sigma) and 
100 IU/ml penicillin-streptomycin, and incubated at 37 °C under humidified atmosphere of 
5% CO2. The medium was changed every 2-3 days, and the cells were passed every 9-10 
days. 
5.1.II.5 hSTS and h17β-HSD1 cellular inhibition assays 
The T47D cells were seeded into a 24-well flat-bottom plate at 5 * 10
5
 cells/well in DMEM 
supplemented with 10% FCS and 100 IU/ml penicillin-streptomycin according to previously 
described procedures.
s5,6
 After incubation for 24 h of adaptation at 37 °C, the medium was 
exchanged by a fresh FCS-free DMEM and the test compound dissolved in DMSO was added 
(final concentration of DMSO was adjusted to 1% in all samples). After 1 h the incubation 
period was started by the addition of a mixture of unlabeled and radioactive substrate [
3
H]-
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E1-S (5 nM) for 24 h or [
3
H]-E1 (50 nM) for 30 min at 37 °C in case of hSTS or h17β-HSD1 
cellular inhibition assays, respectively. The reaction was stopped by the removal of the 
supernatant. The supernatant was injected directly (without any further workup) into the same 
radio-HPLC system mentioned above for h17β-HSD1 and h17β-HSD2 cell free inhibition 
assays and the IC50s are calculated as described. 
5.1.II.6 Nature of inhibition of STS activity 
In order to investigate the mode of inhibition of STS activity, T47D cells were cultivated as 
mentioned above but with some changes described by Purohit et al., 1995.
s7
 The cells were 
pre-incubated with the inhibitors for 2 h at 37 °C, then the medium was removed and the cells 
were washed 3-4 times with PBS (phosphate buffer saline). The remaining STS activity was 
assayed as described in the recent procedure by incubating the cells with using [
3
H]-E1-S for 
24 h at 37 °C, then subsequent quantification of the steroids in the supernatant using HPLC 
coupled to radiodetector and the IC50s are calculated as described. 
5.1.II.7 Proliferation assay 
In 24-well plates, according to previously described procedures
s5
 the T47D cells were grown 
for 2 days in RPMI (without phenol red) serum-free medium supplemented with 100 IU/ml 
penicillin-streptomycin, sodium pyruvate (1 mM) and L-glutamine (2 mM). Then 
charcoal-stripped FCS 5% (v/v), estrogens and/or the compounds were added after the 
dilution in ethanol (the final concentration of ethanol was set to 1% of the medium). Every 
2-3 days the medium was exchanged with fresh medium containing the same additives. Then 
the cell viability is evaluated by MTT assay based on the ability of viable cells to convert the 
yellow water soluble dye 3-(4,5-dimethyl-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to a 
violet water insoluble formazane. After 7 days of culturing (without passage) in the presence 
of the respective additives, 100 µl of MTT-solution (5mg/ml in PBS) was added to the 
medium. After 2 h, the medium was removed and 215 µl of DMSO containing 10% Sodium 
dodecyl sulphate (SDS) and 0.01 N HCl was added to start the cell lysis and dissolve the blue 
formazan which was quantified spectrophotometrically at 590 nM using an Omega plate 
reader spectrometer as described.
s5
 Proliferation in the presence of the vehicle was always 
arbitrary set to 100%. 
5.1.II.8 Monitoring of estrogens during proliferation assay 
The levels of conversion of the estrogens were monitored by treating the cells as described 
above in the proliferation assay with some modifications. Radiolabeled estrogens ([
3
H]-E1-S 





H]-E1) were used. After 2 days of incubation the supernatant were removed and injected 
to the radio HPLC for the separation and quantification of the radioactive steroids. 
5.1.II.9 MTT cell viability assay 
In 24-well plates, HEK293 were seeded in DMEM supplemented with 5% FKS and 
100 IU/ml penicillin-streptomycin. After 3 h, the incubation was started by the addition of 
compound 9 at 0.1, 0.2, 0.4 and 1 µM dissolved in ethanol with a final ethanol concentration 
of 1%. After 48 h, the MTT dye was added and the same procedure as described before was 
followed. Viability in the presence of the vehicle was arbitrarily set to 100%. For results, see 
Figure S2. 
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5.1.III Further results 
5.1.III.1 Table S2 







1 9.1 100 
2 9.0 100 
3 9.4 100 
4 8.2 90 
5 8.2 100 
6 8.2 100 
7 9.3 100 
8 7.9 90 
9 7.8 94 
10 9.5 100 
11 6.9 28 
12 6.7 20 
a 
cpKa values of phenolic parent cpd (RO
-
), determined by ACD/Labs Software; 
b
 % of sulfamated cmpd relative 
to unsulfamated phenolic parent cpd evaluated at least 2 times (standard deviation less than 10%) using LC-MS 
after incubating the sulfamated cmpds in 20mM Tris-HCl buffer pH=7.2 for 30min @ 37°C. 
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5.1.III.2 Table S3 
Percentages of remaining STS and h17β-HSD1 activities within the T47D cells in the presence of 
vehicle or cmpd 9 after treating it according to the procedure proposed for the determination of the 









24 h 48h 24h 48h 
Vehicle
 d
 47.4%  98.5%  100%  100%  
9
 e
 0% 0%  100%  100%  
a
 Mean value of at least two independent experiments each conducted in triplicates, standard deviation less than 
10%; 
b 
remaining STS activity was assayed by incubating the cells with [
3
H]-E1-S [5nM] for 24 h and 48 h then 
quantifying the amount of [
3
H]-E1 produced relative to the amount of [
3
H]-E1-S remaining ; 
c
 remaining h17β-
HSD1 activity was assayed by incubating the cells with [
3
H]-E1 [50nM] for 24 h and 48 h then quantifying the 
amount of [
3




 vehicle: ethanol; 
e
 cmpd 9 [50 nM]. 
5.1.III.3 Table S2 
Inhibitory activities of compounds 9 and 14 towards hSTS in cell-free assay using ELISA kit and 











 143.1  138.8 
14  15.1 12.2 
a
 Mean value of at least two independent experiments each conducted in duplicates, standard deviation less than 
5%; 
b
 substrate E1-S [300 nM];
 c
 exactly the same biochemical steps were followed however the substrate was 
[
3
H]-E1-S + E1-S [300 nM], after the quenching step the reaction mixture (without any further workup) was 
injected into the same radio-HPLC system mentioned above for h17β-HSD1 and h17β-HSD2 cell free inhibition 
assays.  




5.1.III.4 Figure S1 
Concentration dependent inhibition of E1-S- and E1-stimulated cell growth for compounds 5, 6, 8, 9, 
13 and 14 on T47D cells. Cells were grown in phenol red-free RPMI 1640 medium supplemented with 
5% stripped FCS. Medium represents cells grown in non-estrogenic medium. EM (estrogenic medium) 
represents E1-S [50 nM] and E1 [50 nM] treated cells. Compound 5 was tested at 3 different 
concentrations [200, 400 and 800 nM]. Compound 6 was tested at 3 different concentrations [300, 600 
and 1200 nM]. Compounds 8 and 9 were tested at 3 different concentrations [100, 200 and 400 nM]. 
Compounds 13 and 14 were tested at 3 different concentrations [50, 100 and 200 nM]. Cells were 
incubated with the respective additives for 7 days without passage. Medium was changed every 2–3 
days. Vehicle is ethanol.                           




5.1.III.5 Figure S2 
MTT cell viability assay using HEK293 for compound 9. The cells were seeded in DMEM 
supplemented with 5% FKS and 100 IU/ml penicillin-streptomycin. After 3 h, the incubation was 
started by the addition of compound 9 at four different concentrations: 0.1, 0.2, 0.4 and 1 µM 
dissolved in ethanol with a final concentration 1%. After 48 h, the viability of the cells was evaluated 
by the addition of MTT dye setting the viability in the presence of the vehicle arbitrary to 100%. 
Vehicle is ethanol.                           
5.1.III.6 Determination of statistical significances 
Statistical analyses of cell proliferation assays were carried using Student’s t-test (one-tailed, 
two samples, same variance). Differences of the mean were classified as insignificant 
(p>0.05), probable (p<0.05), significant (**, p<0.01) and highly significant (***, p<0.001). 
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5.2 Supporting information for Monograph B 
5.2.I Chemistry 
5.2.I.1 Chemical methods 
Chemical names follow IUPAC nomenclature. 
Starting materials were purchased from Acros Organics, Alfa Aesar, Combi-Blocks, 
Fluorochem and Sigma Aldrich. Column chromatography was performed on silica gel (0.04-
0.063 mm, Macherey-Nagel) and reaction progress was monitored by TLC on aluminum 





C NMR spectra were measured on a Bruker-500 (at 500 MHz and 125 MHz, 
respectively) or Bruker-300 (at 300 MHz). Chemical shifts are reported in δ (parts per 
million: ppm), using residual peaks of the deuterated solvents as internal standard: (CD3)2SO 
(DMSO-d6): 2.50 ppm (
1
H NMR), 39.52 ppm (
13
C NMR); (CD3)2CO (acetone-d6): 2.05 ppm 
(
1
H NMR), 29.84 ppm and 206.26 ppm (
13
C NMR). Signals are described as s, d, t, dd, ddd, 
dt, td and m for singlet, doublet, triplet, doublet of doublets, doublet of doublet of doublets, 
doublet of triplets, triplets of doublets and multiplet, respectively. All coupling constants (J) 
are given in Hertz (Hz). 
All tested compounds have ≥ 95% chemical purity as evaluated by HPLC. The purity of the 
compounds was evaluated by LC/MS. The Surveyor®-LC-system consisted of a pump, an 
auto sampler, and a PDA detector. Mass spectrometry was performed by a TSQ® Quantum 
(ThermoFisher, Dreieich, Germany). The triple quadrupole mass spectrometer was equipped 
with an electrospray interface (ESI). The system was operated by the standard software 
Xcalibur®. A RP C18 NUCLEODUR® 100-5 (3 mm) column (Macherey-Nagel GmbH, 
Dühren, Germany) was used as stationary phase. All solvents were HPLC grade. In a gradient 
run the percentage of acetonitrile (containing 0.1 % trifluoroacetic acid) was increased from 
an initial concentration of 30% at 0 min to 100 % at 12 min and kept at 100 % for 3 min. The 
injection volume was 25 µL and flow rate was set to 700 µL/min. MS analysis was carried out 
at a needle voltage of 3000 V and a capillary temperature of 350 °C. Mass spectra were 
acquired in positive mode from 100 to 1000 m/z and UV spectra were recorded at the wave 
length of 254 nm. High resolution precise mass spectra were recorded on ThermoFisher 
Scientific (TF, Dreieich, Germany) Q Exactive Focus system equipped with heated 
electrospray ionization (HESI)-II source and Xcalibur (version 4.0.27.19) software. Before 
analysis external mass calibration was done according to the manufacturer’s 
recommendations. The samples were dissolved and diluted in methanol in a concentration of 
Supporting information  168 
 
 
5 μM and directly injected onto the Q Exactive Focus using the integrated syringe pump. All 
the data analyses were done in positive ion mode using voltage scans and the data collected in 
continuous mode. The melting points were measured using Stuart™ melting point apparatus 
SMP3. 
5.2.I.2 General procedures 
General procedure for Acyl Chloride formation. (Method A)  
A mixture of 5-bromofuran-2-carboxylic acid (5 mmol, 1 equiv), thionylchloride (10 mmol, 2 
equiv) and DMF (20 drops) in toluene (30 mL) was refluxed at 110 °C for 4 h. The reaction 
mixture was cooled to room temperature; the solvent and the excess of thionyl chloride were 
removed under reduced pressure. The crude product was used in the next step without any 
further purification. 
General procedure for Amide formation. (Method B)  
The corresponding aniline (5 mmol, 1 equiv) and Et3N (7.5 mmol, 1.5 equiv) in CH2Cl2 (25 
mL) was added at 0 °C under N2 atmosphere to the acyl chloride. After 30 min at 0 °C, the ice 
bath was removed and the solution was warmed up and stirred at room temperature overnight. 
The reaction mixture was extracted twice with ethyl acetate (2 x 15 mL); the organic layer 
was dried over MgSO4, filtered and the solution was concentrated under reduced pressure. 
The residue was purified using flash column chromatography. 
General procedure for N-Methylation. (Method C).   
After 30 min of ice-cooled stirring for a mixture of benzamide derivatives (4 mmol, 1 equiv) 
and NaH (60% suspension in mineral oil, 8 mmol, 2 equiv) in DMF (10 mL), iodomethane (8 
mmol, 2 equiv) was added and the reaction was left overnight to stir at room temperature. 
Then the reaction mixture was poured into water. The resulting precipitate was collected, 
washed with water, dried, and purified by flash column chromatography. 
General procedure for ether cleavage (Method D) 
A solution of the methoxyaryl compound (1.5 mmol, 1 equiv) in dry DCM (20 mL) was 
cooled on an ice/water bath. Boron trifluoride dimethyl sulfide complex (30 mmol, 20 equiv) 
was added dropwise under continuous stirring. The mixture was left to stir overnight at room 
temperature. After the reaction was finished, the mixture was quenched with methanol and the 
solvents removed under reduced pressure. The product was purified by flash column 
chromatography. 
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General procedure for Suzuki coupling (Method E) 
Arylbromide (1 mmol, 1 equiv), boronic acid derivative (1.2 mmol, 1.2 equiv), cesium 
carbonate (4 mmol, 4 equiv) and tetrakis(triphenylphosphine) palladium (0.05 mmol, 0.05 
equiv) were added to an oxygen-free DME/water (1:1) (30 mL) and refluxed at 110 
°
C under 
nitrogen atmosphere for 4 h. The reaction mixture was cooled to room temperature. The 
aqueous layer was extracted with ethyl acetate. The organic layers were combined, dried over 
magnesium sulfate and concentrated to dryness under reduced pressure.  The product was 
purified by flash column chromatography.  
General procedure for Sulfamoylation (Method F) 
A solution of phenol derivative (0.5 mmol, 1 equiv) in DMA (10 mL) was cooled to 0 
°
C. A 
freshly prepared sulfamoyl chloride (5 mmol, 10 equiv) was subsequently added over 5 min 
and the reaction mixture was warmed to room temperature overnight. The reaction was 
quenched with water. The resulting precipitate was collected, washed with water, dried, and 
purified by flash column chromatography. 
Preparation of sulfamoyl chloride (Method G) 
A fresh solution was prepared for each reaction. Chlorosulfonyl isocyanate (5 mmol, 1 equiv) 
was cooled to 0 
°
C. Then formic acid 99% (5 mmol, 1 equiv) was then added dropwise to the 
isocyanate slowly over 10 min. Slow, steady evolution of CO2 was observed; eventually a 
white solid was formed. After 20 min, the ice bath was removed and the reaction mixture was 
warmed to room temperature and then used in the next reaction without further workup. 
5.2.I.3 Detailed synthesis procedure and compound characterization 
5-bromofuran-2-carbonyl chloride 
 
The title compound was prepared according to method A by the reaction of 5-bromofuran-2-
carboxylic acid (0.95 g, 5 mmol, 1 equiv) and thionyl chloride (1.20 g, 10 mmol, 2 equiv) in 
the presence of dimethyl formamide (20 drops) in toluene (20 ml). The crude product was 
used in the next step without any further purification. 
5-bromo-N-(3-methoxy-2-methylphenyl)furan-2-carboxamide (4a) 
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The title compound was prepared according to method B by the reaction of 3-methoxy-2-
methylaniline (0.685 g, 5 mmol, 1 equiv) and 5-bromofuran-2-carbonyl chloride (1.05 g, 
5 mmol, 1 equiv) in the presence of Et3N (1.05 ml, 0.76 g, 7.5 mmol, 1.5 equiv) in CH2Cl2 (25 
ml). The product was purified by flash column chromatography (Petrolum ether/Etyl acetate, 
0 - 50 % EtOAc in 30 min), to give 780 mg (2.51 mmol/ 50% yield) of the analytically pure 
compound (purity: 97%). C13H12BrNO3; MW 310.14;
 1
H NMR (500 MHz, DMSO-d6) δ 9.91 
(s, 1H), 7.32 (d, J = 3.6 Hz, 1H), 7.17 (t, J = 8.1 Hz, 1H), 6.88 (d, J = 8.1 Hz, 2H), 6.82 (d, J 





The title compound was prepared by reaction of 4a (775 mg, 2.50 mmol, 1 equiv), sodium 
hydride 60 % suspension in mineral oil (200 mg, 6.5 mmol, 2 equiv) and iodomethane 
(0.31 mL, 5.0 mmol, 2 equiv) in DMF (10 ml) according to method C. The resulting 
precipitate was purified by flash column chromatography (Petrolum ether/Etyl acetate, 0 - 50 
% EtOAc in 30 min), to give 660 mg (2.03 mmol/ 82% yield) of the analytically pure 
compound (purity: 99%). C14H14BrNO3; MW 324.17;
 1
H NMR (500 MHz, DMSO-d6) δ 7.27 
(t, J = 8.1 Hz, 1H), 7.06 (d, J = 8.3 Hz, 1H), 6.88 (d, J = 7.8 Hz, 1H), 6.48 (d, J = 3.6 Hz, 1H), 






The title compound was prepared by reaction of 4b (660 mg, 2.0 mmol, 1 equiv) and boron 
trifluoride dimethyl sulfide (4.2 ml, 40 mmol, 20 equiv) in CH2Cl2 (30 ml) according to 
method D. The resulting product was purified by flash column chromatography 
(CH2Cl2/Methanol, 0 - 5 % methanol in 30 min), to give 400 mg (1.30 mmol/ 65% yield) of 
the analytically pure compound (purity: 98%). C13H12BrNO3; MW 310.14;
 1
H NMR (500 
MHz, DMSO-d6) δ 9.70 (s, 1H), 7.09 (t, J = 8.0 Hz, 1H), 6.88 (d, J = 8.2 Hz, 1H), 6.71 (d, J = 
7.8 Hz, 1H), 6.48 (d, J = 3.6 Hz, 1H), 5.48 (d, J = 3.6 Hz, 1H), 3.18 (s, 3H), 1.90 (s, 3H);
 
MS 
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The title compound was prepared by reaction of 4c (310 mg, 1.0 mmol, 1 equiv), (4-methoxy-
3,5-dimethylphenyl)boronic acid (220 mg, 1.2 mmol, 1.2 equiv), cesium carbonate (1300 mg, 
4.0 mmol, 4 equiv) and tetrakis(triphenylphosphine)palladium (55 mg, 0.05 mmol, 0.05 
equiv) in oxygen-free DME/water (1:1) (30 mL) according to method E. The resulting 
product was purified by flash column chromatography (CH2Cl2/Methanol, 0 - 5 % methanol 
in 30 min), to give 225 mg (0.62 mmol/ 62% yield) of the analytically pure compound (purity: 
95%). C22H23NO4; MW 365.43;
 1
H NMR (500 MHz, DMSO-d6) δ 9.71 (s, 1H), 7.08 (t, J = 
7.9 Hz, 1H), 6.96 (s, 2H), 6.90 (d, J = 8.2 Hz, 1H), 6.75 (d, J = 3.6 Hz, 1H), 6.70 (d, J = 7.8 








The title compound was prepared by reaction of 4d (220 mg, 0.60 mmol, 1 equiv) and 
sulfamoyl chloride (600 mg, 6 mmol, 10 equiv) in water-free DMA (10 mL) according to 
method E. The resulting precipitate was purified by flash column chromatography 
(CH2Cl2/Methanol, 0 - 5 % methanol in 30 min), to give 200 mg (0.45 mmol/ 75% yield) of 
the analytically pure compound (purity: 98%). C22H24N2O6S; MW 444.50;
 1
H NMR (500 
MHz, DMSO-d6) δ 8.16 (s, 2H), 7.44 (d, J = 8.3 Hz, 1H), 7.39 (t, J = 8.0 Hz, 1H), 7.27 (d, J = 
7.7 Hz, 1H), 6.92 (s, 2H), 6.76 (d, J = 3.6 Hz, 1H), 6.61 (d, J = 3.6 Hz, 1H), 3.63 (s, 3H), 3.24 






The title compound was prepared by reaction of 4e (200 mg, 0.45 mmol, 1 equiv) and boron 
trifluoride dimethyl sulfide (0.95 ml, 9.0 mmol, 20 equiv) in CH2Cl2 (20 ml) according to 
method D. The resulting product was purified by flash column chromatography 
(CH2Cl2/Methanol, 0 - 5 % methanol in 30 min), to give 100 mg (0.23 mmol/ 51% yield) of 
the analytically pure compound (purity: 97%). C21H22N2O6S; MW 430.47; mp 138-140 ̊C; 
1
H 
NMR (500 MHz, DMSO-d6) δ 8.58 (s, 1H), 8.15 (s, 2H), 7.43 (d, J = 8.3 Hz, 1H), 7.38 (t, J = 
8.0 Hz, 1H), 7.26 (d, J = 7.7 Hz, 1H), 6.84 (s, 2H), 6.62 (d, J = 3.6 Hz, 1H), 6.55 (d, J = 3.6 
Hz, 1H), 3.23 (s, 3H), 2.15 (s, 3H), 2.14 (s, 6H); 
13
C NMR (126 MHz, DMSO-d6) δ 157.87 , 
155.54 , 154.02 , 149.56 , 145.29 , 144.42 , 129.77 , 127.43 , 126.42 , 124.67 , 124.16 , 122.16 
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, 120.34 , 119.05 , 104.70 , 37.11 , 16.44 , 11.32 ; 
 






The title compound was prepared according to method B by the reaction of 4-methoxy-2-
methylaniline (0.7 g, 5 mmol, 1 equiv) and 5-bromofuran-2-carbonyl chloride (1.05 g, 
5 mmol, 1 equiv) in the presence of Et3N (1.05 ml, 0.76 g, 7.5 mmol, 1.5 equiv) in CH2Cl2 (25 
ml). The product was purified by flash column chromatography (Petrolum ether/Etyl acetate, 
0 - 30 % EtOAc in 30 min), to give 1.45 g (4.67 mmol/ 94% yield) of the analytically pure 
compound (purity: 98%). C13H12BrNO3; MW 310.14;
 1
H NMR (300 MHz, DMSO-d6) δ 9.74 
(s, 1H), 7.29 (d, J = 3.6 Hz, 1H), 7.15 (d, J = 8.6 Hz, 1H), 6.84 (d, J = 2.9 Hz, 1H), 6.81 (d, J 
= 3.6 Hz, 1H), 6.77 (dd, J = 8.6, 2.9 Hz, 1H), 3.74 (s, 3H), 2.16 (s, 3H);
 






The title compound was prepared by reaction of 5a (690 mg, 2.2 mmol, 1 equiv), sodium 
hydride 60 % suspension in mineral oil (186 mg, 4.5 mmol, 2 equiv) and iodomethane 
(0.28 mL, 4.5 mmol, 2 equiv) in DMF (10 ml) according to method C. The resulting 
precipitate was purified by flash column chromatography (Petrolum ether/Etyl acetate, 0 - 50 
% EtOAc in 30 min), to give 529 mg (1.63 mmol/ 73% yield) of the analytically pure 
compound (purity: 99%). C14H14BrNO3; MW 324.17;
 1
H NMR (300 MHz, DMSO-d6) δ 7.18 
(d, J = 8.6 Hz, 1H), 6.93 (d, J = 2.9 Hz, 1H), 6.85 (dd, J = 8.6, 3.0 Hz, 1H), 6.48 (d, J = 3.6 






The title compound was prepared by reaction of 5b (520 mg, 1.6 mmol, 1 equiv) and boron 
trifluoride dimethyl sulfide (3.15 ml, 30 mmol, 20 equiv) in CH2Cl2 (30 ml) according to 
method D. The resulting product was purified by flash column chromatography 
(CH2Cl2/Methanol, 0 - 5 % methanol in 30 min), to give 350 mg (1.13 mmol/ 70% yield) of 
the analytically pure compound (purity: 99%). C13H12BrNO3; MW 310.14;
 










The title compound was prepared by reaction of 5c (350 mg, 1.13 mmol, 1 equiv), (4-
methoxy-3,5-dimethylphenyl)boronic acid (250 mg, 1.4 mmol, 1.2 equiv), cesium carbonate 
(1460 mg, 4.5 mmol, 4 equiv) and tetrakis(triphenylphosphine)palladium (60 mg, 0.06 mmol, 
0.05 equiv) in oxygen-free DME/water (1:1) (30 mL) according to method E. The resulting 
product was purified by flash column chromatography (Petrolum ether/Etyl acetate, 0 - 50 % 
EtOAc in 30 min), to give 347 mg (0.95 mmol/ 84% yield) of the analytically pure compound 
(purity: 95%). C22H23NO4; MW 365.43;
 1
H NMR (300 MHz, DMSO-d6) δ 9.62 (s, 1H), 7.06 
(d, J = 8.4 Hz, 1H), 7.02 (s, 2H), 6.79 – 6.73 (m, 2H), 6.68 (dd, J = 8.5, 2.8 Hz, 1H), 6.46 (d, 







The title compound was prepared by reaction of 5d (340 mg, 0.95 mmol, 1 equiv) and 
sulfamoyl chloride (1100 mg, 9.5 mmol, 10 equiv) in water-free DMA (10 mL) according to 
method E. The resulting precipitate was purified by flash column chromatography 
(CH2Cl2/Methanol, 0 - 5 % methanol in 30 min), to give 250 mg (0.56 mmol/ 60% yield) of 
the analytically pure compound (purity: 95%). C22H24N2O6S; MW 444.50; 
1
H NMR (300 
MHz, DMSO-d6) δ 8.1 (s, 2H), 7.41 (d, J = 8.4 Hz, 1H), 7.34 (d, J = 2.7 Hz, 1H), 7.25 (dd, J 
= 8.5, 2.8 Hz, 1H), 6.95 (s, 2H), 6.79 (d, J = 3.6 Hz, 1H), 6.76 (d, J = 3.6 Hz, 1H),  3.64 (s, 
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The title compound was prepared by reaction of SN12 (235 mg, 0.52 mmol, 1 equiv) and 
boron trifluoride dimethyl sulfide (1.05 ml, 10 mmol, 20 equiv) in CH2Cl2 (20 ml) according 
to method D. The resulting product was purified by flash column chromatography 
(CH2Cl2/Methanol, 0 - 5 % methanol in 30 min), to give 95 mg (0.22 mmol/ 45% yield) of the 
analytically pure compound (purity: 98%). C21H22N2O6S; MW 430.47; mp 192-194 ̊C;
 1
H 
NMR (500 MHz, DMSO-d6) δ 8.57 (s, 1H), 8.08 (s, 2H), 7.39 (d, J = 8.5 Hz, 1H), 7.31 (d, J = 
2.8 Hz, 1H), 7.23 (dd, J = 8.6, 2.8 Hz, 1H), 6.85 (s, 2H), 6.63 (d, J = 3.6 Hz, 1H), 6.56 (d, J = 
3.7 Hz, 1H), 3.23 (s, 3H), 2.17 (s, 3H), 2.14 (s, 6H); 
13
C NMR (75 MHz, Acetone-d6) δ 
158.30, 156.09, 154.00, 149.95, 146.18, 141.85, 137.76, 129.47, 124.52, 124.39, 121.41, 






The title compound was prepared according to method B by the reaction of 5-methoxy-2-
methylaniline (0.685 g, 5 mmol, 1 equiv) and 5-bromofuran-2-carbonyl chloride (1.05 g, 
5 mmol, 1 equiv) in the presence of Et3N (1.05 ml, 0.76 g, 7.5 mmol, 1.5 equiv) in CH2Cl2 (25 
ml). The product was purified by flash column chromatography (Petrolum ether/Etyl acetate, 
0 - 50 % EtOAc in 30 min), to give 1.05 g (3.38 mmol/ 70% yield) of the analytically pure 
compound (purity: 95%). C13H12BrNO3; MW 310.14;
 1
H NMR (500 MHz, Acetone-d6) δ 8.94 
(s, 1H), δ 7.34 (dd, J = 8.4, 2.7 Hz, 1H), 7.22 (d, J = 2.7 Hz, 1H), 7.15 (d, J = 8.4 Hz, 1H), 






The title compound was prepared by reaction of 6a (1000 mg, 3.25 mmol, 1 equiv), sodium 
hydride 60 % suspension in mineral oil (260 mg, 6.5 mmol, 2 equiv) and iodomethane 
(0.41 mL, 6.5 mmol, 2 equiv) in DMF (10 ml) according to method C. The resulting 
precipitate was purified by flash column chromatography (Petrolum ether/Etyl acetate, 0 - 50 
% EtOAc in 30 min), to give 730 mg (2.25 mmol/ 70% yield) of the analytically pure 
compound (purity: 95%). C14H14BrNO3; MW 324.17;
 1
H NMR (500 MHz, Acetone-d6) δ 7.25 
(d, J = 8.4 Hz, 1H), 6.95 (dd, J = 8.4, 2.7 Hz, 1H), 6.90 (d, J = 2.7 Hz, 1H), 6.35 (d, J = 3.6 









The title compound was prepared by reaction of 6b (400 mg, 1.25 mmol, 1 equiv) and boron 
trifluoride dimethyl sulfide (2.7 ml, 25 mmol, 20 equiv) in CH2Cl2 (30 ml) according to 
method D. The resulting product was purified by flash column chromatography 
(CH2Cl2/Methanol, 0 - 5 % methanol in 30 min), to give 280 mg (0.90 mmol/ 73% yield) of 
the analytically pure compound (purity: 95%). C13H12BrNO3; MW 310.14;
 1
H NMR (500 
MHz, DMSO-d6) δ 9.56 (s, 1H), 7.14 (d, J = 8.3 Hz, 1H), 6.77 (dd, J = 8.4, 2.5 Hz, 1H), 6.62 
(d, J = 2.5 Hz, 1H), 6.50 (d, J = 3.6 Hz, 1H), 5.53 (d, J = 3.6 Hz, 1H), 3.17 (s, 3H), 1.98 (s, 
3H);
 






The title compound was prepared by reaction of 6c (280 mg, 0.90 mmol, 1 equiv), (4-
methoxy-3,5-dimethylphenyl)boronic acid (200 mg, 1.1 mmol, 1.2 equiv), cesium carbonate 
(1170 mg, 3.6 mmol, 4 equiv) and tetrakis(triphenylphosphine)palladium (50 mg, 0.05 mmol, 
0.05 equiv) in oxygen-free DME/water (1:1) (30 mL) according to method E. The resulting 
product was purified by flash column chromatography (Petrolum ether/Etyl acetate, 0 - 50 % 
EtOAc in 30 min), to give 180 mg (0.50 mmol/ 55% yield) of the analytically pure compound 
(purity: 95%). C22H23NO4; MW 365.43;
 1
H NMR (500 MHz, DMSO-d6) δ 9.52 (s, 1H), 7.16 
(d, J = 8.3 Hz, 1H), 6.98 (s, 2H), 6.79 (dd, J = 8.4, 2.4 Hz, 1H), 6.77 (d, J = 2.6 Hz, 1H), 6.67 
(d, J = 2.5 Hz, 1H), 6.60 (d, J = 3.6 Hz, 1H), 3.63 (s, 3H), 3.20 (s, 3H), 2.20 (s, 6H), 2.00 (s, 






The title compound was prepared by reaction of 6d (180 mg, 0.50 mmol, 1 equiv) and 
sulfamoyl chloride (500 mg, 5 mmol, 10 equiv) in water-free DMA (10 mL) according to 
method E. The resulting precipitate was purified by flash column chromatography 
(CH2Cl2/Methanol, 0 - 5 % methanol in 30 min), to give 130 mg (0.30 mmol/ 60% yield) of 
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the analytically pure compound (purity: 98%). C22H24N2O6S; MW 444.50;
 1
H NMR (500 
MHz, DMSO-d6) δ 8.06 (s, 2H), 7.47 (d, J = 8.3 Hz, 1H), 7.30 (dd, J = 8.1, 2.5 Hz, 1H), 7.28 
(d, J = 2.4 Hz, 1H),  6.92 (s, 2H), 6.78 (d, J = 3.6 Hz, 1H), 6.67 (d, J = 3.6 Hz, 1H), 3.63 (s, 






The title compound was prepared by reaction of 6e (125 mg, 0.28 mmol, 1 equiv) and boron 
trifluoride dimethyl sulfide (0.6 ml, 5.6 mmol, 20 equiv) in CH2Cl2 (20 ml) according to 
method D. The resulting product was purified by flash column chromatography 
(CH2Cl2/Methanol, 0 - 5 % methanol in 30 min), to give 80 mg (0.18 mmol/ 66% yield) of the 
analytically pure compound (purity: 97%). C21H22N2O6S; MW 430.47; mp 142-144 ̊C; 
1
H 
NMR (500 MHz, DMSO-d6) δ 8.58 (s, 1H), 8.05 (s, 2H), 7.45 (d, J = 8.3 Hz, 1H), 7.29 (dd, J 
= 8.2, 2.5 Hz, 1H), 7.27 (d, J = 2.4 Hz, 1H), 6.84 (s, 2H), 6.64 (d, J = 3.5 Hz, 1H), 6.60 (d, J = 
3.7 Hz, 1H), 3.25 (s, 3H), 2.14 (s, 6H), 2.12 (s, 3H); 
13
C NMR (126 MHz, DMSO-d6) δ 
157.82 , 155.53 , 154.03 , 148.93 , 145.35 , 143.59 , 133.66 , 131.88 , 124.66 , 124.21 , 121.70 
, 121.66 , 120.34 , 119.07 , 104.69 , 36.96 , 16.53 , 16.45  ; 
 






The title compound was prepared according to method B by the reaction of 2-methoxy-6-
methylaniline (0.685 g, 5 mmol, 1 equiv) and 5-bromofuran-2-carbonyl chloride (1.05 g, 
5 mmol, 1 equiv) in the presence of Et3N (1.05 ml, 0.76 g, 7.5 mmol, 1.5 equiv) in CH2Cl2 (25 
ml). The product was purified by flash column chromatography (Petrolum ether/Etyl acetate, 
0 - 30 % EtOAc in 30 min), to give 1300 mg (4.21 mmol/ 84% yield) of the analytically pure 
compound (purity: 97%). C13H12BrNO3; MW 310.14;
 1
H NMR (500 MHz, DMSO-d6) δ 9.56 
(s, 1H), 7.31 (d, J = 3.6 Hz, 1H), 7.19 (t, J = 7.9 Hz, 1H), 6.91 (d, J = 8.4 Hz, 1H), 6.86 (d, J 









The title compound was prepared by reaction of 7a (1300 mg, 4.20 mmol, 1 equiv), sodium 
hydride 60 % suspension in mineral oil (340 mg, 8.5 mmol, 2 equiv) and iodomethane 
(0.31 mL, 5.0 mmol, 2 equiv) in DMF (10 ml) according to method C. The resulting 
precipitate was purified by flash column chromatography (Petrolum ether/Etyl acetate, 0 - 50 
% EtOAc in 30 min), to give 750 mg (2.31 mmol/ 55% yield) of the analytically pure 
compound (purity: 99%). C14H14BrNO3; MW 324.17;
 1
H NMR (500 MHz, DMSO-d6) δ 7.32 
(t, J = 8.0 Hz, 1H), 6.98 (d, J = 8.4 Hz, 1H), 6.94 (d, J = 7.6 Hz, 1H), 6.46 (d, J = 3.6 Hz, 1H), 






The title compound was prepared by reaction of 7b (730 mg, 2.25 mmol, 1 equiv) and boron 
trifluoride dimethyl sulfide (4.75 ml, 45 mmol, 20 equiv) in CH2Cl2 (30 ml) according to 
method D. The resulting product was purified by flash column chromatography 
(CH2Cl2/Methanol, 0 - 10 % methanol in 30 min), to give 500 mg (1.61 mmol/ 72% yield) of 
the analytically pure compound (purity: 98%). C13H12BrNO3; MW 310.14;
 1
H NMR (500 
MHz, DMSO-d6) δ 9.77 (s, 1H), 7.13 (t, J = 7.9 Hz, 1H), 6.78 (d, J = 8.3 Hz, 1H), 6.77 (d, J = 
7.7 Hz, 1H),6.47 (d, J = 3.6 Hz, 1H), 5.54 (d, J = 3.6 Hz, 1H), 3.11 (s, 3H), 2.08 (s, 3H);
 
MS 






The title compound was prepared by reaction of 7c (310 mg, 1.0 mmol, 1 equiv), (4-methoxy-
3,5-dimethylphenyl)boronic acid (220 mg, 1.2 mmol, 1.2 equiv), cesium carbonate (1300 mg, 
4.0 mmol, 4 equiv) and tetrakis(triphenylphosphine)palladium (55 mg, 0.05 mmol, 0.05 
equiv) in oxygen-free DME/water (1:1) (30 mL) according to method E. The resulting 
product was purified by flash column chromatography (CH2Cl2/Methanol, 0 - 5 % methanol 
in 30 min), to give 191 mg (0.52 mmol/ 52% yield) of the analytically pure compound (purity: 
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95%). C22H23NO4; MW 365.43;
 1
H NMR (500 MHz, DMSO-d6) δ 9.67 (s, 1H), 7.15 (t, J = 
7.8 Hz, 1H), 6.99 (s, 2H), 6.82 (t, J = 8.2 Hz, 2H), 6.75 (d, J = 3.6 Hz, 1H), 6.54 (d, J = 3.5 






The title compound was prepared by reaction of 7d (190 mg, 0.50 mmol, 1 equiv) and 
sulfamoyl chloride (500 mg, 5 mmol, 10 equiv) in water-free DMA (10 mL) according to 
method E. The resulting precipitate was purified by flash column chromatography 
(CH2Cl2/Methanol, 0 - 5 % methanol in 30 min), to give 140 mg (0.32 mmol/ 64% yield) of 
the analytically pure compound (purity: 97%). C22H24N2O6S; MW 444.50;
 1
H NMR (500 
MHz, DMSO-d6) δ 8.25 (s, 2H), 7.50 – 7.40 (m, 2H), 7.38 – 7.31 (m, 1H), 6.90 (s, 2H), 6.77 







The title compound was prepared by reaction of 7d (130 mg, 0.30 mmol, 1 equiv) and boron 
trifluoride dimethyl sulfide (0.70 ml, 6.0 mmol, 20 equiv) in CH2Cl2 (20 ml) according to 
method D. The resulting product was purified by flash column chromatography 
(CH2Cl2/Methanol, 0 - 5 % methanol in 30 min), to give 30 mg (0.07 mmol/ 24% yield) of the 
analytically pure compound (purity: 98%). C21H22N2O6S; MW 430.47; mp 178-180 ̊C; 
1
H 
NMR (500 MHz, DMSO-d6) δ 8.56 (s, 1H), 8.25 (s, 2H), 7.51 – 7.40 (m, 2H), 7.33 (dd, J = 
7.7, 1.7 Hz, 1H), 6.82 (s, 2H), 6.63 (d, J = 3.7 Hz, 1H), 6.61 (d, J = 3.6 Hz, 1H), 3.22 (s, 3H), 
2.19 (s, 3H), 2.14 (s, 6H);
13
C NMR (126 MHz, DMSO) δ 158.04, 155.34, 153.92, 147.32, 
145.63, 137.88, 134.96, 128.73, 128.24, 124.58, 124.19, 120.39, 119.33, 118.53, 104.59, 
36.33, 17.23, 16.43; 
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The title compound was prepared according to method B by the reaction of 4-methoxy-N-
methylaniline (0.685 g, 5 mmol, 1 equiv) and 5-bromofuran-2-carbonyl chloride (1.05 g, 
5 mmol, 1 equiv) in the presence of Et3N (1.05 ml, 0.76 g, 7.5 mmol, 1.5 equiv) in CH2Cl2 (25 
ml). The product was purified by flash column chromatography (Petrolum ether/Etyl acetate, 
0 - 30 % EtOAc in 30 min), to give 980 mg (3.16 mmol/ 63% yield) of the analytically pure 
compound (purity: 95%). C13H12BrNO3; MW 310.14;
 1
H NMR (300 MHz, DMSO-d6) δ 7.25 
(d, J = 8.9 Hz, 2H), 6.99 (d, J = 8.9 Hz, 2H), 6.50 (d, J = 3.6 Hz, 1H), 5.67 (d, J = 3.6 Hz, 





The title compound was prepared by reaction of 8ab (960 mg, 3.1 mmol, 1 equiv) and boron 
trifluoride dimethyl sulfide (6.0 ml, 60 mmol, 20 equiv) in CH2Cl2 (30 ml) according to 
method D. The resulting product was purified by flash column chromatography 
(CH2Cl2/Methanol, 0 - 10 % methanol in 30 min), to give 780 mg (2.63 mmol/ 85% yield) of 
the analytically pure compound (purity: 95%). C12H10BrNO3; MW 296.12;
 1
H NMR (300 
MHz, DMSO-d6) δ 9.74 (s, 1H), 7.11 (d, J = 8.7 Hz, 2H), 6.80 (d, J = 8.7 Hz, 2H), 6.50 (d, J 






The title compound was prepared by reaction of 8c (220 mg, 0.75 mmol, 1 equiv), (4-
methoxy-3,5-dimethylphenyl)boronic acid (160 mg, 0.9 mmol, 1.2 equiv), cesium carbonate 
(975 mg, 3.0 mmol, 4 equiv) and tetrakis(triphenylphosphine)palladium (45 mg, 0.04 mmol, 
0.05 equiv) in oxygen-free DME/water (1:1) (30 mL) according to method E. The resulting 
product was purified by flash column chromatography (CH2Cl2/Methanol, 0 - 5 % methanol 
in 30 min), to give 110 mg (0.31 mmol/ 42% yield) of the analytically pure compound (purity: 
96%). C21H21NO4; MW 351.40;
 1
H NMR (300 MHz, DMSO-d6) δ 9.69 (s, 1H), 7.13 (d, J = 
8.7 Hz, 2H), 6.99 (s, 2H), 6.83 (d, J = 8.7 Hz, 2H), 6.75 (d, J = 3.6 Hz, 1H), 6.56 (d, J = 3.6 









The title compound was prepared by reaction of 8d (110 mg, 0.31 mmol, 1 equiv) and 
sulfamoyl chloride (300 mg, 3 mmol, 10 equiv) in water-free DMA (10 mL) according to 
method E. The resulting precipitate was purified by flash column chromatography 
(CH2Cl2/Methanol, 0 - 5 % methanol in 30 min), to give 80 mg (0.18 mmol/ 60% yield) of the 
analytically pure compound (purity: 95%). C21H22N2O6S; MW 430.47;
 1
H NMR (300 MHz, 
DMSO-d6) δ 8.09 (s, 2H), 7.46 (d, J = 8.9 Hz, 2H), 7.37 (d, J = 8.8 Hz, 2H), 6.93 (s, 2H), 6.79 







The title compound was prepared by reaction of 8d (80 mg, 0.18 mmol, 1 equiv) and boron 
trifluoride dimethyl sulfide (0.40 ml, 4 mmol, 20 equiv) in CH2Cl2 (20 ml) according to 
method D. The resulting product was purified by flash column chromatography 
(CH2Cl2/Methanol, 0 - 5 % methanol in 30 min), to give 35 mg (0.08 mmol/ 46% yield) of the 
analytically pure compound (purity: 98%). C20H20N2O6S; MW 416.44; mp 186-188 ̊C; 
1
H 
NMR (300 MHz, Acetone-d6) δ 7.57 (s, 1H), 7.49 (d, J = 8.9 Hz, 2H), 7.39 (d, J = 8.8 Hz, 
2H), 7.22 (s, 2H), 6.93 (s, 2H), 6.68 (d, J = 3.6 Hz, 1H), 6.57 (d, J = 3.6 Hz, 1H), 3.39 (s, 3H), 
2.21 (s, 6H); 
13
C NMR (75 MHz, Acetone-d6) δ 159.19 , 156.80 , 154.87 , 150.39 , 146.94 , 
144.28 , 129.49 , 125.41 , 125.25 , 124.06 , 122.24 , 119.94 , 105.07 , 38.61 , 16.52; 
 
HRMS 





The title compound was prepared according to method B by the reaction of 3-methoxy-N-
methylaniline (0.685 g, 5 mmol, 1 equiv) and 5-bromofuran-2-carbonyl chloride (1.05 g, 
5 mmol, 1 equiv) in the presence of Et3N (1.05 ml, 0.76 g, 7.5 mmol, 1.5 equiv) in CH2Cl2 (25 
ml). The product was purified by flash column chromatography (Petrolum ether/Etyl acetate, 
0 - 30 % EtOAc in 30 min), to give 1100 mg (3.60 mmol/ 72% yield) of the analytically pure 
compound (purity: 99%). C13H12BrNO3; MW 310.14;
 1
H NMR (300 MHz, DMSO-d6) δ 7.33 
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(t, J = 8.0 Hz, 1H), 7.02 – 6.91 (m, 2H), 6.90 – 6.81 (m, 1H), 6.52 (d, J = 3.6 Hz, 1H), 5.89 





The title compound was prepared by reaction of 9ab (1100 mg, 3.5 mmol, 1 equiv) and boron 
trifluoride dimethyl sulfide (7.0 ml, 70 mmol, 20 equiv) in CH2Cl2 (30 ml) according to 
method D. The resulting product was purified by flash column chromatography 
(CH2Cl2/Methanol, 0 - 10 % methanol in 30 min), to give 800 mg (2.70 mmol/ 77% yield) of 
the analytically pure compound (purity: 99%). C12H10BrNO3; MW 296.12;
 1
H NMR (300 
MHz, DMSO-d6) δ 9.73 (s, 1H), 7.23 (t, J = 8.0 Hz, 1H), 6.79 (ddd, J = 8.2, 2.4, 1.0 Hz, 1H), 
6.72 (ddd, J = 7.8, 2.0, 1.0 Hz, 1H), 6.66 (t, J = 2.2 Hz, 1H), 6.53 (d, J = 3.5 Hz, 1H), 5.85 (d, 






The title compound was prepared by reaction of 9c (400 mg, 1.35 mmol, 1 equiv), (4-
methoxy-3,5-dimethylphenyl)boronic acid (290 mg, 1.62 mmol, 1.2 equiv), cesium carbonate 
(1755 mg, 5.4 mmol, 4 equiv) and tetrakis(triphenylphosphine)palladium (75 mg, 0.07 mmol, 
0.05 equiv) in oxygen-free DME/water (1:1) (30 mL) according to method E. The resulting 
product was purified by flash column chromatography (CH2Cl2/Methanol, 0 - 5 % methanol 
in 30 min), to give 270 mg (0.77 mmol/ 56% yield) of the analytically pure compound (purity: 
96%). C21H21NO4; MW 351.40;
 1
H NMR (300 MHz, DMSO-d6) δ 9.70 (s, 1H), 7.24 (t, J = 
8.3 Hz, 1H), 6.99 – 6.92 (m, 2H), 6.82 (ddd, J = 8.2, 2.2, 1.1 Hz, 1H), 6.77 (d, J = 3.6 Hz, 
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The title compound was prepared by reaction of 9d (270 mg, 0.60 mmol, 1 equiv) and 
sulfamoyl chloride (600 mg, 6 mmol, 10 equiv) in water-free DMA (10 mL) according to 
method E. The resulting precipitate was purified by flash column chromatography 
(CH2Cl2/Methanol, 0 - 5 % methanol in 30 min), to give 190 mg (0.44 mmol/ 73% yield) of 
the analytically pure compound (purity: 99%). C21H22N2O6S; MW 430.47;
 1
H NMR (300 
MHz, DMSO-d6) δ 8.09 (s, 2H), 7.54 (t, J = 8.3 Hz, 1H), 7.36 – 7.29 (m, 2H), 6.96 (s, 1H), 
6.92 (s, 2H), 6.77 (d, J = 3.5 Hz, 1H), 6.71 (d, J = 3.5 Hz, 1H),  3.36 (s, 3H), 2.20 (s, 3H), 






The title compound was prepared by reaction of 9e (90 mg, 0.21 mmol, 1 equiv) and boron 
trifluoride dimethyl sulfide (0.40 ml, 4 mmol, 20 equiv) in CH2Cl2 (20 ml) according to 
method D. The resulting product was purified by flash column chromatography 
(CH2Cl2/Methanol, 0 - 5 % methanol in 30 min), to give 35 mg (0.08 mmol/ 39% yield) of the 
analytically pure compound (purity: 98%). C20H20N2O6S; MW 416.44; mp 198-200 ̊C; 
1
H 
NMR (300 MHz, Acetone-d6) δ 7.57 (s, 1H), 7.54 (t, J = 8.3 Hz, 1H), 7.42 – 7.35 (m, 2H), 
7.31 (ddd, J = 7.9, 2.0, 1.1 Hz, 1H), 7.15 (s, 2H), 6.90 (s, 2H), 6.75 (d, J = 3.6 Hz, 1H), 6.57 
(d, J = 3.6 Hz, 1H), 3.40 (s, 3H), 2.21 (s, 6H); 
13
C NMR (75 MHz, Acetone-d6) δ 159.14 , 
156.83 , 154.87 , 152.10 , 147.11 , 146.81 , 131.14 , 126.40 , 125.40 , 125.24 , 122.17 , 
122.09, 121.89 , 120.11 , 105.12 , 38.51 , 16.47  ; 
 






The title compound was prepared according to method B by the reaction of 3-fluoro-4-
methoxyaniline (0.705 g, 5 mmol, 1 equiv) and 5-bromofuran-2-carbonyl chloride (1.05 g, 
5 mmol, 1 equiv) in the presence of Et3N (1.05 ml, 0.76 g, 7.5 mmol, 1.5 equiv) in CH2Cl2 (25 
ml). The product was purified by flash column chromatography (Petrolum ether/Etyl acetate, 
0 - 30 % EtOAc in 30 min), to give 1150 mg (3.66 mmol/ 74% yield) of the analytically pure 
compound (purity: 97%). C12H9BrFNO3; MW 314.11; 
1
H NMR (300 MHz, DMSO-d6) δ 
10.24 (s, 1H), 7.67 (dd, J = 12.5, 2.5 Hz, 1H), 7.46 (ddd, J = 9.0, 2.6, 1.5 Hz, 1H), 7.34 (d, J = 









The title compound was prepared by reaction of 10a (630 mg, 2.0 mmol, 1 equiv), sodium 
hydride 60 % suspension in mineral oil (167 mg, 4.0 mmol, 2 equiv) and iodomethane 
(0.25 mL, 4.0 mmol, 2 equiv) in DMF (10 ml) according to method C. The resulting 
precipitate was purified by flash column chromatography (Petrolum ether/Etyl acetate, 0 - 40 
% EtOAc in 30 min), to give 550 mg (1.66 mmol/ 84% yield) of the analytically pure 
compound (purity: 99%). C13H11BrFNO3; MW 328.14;
 1
H NMR (300 MHz, DMSO-d6) δ 
7.36 (dd, J = 12.2, 2.5 Hz, 1H), 7.20 (t, J = 9.0 Hz, 1H), 7.11 (ddd, J = 9.0, 2.5, 1.2 Hz, 1H), 






The title compound was prepared by reaction of 10b (550 mg, 1.7 mmol, 1 equiv) and boron 
trifluoride dimethyl sulfide (3.5 ml, 35 mmol, 20 equiv) in CH2Cl2 (30 ml) according to 
method D. The resulting product was purified by flash column chromatography 
(CH2Cl2/Methanol, 0 - 10 % methanol in 30 min), to give 460 mg (1.46 mmol/ 86% yield) of 
the analytically pure compound (purity: 98%). C12H9BrFNO3; MW 314.11;
 1
H NMR (300 
MHz, DMSO-d6) δ 10.18 (s, 1H), 7.39 – 7.12 (m, 1H), 7.12 – 6.82 (m, 2H), 6.53 (d, J = 3.6 






The title compound was prepared by reaction of 10c (460 mg, 1.5 mmol, 1 equiv), (4-
methoxy-3,5-dimethylphenyl)boronic acid (300 mg, 1.8 mmol, 1.2 equiv), cesium carbonate 
(1950 mg, 6.0 mmol, 4 equiv) and tetrakis(triphenylphosphine)palladium (85 mg, 0.075 
mmol, 0.05 equiv) in oxygen-free DME/water (1:1) (30 mL) according to method E. The 
resulting product was purified by flash column chromatography (CH2Cl2/Methanol, 0 - 5 % 
methanol in 30 min), to give 270 mg (0.73 mmol/ 48% yield) of the analytically pure 
compound (purity: 99%). C21H20FNO4; MW 369.39;
 1
H NMR (300 MHz, DMSO-d6) δ 10.13 
(s, 1H), 7.35 – 7.23 (m, 1H), 7.01 (d, J = 8.5 Hz, 1H), 6.97 (s, 2H), 6.94 (d, J = 8.6 Hz, 1H), 
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The title compound was prepared by reaction of 10d (270 mg, 0.70 mmol, 1 equiv) and 
sulfamoyl chloride (700 mg, 7 mmol, 10 equiv) in water-free DMA (10 mL) according to 
method E. The resulting precipitate was purified by flash column chromatography 
(CH2Cl2/Methanol, 0 - 5 % methanol in 30 min), to give 183 mg (0.41 mmol/ 58% yield) of 
the analytically pure compound (purity: 99%). C21H21FN2O6S; MW 448.46;
 1
H NMR (300 
MHz, DMSO-d6) δ 8.32 (s, 2H), 7.63 (dd, J = 11.2, 2.5 Hz, 1H), 7.50 (t, J = 8.7 Hz, 1H), 7.26 
(ddd, J = 8.7, 2.5, 1.3 Hz, 1H), 6.95 (s, 2H), 6.86 (d, J = 3.6 Hz, 1H), 6.83 (d, J = 3.6 Hz, 1H), 






The title compound was prepared by reaction of SN04 (175 mg, 0.40 mmol, 1 equiv) and 
boron trifluoride dimethyl sulfide (0.80 ml, 8 mmol, 20 equiv) in CH2Cl2 (20 ml) according to 
method D. The resulting product was purified by flash column chromatography 
(CH2Cl2/Methanol, 0 - 5 % methanol in 30 min), to give 73 mg (0.17 mmol/ 42% yield) of the 
analytically pure compound (purity: 98%). C20H19FN2O6S; MW 434.43; mp 186-188 ̊C; 
1
H 
NMR (300 MHz, DMSO-d6) δ 8.60 (s, 1H), 8.22 (s, 2H), 7.61 (dd, J = 11.2, 2.5 Hz, 1H), 7.49 
(t, J = 8.7 Hz, 1H), 7.33 – 7.15 (m, 1H), 6.85 (s, 2H), 6.83 (d, J = 3.7 Hz, 1H), 6.69 (d, J = 3.6 
Hz, 1H), 3.34 (s, 3H), 2.14 (s, 6H); 
13
C NMR (126 MHz, Acetone-d6) δ 158.02 (d, J = 271.7 
Hz), 156.66 , 154.82 (d, J = 37.6 Hz), 146.75 , 145.26 (d, J = 8.5 Hz), 137.69 (d, J = 12.1 Hz), 
125.95 , 125.38 , 125.27 (d, J = 9.5 Hz), 124.67 (d, J = 3.5 Hz), 122.17 , 120.24 , 117.22 , 
117.06 , 105.21 , 38.49 , 16.54 ; 
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The title compound was prepared according to method B by the reaction of 3-chloro-4-
methoxyaniline (0.790 g, 5 mmol, 1 equiv) and 5-bromofuran-2-carbonyl chloride (1.05 g, 
5 mmol, 1 equiv) in the presence of Et3N (1.05 ml, 0.76 g, 7.5 mmol, 1.5 equiv) in CH2Cl2 (25 
ml). The product was purified by flash column chromatography (Petrolum ether/Etyl acetate, 
0 - 30 % EtOAc in 30 min), to give 1400 mg (4.25 mmol/ 85% yield) of the analytically pure 
compound (purity: 97%). C12H9BrClNO3; MW 330.56; 
1
H NMR (300 MHz, DMSO-d6) δ 
10.22 (s, 1H), 7.86 (d, J = 2.6 Hz, 1H), 7.63 (dd, J = 9.0, 2.6 Hz, 1H), 7.33 (d, J = 3.6 Hz, 






The title compound was prepared by reaction of 11a (940 mg, 2.9 mmol, 1 equiv), sodium 
hydride 60 % suspension in mineral oil (240 mg, 5.8 mmol, 2 equiv) and iodomethane 
(0.35 mL, 5.8 mmol, 2 equiv) in DMF (10 ml) according to method C. The resulting 
precipitate was purified by flash column chromatography (Petrolum ether/Etyl acetate, 0 - 40 
% EtOAc in 30 min), to give 780 mg (2.26 mmol/ 79% yield) of the analytically pure 
compound (purity: 97%). C13H11BrClNO3; MW 344.58;
 1
H NMR (300 MHz, DMSO-d6) δ 
7.53 (d, J = 2.5 Hz, 1H), 7.28 (dd, J = 8.7, 2.5 Hz, 1H), 7.18 (d, J = 8.8 Hz, 1H), 6.54 (d, J = 






The title compound was prepared by reaction of 11b (780 mg, 2.3 mmol, 1 equiv) and boron 
trifluoride dimethyl sulfide (4.5 ml, 46 mmol, 20 equiv) in CH2Cl2 (30 ml) according to 
method D. The resulting product was purified by flash column chromatography 
(CH2Cl2/Methanol, 0 - 10 % methanol in 30 min), to give 614 mg (1.86 mmol/ 81% yield) of 
the analytically pure compound (purity: 99%). C12H9BrClNO3; MW 330.56;
 1
H NMR (300 
MHz, DMSO-d6) δ 10.48 (s, 1H), 7.41 (d, J = 2.5 Hz, 1H), 7.10 (dd, J = 8.6, 2.5 Hz, 1H), 
6.98 (d, J = 8.6 Hz, 1H), 6.54 (d, J = 3.6 Hz, 1H), 5.85 (d, J = 3.5 Hz, 1H), 3.23 (s, 3H); MS 









The title compound was prepared by reaction of 11c (500 mg, 1.5 mmol, 1 equiv), (4-
methoxy-3,5-dimethylphenyl)boronic acid (300 mg, 1.8 mmol, 1.2 equiv), cesium carbonate 
(1950 mg, 6.0 mmol, 4 equiv) and tetrakis(triphenylphosphine)palladium (85 mg, 0.075 
mmol, 0.05 equiv) in oxygen-free DME/water (1:1) (30 mL) according to method E. The 
resulting product was purified by flash column chromatography (CH2Cl2/Methanol, 0 - 5 % 
methanol in 30 min), to give 500 mg (1.29 mmol/ 86% yield) of the analytically pure 




H NMR (300 MHz, DMSO-d6) δ 
10.46 (s, 1H), 7.47 (d, J = 2.5 Hz, 1H), 7.08 (dd, J = 8.6, 2.5 Hz, 1H), 6.99 (d, J = 8.6 Hz, 
1H), 6.94 (s, 2H), 6.80 (d, J = 3.6 Hz, 1H), 6.78 (d, J = 3.6 Hz, 1H), 3.63 (s, 3H), 3.27 (s, 3H), 






The title compound was prepared by reaction of 11d (500 mg, 1.29 mmol, 1 equiv) and 
sulfamoyl chloride (1300 mg, 13 mmol, 10 equiv) in water-free DMA (10 mL) according to 
method E. The resulting precipitate was purified by flash column chromatography 
(CH2Cl2/Methanol, 0 - 5 % methanol in 30 min), to give 482 mg (1.04 mmol/ 80% yield) of 
the analytically pure compound (purity: 99%). C21H21ClN2O6S; MW 464.91;
 1
H NMR (300 
MHz, DMSO-d6) δ 8.35 (s, 2H), 7.79 (d, J = 2.5 Hz, 1H), 7.54 (d, J = 8.7 Hz, 1H), 7.39 (dd, J 
= 8.7, 2.6 Hz, 1H), 6.92 (s, 2H), 6.90 (d, J = 3.6 Hz, 1H), 6.84 (d, J = 3.6 Hz, 1H), 3.64 (s, 






The title compound was prepared by reaction of SN07 (235 mg, 0.50 mmol, 1 equiv) and 
boron trifluoride dimethyl sulfide (1.00 ml, 10 mmol, 20 equiv) in CH2Cl2 (20 ml) according 
to method D. The resulting product was purified by flash column chromatography 
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(CH2Cl2/Methanol, 0 - 5 % methanol in 30 min), to give 95 mg (0.21 mmol/ 42% yield) of the 
analytically pure compound (purity: 98%). C20H19ClN2O6S; MW 450.89; mp 174-176 ̊C; 
1
H 
NMR (500 MHz, Acetone-d6) δ 11.62 (s, 1H), 7.67 (d, J = 2.6 Hz, 1H), 7.63 (d, J = 8.6 Hz, 
1H), 7.48 (s, 2H), 7.37 (dd, J = 8.7, 2.6 Hz, 1H), 6.91 (s, 2H), 6.85 (d, J = 3.7 Hz, 1H), 6.62 
(d, J = 3.5 Hz, 1H), 3.41 (s, 3H), 2.22 (s, 6H); 
13
C NMR (126 MHz, Acetone-d6) δ 159.11 , 
157.07 , 154.98 , 146.73 , 146.45 , 144.84 , 130.29 , 128.36 , 128.03 , 125.39 , 125.32 , 
125.17, 122.14 , 120.47 , 105.27 , 38.59 , 16.57; 
 






The title compound was prepared according to method B by the reaction of 5-chloro-4-
methoxy-2-methylaniline (0.855 g, 5 mmol, 1 equiv) and 5-bromofuran-2-carbonyl chloride 
(1.05 g, 5 mmol, 1 equiv) in the presence of Et3N (1.05 ml, 0.76 g, 7.5 mmol, 1.5 equiv) in 
CH2Cl2 (25 ml). The product was purified by flash column chromatography (Petrolum 
ether/Etyl acetate, 0 - 30 % EtOAc in 30 min), to give 1200 mg (3.48 mmol/ 70% yield) of the 
analytically pure compound (purity: 97%). C13H11BrClNO3; MW 344.59; 
1
H NMR (500 
MHz, DMSO-d6) δ 9.84 (s, 1H), 7.32 (s, 1H), 7.30 (d, J = 3.6 Hz, 1H), 7.07 (s, 1H), 6.83 (d, J 





The title compound was prepared by reaction of 12a (1200 mg, 3.5 mmol, 1 equiv), sodium 
hydride 60 % suspension in mineral oil (360 mg, 7.0 mmol, 2 equiv) and iodomethane 
(0.45 mL, 7.0 mmol, 2 equiv) in DMF (10 ml) according to method C. The resulting 
precipitate was purified by flash column chromatography (Petrolum ether/Etyl acetate, 0 - 40 
% EtOAc in 30 min), to give 920 mg (2.56 mmol/ 73% yield) of the analytically pure 
compound (purity: 96%). C14H13BrClNO3; MW 358.61;
 1
H NMR (500 MHz, DMSO-d6) δ 
7.46 (s, 1H), 7.16 (s, 1H), 6.52 (d, J = 3.7 Hz, 1H), 5.64 (d, J = 3.7 Hz, 1H), 3.88 (s, 3H), 3.18 
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The title compound was prepared by reaction of 12b (920 mg, 2.6 mmol, 1 equiv) and boron 
trifluoride dimethyl sulfide (5.5 ml, 50 mmol, 20 equiv) in CH2Cl2 (30 ml) according to 
method D. The resulting product was purified by flash column chromatography 
(CH2Cl2/Methanol, 0 - 10 % methanol in 30 min), to give 800 mg (2.32 mmol/ 89% yield) of 
the analytically pure compound (purity: 99%). C13H11BrClNO3; MW 344.58;
 1
H NMR (500 
MHz, DMSO-d6) δ 10.47 (s, 1H), 7.34 (s, 1H), 6.90 (s, 1H), 6.52 (d, J = 3.6 Hz, 1H), 5.60 (d, 






The title compound was prepared by reaction of 12c (340 mg, 1.0 mmol, 1 equiv), (4-
methoxy-3,5-dimethylphenyl)boronic acid (220 mg, 1.2 mmol, 1.2 equiv), cesium carbonate 
(1300 mg, 4.0 mmol, 4 equiv) and tetrakis(triphenylphosphine)palladium (55 mg, 0.05 mmol, 
0.05 equiv) in oxygen-free DME/water (1:1) (30 mL) according to method E. The resulting 
product was purified by flash column chromatography (CH2Cl2/Methanol, 0 - 5 % methanol 
in 30 min), to give 300 mg (0.75 mmol/ 75% yield) of the analytically pure compound (purity: 
99%). C22H22ClNO4; MW 399.87; 
1
H NMR (500 MHz, DMSO-d6) δ 10.40 (s, 1H), 7.39 (s, 
1H), 6.96 (s, 2H), 6.92 (s, 1H), 6.80 (d, J = 3.6 Hz, 1H), 6.72 (d, J = 3.6 Hz, 1H), 3.63 (s, 3H), 




methylphenyl sulfamate (12e) 
 
 
The title compound was prepared by reaction of 12d (300 mg, 0.75 mmol, 1 equiv) and 
sulfamoyl chloride (750 mg, 7.5 mmol, 10 equiv) in water-free DMA (10 mL) according to 
method E. The resulting precipitate was purified by flash column chromatography 
(CH2Cl2/Methanol, 0 - 5 % methanol in 30 min), to give 210 mg (0.43 mmol/ 59% yield) of 
the analytically pure compound (purity: 98%). C22H23ClN2O6S; MW 478.94;
 1
H NMR (500 
MHz, DMSO-d6) δ 8.35 (s, 2H), 7.75 (s, 1H), 7.52 (s, 1H), 6.91 (s, 2H), 6.83 (d, J = 3.5 Hz, 








methylphenyl sulfamate (12) 
 
The title compound was prepared by reaction of 12e (200 mg, 0.42 mmol, 1 equiv) and boron 
trifluoride dimethyl sulfide (0.90 ml, 8.5 mmol, 20 equiv) in CH2Cl2 (20 ml) according to 
method D. The resulting product was purified by flash column chromatography 
(CH2Cl2/Methanol, 0 - 5 % methanol in 30 min), to give 98 mg (0.21 mmol/ 50% yield) of the 
analytically pure compound (purity: 98%). C21H21ClN2O6S; MW 464.91; mp 202-204 ̊C; 
1
H 
NMR (500 MHz, DMSO-d6) δ 8.59 (s, 1H), 8.34 (s, 2H), 7.72 (s, 1H), 7.50 (s, 1H), 6.82 (s, 
2H), 6.77 (d, J = 3.9 Hz, 1H), 6.68 (d, J = 3.7 Hz, 1H), 3.24 (s, 3H), 2.14 (s, 6H), 2.12 (s, 
3H);
13
C NMR (126 MHz, DMSO) δ 157.64, 155.64, 154.08, 145.42, 145.37, 141.61, 136.03, 
130.05, 125.25, 124.73, 124.12, 124.08, 120.31, 119.39, 104.81, 36.97, 16.81, 16.49; 
 
HRMS 
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5.2.I.4 Representative 1HNMR and 13CNMR spectra
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11.707.91 11.660.17 8.046.98 11.4511.0210.3810.130.21 6.810.68 8.811.10 1.49 1.78 8.253.102.25 6.422.59 3.49 5.444.04 5.19 8.854.68
NL:
5.90E7
TIC  MS 
MSR-217-
2nd-pure
MSR-217-2nd-pure #345 RT: 7.32 AV: 1 NL: 2.38E7
T: {0,0}  + c ESI !corona sid=55.00  det=1353.00 Full ms [100.00-1000.00]


























709.24 782.31124.12 447.09 486.24323.04 673.04355.13279.00145.01 883.29557.04196.15 962.63837.54632.05
RT: 0.00 - 12.10
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5.832.791.73 10.86 11.882.20 4.181.52 9.643.80 4.273.21 9.856.43 7.231.27 7.577.02 9.470.38 8.588.20
NL:
4.20E6
TIC  MS 
MSR-226-
p2
MSR-226-p2 #582 RT: 12.39 AV: 1 NL: 5.84E6
T: {0,0}  + c ESI !corona sid=55.00  det=1306.00 Full ms [150.00-750.00]

























453.10395.10352.18 657.31252.02 283.08212.10 469.16166.54 529.88299.29 570.53 709.88610.23 673.74 732.06
RT: 0.00 - 24.00
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8.211.93 9.62 9.919.242.45 10.079.117.47 11.681.54 10.522.48
7.272.931.51 3.51 6.343.77 6.154.28 4.70 4.960.23 1.380.74
NL:
6.94E6
TIC  MS 
MSR-244-
pure
MSR-244-pure #464 RT: 7.56 AV: 1 NL: 2.41E6
T: {0,0}  + c ESI !corona sid=55.00  det=1306.00 Full ms [100.00-600.00]


























234.98 386.15 469.16280.08145.10 431.12419.33214.96 445.12255.00158.15 324.69 362.55 506.25183.34 523.23 570.64 589.44
RT: 0.00 - 11.99
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5.2.II Biological methods  
5.2.II.1 Chemicals 





H]-E1 (50-100 Ci/mmol) and [2,4,6,7-
3
H]-E2 ( >110 Ci/mmol) 
were obtained from Perkin Elmer, Boston. Quickszint Flow 302 scintillator fluid was bought 
from Zinsser Analytic, Frankfurt. Charcoal-stripped FCS was received from Biowest. Other 
chemicals were purchased from Sigma, Merck or Gibco. 
5.2.II.2 h17β-HSD1 and h17β-HSD2 cell free inhibition assays 
The human enzymes were partially purified from human placental tissue according to 
previously described procedures.
1
 Fresh human placenta was homogenized and by fractional 
centrifugation the cytosolic and microsomal fractions were separated. In case of the h17β-
HSD1 assay the cytosolic fraction was incubated with NADH (500 µM), while in the case of 
the h17β-HSD2 assay the microsomal fraction was incubated with NAD
+
 (1500 µM) at 37 °C 
in a phosphate buffer (50 mM) with 20% of glycerol and EDTA (1 mM) in the presence of 
potential inhibitors which were prepared in DMSO (final DMSO concentration in the assay 
was 1%). The enzymatic reaction was started by the addition of a mixture of unlabeled and 
radiolabeled substrate (final concentration: 500 nM), [
3
H]-E1 in the case of h17β-HSD1 assay 
for 10 min or with [
3
H]-E2 in the case of h17β-HSD2 assay for 20 min.
1
 HgCl2 (10mM) was 
used to stop the enzymatic reactions and the steroids were extracted with diethylether. After 
evaporation, they were dissolved in acetonitrile/water (45:55). E1 and E2 were separated on a 
C18 reverse phase chromatography column (Nucleodur C18 Isis, Macherey-Nagel) connected 
to an Agilent 1200 Series (Agilent Technologies) HPLC-system using acetonitrile/water 
(45:55) as mobile phase. A radioflow detector (Ramona, raytest) was coupled to the HPLC-
system for the detection and quantification of the steroids. After the analysis of the resulting 
chromatograms, the conversion rates were calculated according to the following equation: 
%𝑐𝑜𝑛𝑣𝑒𝑟𝑠𝑖𝑜𝑛 = [
%𝑝𝑟𝑜𝑑𝑢𝑐𝑡
%𝑝𝑟𝑜𝑑𝑢𝑐𝑡 + % 𝑆𝑢𝑏𝑠𝑡𝑟𝑎𝑡𝑒
] ∗ 100 
Each value was calculated from at least two independent experiments. 
Then the percentage inhibition corresponding to each inhibitor concentration was calculated 
according to the following equation: 
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%𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 = [1 − (
%𝑐𝑜𝑛𝑣𝑒𝑟𝑠𝑖𝑜𝑛 𝑜𝑓 𝑡ℎ𝑒 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟
%𝑐𝑜𝑛𝑣𝑒𝑟𝑠𝑖𝑜𝑛 𝑜𝑓 𝑡ℎ𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 (𝐷𝑀𝑆𝑂)
)] ∗ 100 
At least three different concentrations of each inhibitor leading to inhibitions ranging from 
30% to 80% were chosen to deduce the IC50 of each inhibitor. The IC50 of each inhibitor was 
calculated from at least two independent experiments.  
5.2.II.3 Cell culture 
T47D human mammary cancer cell line was purchased from ECACC, Salisburry. The cells 
were routinely cultivated in DMEM (Sigma) supplemented with 10% FCS (Sigma) and 
100 IU/ml penicillin-streptomycin, and incubated at 37 °C under humidified atmosphere of 
5% CO2. The medium was changed every 2-3 days, and the cells were passed every 9-10 
days. 
5.2.II.4 hSTS and h17β-HSD1 cellular inhibition assays 
The T47D cells were seeded into a 24-well flat-bottom plate at 5 * 10
5
 cells/well in DMEM 
supplemented with 10% FCS and 100 IU/ml penicillin-streptomycin according to previously 
described procedures.
2,3
 After incubation for 24 h of adaptation at 37 °C, the medium was 
exchanged by a fresh FCS-free DMEM and the test compound dissolved in DMSO was added 
(final concentration of DMSO was adjusted to 1% in all samples). After 1 h the incubation 
period was started by the addition of a mixture of unlabeled and radioactive substrate [
3
H]-
E1-S (5 nM) for 24 h or [
3
H]-E1 (50 nM) for 40 min at 37 °C in case of hSTS or h17β-HSD1 
cellular inhibition assays, respectively. The reaction was stopped by the removal of the 
supernatant. The supernatant was injected directly (without any further workup) into the same 
radio-HPLC system mentioned above for h17β-HSD1 and h17β-HSD2 cell free inhibition 
assays and the IC50s are calculated as described. 
5.2.II.5 Nature of inhibition of STS activity 
In order to investigate the mode of inhibition of STS activity, T47D cells were cultivated as 
mentioned above but with some changes described by Purohit et al., 1995.
4
 The cells were 
pre-incubated with the inhibitors for 2 h at 37 °C, then the medium was removed and the cells 
were washed 3-4 times with PBS (phosphate buffer saline). The remaining STS activity was 
assayed as described in the recent procedure by incubating the cells with using [
3
H]-E1-S for 
24 h at 37 °C, then subsequent quantification of the steroids in the supernatant using HPLC 
coupled to radiodetector and the IC50s are calculated as described. 
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5.2.II.6 Metabolic stability in a cell-free assay 
For evaluation of phase I and II metabolic stability 1 µM compound was incubated with 1 
mg/ml pooled mammalian (human or mouse) liver S9 fraction (BD Gentest, Heidelberg, 
Germany), 2 mM NADPH regenerating system, 1 mM UDPGA, 10mM MgCl2 and 0.1 mM 
PAPS at 37°C for 0, 5, 15 and 60 minutes at a final volume of 100 µL of 100 mM Potassium 
hydrogen phosphate buffer pH=7.4. The incubation was stopped by precipitation of S9 
enzymes with 2 volumes of cold acetonitrile containing internal standard, then centrifuged for 
10 minutes at 4◦C and 12500 rpm.  For quantification, a calibration curve was developed for 
each compound assayed by LC-MS/MS (Accucore RP-MS, TSQ Quantum triple quadrupole 
mass spectrometer, ESI interface) using a serial dilution of 6 standards in the range 10-500 
nM. Then, LC-MS/MS was used to analyze the remaining concentration of the test compound 













Then the intrinsic clearance (Clint) [μL/min/mg protein] estimates of the compounds were 
determined using the following equation: 





 = 1000 [μL /mg protein] 
 𝑓𝑢 = unbound fraction of the tested compounds (unknown)= 1 
5.2.II.7 In vivo pharmacokinetic study 
All animal procedures were approved by the local government animal care committee and 
performed in accordance with the Guide for the Care and Use of Laboratory Animals. The 
pharmacokinetic study was performed on C57B1/6 mice (body weight 20-25 g) in a group of 
3 per compound. Compounds were administered subcutaneously and orally at a dose of 50 
mg/kg body weight, and intravenously at a dose of 5 mg/kg body weight. For subcutaneous 
and oral administrations, the compounds were prepared as a suspension in 0.5% gelatine/5% 
mannitol (w/w) in water followed by 25 min in an ultrasonic bath 60-90 min before 
administration (8 µl suspension/gram body weight). For iv administration (4 µl solution/gram 
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body weight), the compound was dissolved in PEG400/ethanol/water (60/10/30). Before the 
drug application, the mice were anesthetized with 2% isoflurane. Blood samples of 50 µl 
volume were collected from the tail vein into 0.2 mL PCR-tubes containing 10 µl citrate 
buffer as an anticoagulant at 0.25, 0.5, 1, 2, 6, 7 and 24 h post-dosing. Plasma was harvested 
by centrifuging the blood for 5 min at 3000 rpm and 4◦C. 10 µl samples were stored frozen at 
-80◦C until analysis. For bioanalysis, 5 µl of plasma aliquot was added to 25 µl of 500 nM 
diphenhydramine as internal standard in ACN and vortexed for 1 minute using mini-
centrifuge. Samples and calibration standards (in mouse plasma) were centrifuged for 5 min at 
14000 rpm and 4◦C. The supernatant was then transferred into HPLC vial and quantified by 
LC-MS/MS (Accucore RP-MS, TSQ Quantum triple quadrupole mass spectrometer, ESI 
interface) as described in the previous section. 
5.2.II.8 Aqeous soluibility assay 
Final concentrations of 5, 10, 20, 40, 60, 100 and 200 µM of the desired compound in 
phosphate saline buffer (PBS) containing 1% DMSO were prepared, then the solution clarity 
and potential perciptation of the compound were examined after 1 and 24 h at room 
temperature (19-24 ̊C). 
5.2.II.9 MTT cell viability assay 
In 24-well plates, HEK293 or HepG2 were seeded in DMEM supplemented with 5% FKS and 
100 IU/ml penicillin-streptomycin. After 3 h, the incubation was started by the addition of the 
tested compound at 100, 50, 40, 25, 20, 12.5, 10 and 5 µM dissolved in ethanol with a final 
ethanol concentration of 1%. Then the cell viability is evaluated by MTT assay based on the 
ability of viable cells to convert the yellow water soluble dye 3-(4,5-dimethyl-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) to a violet water insoluble formazane. After incubation 
time of 72 h in case of HEK293 and 48 h in case of HepG2 cells, 100 µl of MTT-solution 
(5mg/ml in PBS) was added to the medium. After 30 min, the medium was removed and 250 
µl of DMSO containing 10% Sodium dodecyl sulphate (SDS) and 0.01 N HCl was added to 
start the cell lysis and dissolve the blue formazan which was then quantified 
spectrophotometrically at 590 nM using an Omega plate reader spectrometer as described. 
Proliferation in the presence of the vehicle was always arbitrary set to 100%. 
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5.2.II.10 Aryl hydrocarbon receptor assay 
The AhR activity was evaluated as described before.
5
 The aryl hydrocarbon receptor agonistic 
activity of compounds was determined in a human hepatocellular carcinoma cell line (HepG2) 
by measuring the CYP1A1 activity. Cells were split on a 24-well plate (each compound in 
quadruplicate) and incubated for 16−24 h before compounds or vehicle was added to a final 
DMSO concentration of 0.1%. After 48 h of incubation with compound (3.16 μM) or vehicle, 
cells were washed with 1 mL of warm PBS (37 °C). Then, 500 μL of 3-cyano-7-
ethoxycoumarin (CEC, specific CYP1A1 substrate), which forms a fluorescent product, was 
added to the cells at a final concentration of 40 μM in DME medium with 10% fetal calf 
serum + 1% penicillin +streptomycin (37 °C). After an incubation of 30 min, the fluorescence 
was measured in the BMG Labtech Clariostar reader (excitation, 409 nm; emission, 460 nm). 
The increase in fluorescence induced by test compound was expressed relative to the increase 
induced by the reference compound omeprazole (50 μM).  
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5.2.III Oral bioavailability  
 
Figure S1. Mean profile (±SD) of plasma concentration [nM] in C57B1/6 mice vs time after oral (50 
mg/kg) and intravenous (5 mg/kg) application of compounds 5 in single dosing experiments (n=3). 
Dotted lines represent the cellular IC80 values of STS and 17β-HSD1 values for compound 5. 
 




%𝐹 =  





∗ 100 = 1.47% 
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